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ABSTRACT 
Modern mass spectrometry (MS)-based neuropeptidomics continues to reveal an unprecedented 
level of chemical complexity in the nervous system on the peptide level, with sometimes hundreds of 
peptides expressed by or secreted onto specific structures. These neuropeptides have evolved for animal 
behaviors and regulating neuronal circuits. Neuropeptides exert their responses through GPCRs in most 
cases, and in order to interact with the GPCR, their structure is important.  Their structures are not solely 
defined by their peptide sequence, but may instead depend on the myriad post-translational modifications 
(PTMs) they undergo. Thus, the hunt for neuropeptides must include the discovery of the exact chemical 
forms of the physiologically active peptides as these are required to achieve their receptor binding 
capability, degradation and uptake pathways, and hence bioactivity. 
Life, on a molecular level, has a stereoselective preference for many biochemical processes. This 
is especially true for protein-derived neuropeptides, which are translated by ribosomes using exclusively 
L-amino acids. However, D-amino acids are present in animal peptides, first evidenced by dermorphin, an 
analgesic skin peptide in Phyllomedusa sauvagei. Dermorphin’s existence as a D-amino acid-containing 
peptide (DAACP) proved not to be a singularity, but instead revealed a novel post-translational 
modification: peptide isomerization. Roughly 40 endogenous animal DAACPs have been found in 3 
evolutionarily distinct phyla as toxins, hormones, and importantly for this work, neuropeptides. 
Isomerization alters the three-dimensional shape of a peptide. This change in shape has been 
associated with a change in bioactivity of a peptide, with the DAACP being the sole bioactive form. 
However, isomerization does not change the molecular weight of a peptide, making it difficult to detect 
using MS. Thus, bioactive peptides are likely hiding in neuropeptidomics study under the assumption that 
these peptides, like the majority of life, are formed solely of L-amino acids. 
Understanding the physiological purpose of DAACPs requires their further discovery. An 
approach to characterize unknown DAACPs, the DAACP discovery funnel, is presented in this work. It 
aims to solve this problem through a series of adapted MS-based analytical techniques capable of 
identifying potential DAACPs and assaying their amino acids for their chiral state. The discovery funnel 
is used to discover new DAACPs in the Aplysia californica nervous system and is applied, as pioneering 
work, to nervous system structures in rodents.  
  
 iii 
 
ACKNOWLEDGMENTS 
My thesis work was achieved through the support of many individuals, and I cannot feel lucky enough for 
their help. In particular, Professor Jonathan Sweedler, my thesis advisor, has been extremely helpful and 
supportive through the course of this work. His insight and enthusiasm for this project has made so much 
of this work feasible and enjoyable to perform. Truly, it has been a privilege to work with him, and I look 
forward to continuing to support this project while I am in medical school. The insight and support of my 
committee members has been vital to the achievement of my work, as well. Professor Martha Gillette has 
been an extremely valuable collaborator for the pioneering work into investigating D-amino acid-
containing peptides (DAACPs) in the rodent nervous system. Her insight and advice about the 
suprachiasmatic nucleus, as well as giving me access to her animals and lab members, is something for 
which I am incredibly grateful. It was only through her support that I earned not one but two graduate 
student fellowships during my time here. I also rotated through Martha Gillette’s laboratory, learning 
about the importance of circadian rhythms, which helped motivate me to take on this difficult and 
exciting aspect of the project. Professor Justin Rhodes has been a very inquisitive and encouraging 
committee member, taking such an interest in the research topic that talking to him about it always would 
remind me just how cutting edge this work is. Professor Lori Raetzman has provided kind support and 
discerning questions, and her expertise has helped guide some of the D-amino acid-containing peptide 
work in the pituitary. 
 The Sweedler laboratory has been a fantastic working environment, with great support from 
students, post-doctoral scholars, and staff. Dr. Lu Bai was a fantastic student mentor while she was at the 
University of Illinois, and she continued to support the project even after her graduation. Without her 
help, this project would not be as far along as it is, as she developed the ideas for the discovery funnel 
approach. Dr. Erik Jansson worked on this project as a post-doctoral scholar, and his help was critical for 
the discovery of GdYFD as a DAACP in Aplysia. Dr. James Checco has been an enthusiastic post-
doctoral scholar, who has helped take this project in new directions that continues to motivate me to 
understanding the potential of this field. The number of projects he has taken charge of has been nothing 
short of impressive, including characterizing the peptide specificity of the achatin-like receptor, 
improving aspects of the discovery funnel that I have suggested in this work, working on new and 
exciting organisms for DAACP analysis, and continuing to work on the rodent nervous system. Hua-Chia 
Tai is a graduate student in the lab who is going to take over my project. She has proven to be a capable 
and enthusiastic student on the project, and her contributions have been very important. I believe that her 
work on other DAACPs in Aplysia, as well as discovery of the isomerase, will help advance the field 
 iv 
 
considerably. I have great confidence in both of these current lab mates to achieve great results for this 
project. Dr. Elena Romanova has been a critical lab member, helping me in so many technical aspects of 
this project and furthering my training in mass spectrometry and data analysis techniques. Her thoughtful 
insights and help with dissecting Aplysia helped this project considerably. Dr. Stanislav Rubakhin has 
helped in many of the same ways as Dr. Elena Romanova, providing dissections, project insights, and 
general help on many technical and intellectual levels. I would also like to thank many of my other fellow 
Sweedler group members for their advice, friendship, and support: Dr. Eric Lanni, Dr. Callie Croushore, 
Dr. Nobutoshi Ota, Dr. Sarah Dowd, Dr. Ta-Hsuan Ong, Ning Yang, Jordan Aerts, Emily Tillmaand, Amit 
Patel, Sage Dunham, and Troy Comi. 
 This research also benefited from individuals outside of the lab at the University of Illinois. Dr. 
Peter Yau and Dr. Brian Imai from the Roy J. Carver Proteomics Center have provided wonderful insight 
and support in various aspects of the discovery funnel, especially with deuterium-assisted acid hydrolysis. 
Dr. Lucas Li of the Roy J. carver Metabolomics Center provided experimental help and insight in the use 
of multiple reaction monitoring in the discovery funnel. From the Gillette laboratory, James Chu and Dr. 
Jennifer Mitchell provided training and help with suprachiasmatic nucleus and supraoptic nucleus 
dissections and insights into the rodent nervous system. I would also like to thank Dr. Wilfred Van Der 
Donk for his support and his efforts in the Chemistry-Biology Interface Graduate Fellowship. For the 
work on structural characterization on streptomonomicin, I would like to thank the Mitchell laboratory, in 
particular Jonathan Tietz and Professor Douglas A. Mitchell. 
 I would also like to give a deep thanks to the wonderful collaboration we have with Professor 
Klaudiusz R. Weiss (Mt. Sinai), Dr. Ferdinand S. Vilim (Mt. Sinai), and Professor Jian Jing (Nanjing 
University). Dr. Jian Jing, in particular, has been an extremely enthusiastic supporter of my work, and I 
feel very fortunate to continue to work with him on the discovery funnel manuscript we are developing. I 
would also like to thank Professor Lingjun Li (University of Wisconsin, Madison), whose laboratory has 
also studied DAACPs, who has always made it a point to stop by my posters and showing such interest 
for the project. 
 The support of my family and friends has been nothing short of amazing. I would especially like 
to thank my lovely parents for their love and support me during my entire academic career!  
 
 
 
 
 
 
 v 
 
TABLE OF CONTENTS 
Chapter 1 INTRODUCTION AND DISSERTATION OVERVIEW……………………………….. 1 
Chapter 2 D-AMINO ACID-CONTAINING PEPTIDES: BIOLOGY, DISCOVERY, AND 
CHARACTERIZATION TECHNIQUES………………………………………………... 11 
Chapter 3 RECENT AND MS-DRIVEN TECHNIQUES FOR THE DETECTION OF D-
AMINO ACIDS IN PEPTIDES…………………………………………………………… 38 
Chapter 4 CHARACTERIZATION OF G(D)FFD, A D-AMINO ACID-CONTAINING 
NEUROPEPTIDE THAT FUNCTIONS AS AN EXTRINSIC MODULATOR OF 
THE APLYSIA FEEDING CIRCUIT…………………………………………………….. 59 
Chapter 5 OPTIMIZATION OF THE D-AMINO ACID-CONTAINING NEUROPEPTIDE 
DISCOVERY FUNNEL…………………………………………………………………… 103 
Chapter 6 A D-AMINO ACID-CONTAINING NEUROPEPTIDE DISCOVERY FUNNEL…….. 128 
Chapter 7 THE SEARCH FOR D-AMINO ACID-CONTAINING PEPTIDES IN THE 
RODENT NERVOUS SYSTEM………………………………………………………….. 168 
Chapter 8 CONCLUSIONS AND FUTURE DIRECTIONS………………………………………... 192 
Appendix A STRUCTURE, BIOACTIVITY, AND RESISTANCE MECHANISM OF 
STREPTOMONOMICIN, AN UNUSUAL LASSO PEPTIDE FROM AN 
UNDERSTUDIED HALOPHILIC ACTINOMYCETE………………………………… 198 
 
 
  
 1 
 
CHAPTER 1  
INTRODUCTION AND DISSERTATION OVERVIEW 
1.1 Introduction 
Life, on a molecular level, has a stereoselective preference for many biochemical processes. This 
is especially true for proteins, which are translated by ribosomes using exclusively L-amino acids. 
However, D-amino acids are present in protein-derived animal peptides, first evidenced by dermorphin, 
an analgesic skin peptide in Phyllomedusa sauvagei.1 Dermorphin’s existence as a D-amino acid-
containing peptide (DAACP) proved not to be a singularity, but instead revealed a novel post-
translational modification (PTM): peptide isomerization.2 DAACPs have been found as toxins,1,3-16 
hormones,17-19 and importantly for the present work, neuropeptides.20-26  
Neuropeptides are a complex class of nervous system cell-to-cell signaling molecules that act as 
neurotransmitters, neurohormones, and neuromodulators. They are interesting as a clinically relevant 
research topic because they are known to be involved in a variety of behavioral functions, such as pain 
modulation and feeding behavior.27 Neuropeptides, unlike small molecular neurotransmitters, are formed 
from protein precursors. The preporhormone contains a signal sequence that marks it for transfer to the 
rough endoplasmic reticulum and eventual secretion. In the rough endoplasmic reticulum, the signal 
sequence is cleaved and the full prohormone is ribosomally translated. The prohormone undergoes further 
processing in the Golgi network and vesicles, eventually being cleaved to form to the neuropeptide 
products. The neuropeptides are stored in the large dense-core vesicles where they were formed until they 
are eventually released. To carry out their activity, most neuropeptides bind G-protein coupled-receptors 
(GPCRs), which in turn elicits responses in target cells. Importantly, the ability to bind a GPCR requires 
depends on the structure of the peptide, which involves both its primary sequence and any PTMs. The 
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PTM peptide isomerization has been shown to be necessary for the bioactivity of neuropeptide DAACPs, 
which means that understanding the extent to which DAACPs exist in the nervous system of animals is 
critical for discovering bioactive neuropeptides.20-26 
However, isomerization does not change the molecular weight of a peptide, making it difficult to 
detect using most traditional mass spectrometry (MS)-based techniques. While some techniques do exist 
to characterize DAACPs, DAACP discovery was historically driven by bioactivity-based approaches or 
by homology. In these approaches, only peptides where bioactivity of a well-characterized endogenous 
peptide was lacking in a synthetic peptide could give the indication of an unexpected modification, such 
as isomerization of the one of the residues. This explains the distinct prevalence of toxic peptides in the 
list of known endogenous DAACPs, because their bioactivity is known even before the peptide’s isolation 
and characterization. The shortcomings of using homology is that not very many DAACPs are known, so 
there are a limited set of sequences from which to search using homology.  
More recently, the need to characterize spontaneously forming DAACPs has spawned several 
methods with which to discover them. Spontaneously forming DAACPs are an important class of 
DAACPs that are distinct from endogenous DAACPs as they are theorized to occur in long-lived proteins 
and preferentially form in especially aspartic acid, but also serine and alanine, residues.28 Other methods 
have taken advantage of differential fragmentation patterns of DAACPs and their all-L-counterparts.29-45 
However, these methods lack direct assay of the chirality of the amino acid content that can 
simultaneously detect all of the amino acids commonly occurring in peptides. Also, many of these 
methods rely on synthetic standards to be available for screening purposes, which is both time and cost 
prohibitive. Towards the effort of further endogenous DAACP discovery, a method to characterize 
unknown DAACPs, the DAACP discovery funnel, is developed in this dissertation. It aims to solve this 
problem through a series of analytical techniques capable of identifying potential DAACPs, isolating 
them, and assaying their amino acids for their chiral state. Then, DAACPs are confirmed by synthesizing 
peptides with the suspected chirality at each residue and comparing those synthetic peptides to 
endogenous ones for their retention time on liquid chromatography (LC) as well as their bioactivity. 
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Importantly, this work uses the mollusk Aplysia californica as a model organism for DAACP 
discovery and method development. This organism is appropriate for method development due to the 
presence of two DAACPs in its nervous system, NdWFamide and GdFFD.26,46 However, this alone does 
not make it a suitable model organism. The Sweedler lab has studied its neuropeptide content by 
combining genomic information with MS assay.47 Also, it has a simple, well-characterized nervous 
system where DAACP discovery can be linked to function by virtue of the neurons the DAACPS are 
expressed in. Ultimately, it is expected to have the enzymatic process for isomerization present in its 
nervous system, and thus other DAACPs could be more readily discovered. 
1.2 Dissertation overview 
Chapter 2 gives a historical review of DAACP discovery. The unique properties of DAACPs will 
be discussed in context of the DAACPs that have been discovered so far, with a focus on neuropeptide 
DAACPs. These have all been discovered in phylum molluska, yet there is reason to believe it is not 
unique to only these animals. This chapter will also discuss techniques that have been used to characterize 
and discover DAACPs in the past, including separations and characterization of free L- and D-amino acid 
enantiomers. 
Recent work on DAACP discovery method development has focused mostly on those peptides that 
are formed spontaneously in mammalian peptides, with some characterization and discovery of 
endogenous DAACPs. Chapter 3 discusses the most recent of these methods, including other techniques 
that are being used to characterize DAACPs which may form the basis for future discoveries. These 
include fragment ion intensities, ion mobility spectrometry, deuterium-assisted acid hydrolysis, and other 
enzymatic-based screens. 
 While a large focus of this dissertation is on the non-targeted D-amino acid-containing 
neuropeptide discovery funnel, the topic of Chapter 4 is the targeted discovery and characterization of 
another DAACP in A. californica. This discovery was important to develop some of the known 
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techniques for characterizing DAACPs in the laboratory, as well as further our understanding of the extent 
of DAACP expression in Aplysia, with the Sweedler lab having already characterized NdWFamide.46 The 
peptide that was discovered is a neuropeptide from the achatin-like prohormone. By genomic data, its 
amino acid sequence is predicted to be GFFD (Gly-Phe-Phe-Asp). But the peptide that was identified 
contained a D-amino acid in the second position, thus forming the peptide GdFFD (Gly-D-Phe-Phe-Asp). 
This peptide was targeted because of the homology of its prohormone to that of achatin-1, a neuropeptide 
from the mollusk Achatina fulica. Its sequence is GdFAD, so it differs only in the third position being 
converted to an Ala instead of a Phe. As changes to bursting activities in specific neurons can be linked to 
behavior in A. californica, GdFFD was found to be bioactive in the Aplysia feeding network. 
 With the discovery of another DAACP in A. californica, the methodology for non-targeted 
discovery of D-amino acid-containing neuropeptides in A. californica was focused on and refined. In 
Chapter 5, these refinements are introduced which were necessary for DAACP discovery in later chapters. 
Briefly, there are three steps to DAACP discovery: finding those peptides that are resistant to enzymatic 
digestion, chiral analysis, and finally confirmation. 
The D-amino acid-containing neuropeptide discovery funnel is presented in its final form in 
Chapter 6, as well as with the first discoveries to come from using it in A. californica. Using a non-
targeted enzymatic digestion with aminopeptidase M, several potential DAACPs were identified. 
Increasing our confidence in the nature of these potential DAACPs was the fact that they both came from 
the achatin-like prohormone. One of the peptides, GYFD, is homologous to GdFFD, whose discovery is 
presented in Chapter 4. More surprising is another sequence in the achatin-like prohormone, 
SYADSKDEESNAALSDFA. This peptide, much longer than the other two tetrapeptides, was found to 
resist digestion from aminopeptidase M. However, the N-terminal sequence does bear homology to our 
previously discovered DAACPs: SYAD is not dissimilar from GFAD or GYFD, both which are 
discovered to be DAACPs. And appropriately, both peptides are shown to be DAACPs: GdYFD and 
SdYADSKDEESNAALSDFA. This indicates a similarity between the isomerizing enzymes between frog 
and mollusk, as both appear to act on N-terminal sequences even when the peptide length can be quite 
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different. Only GdYFD was found to be bioactive in the Aplysia nervous system, indicating that while this 
is a bioactive peptide, SdYADSKDEESNAALSDFA was not found to be active in the feeding network. 
Endogenous DAACPs have been shown to be present in the molluskan nervous system in this 
dissertation and elsewhere, but it is interesting to speculate that this PTM also exists in the mammalian 
nervous system. Thus far, the only DAACPs discovered in mammals have been shown to form 
spontaneously. The discovery of an endogenous DAACP in mammals (that is, one which is purposefully 
enzymatically formed and plays an important role in cell-to-cell communication in the nervous system of 
mammals) would open the possibility that orphan GPCRs and peptides with no characterized activities are 
in fact mischaracterized because DAACPS are not even searched for in most labs that study mammalian 
neuropeptides. Thus, the DAACP discovery funnel was applied to the mammalian nervous system in 
Chapter 7. While no discoveries have been made yet, the progress is reported with some reflection on the 
reasons why the discovery funnel could lead to false hits as potential DAACPs. 
Chapter 8 discusses conclusions and future directions. The contribution of this work is put in the 
larger context of DAACP discovery, and a future DAACP of interest in the mammalian nervous system is 
discussed. Importantly, discovery of the first signaling DAACP in the mammalian nervous system would 
reveal this as a PTM that could have relevance for human health, since DAACPs may exert a yet 
unstudied activity in a disease context. In addition, this would fill the gaps of neuropeptidomic studies 
driven largely by mass spectrometry, which cannot detect DAACPs without the use of targeted standards. 
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CHAPTER 2  
D-AMINO ACID-CONTAINING PEPTIDES: BIOLOGY, 
DISCOVERY, AND CHARACTERIZATION 
TECHNIQUES 
2.1 Introduction 
Proteins are known to be ribosomally translated using exclusively L-amino acids (LAA). L- and 
D-amino acids (DAA) are non-superimposable mirror images, distinguished by the arrangement of the 
atoms around the central α-carbon (Fig. 2.1). While this does represent the chiral state of these amino 
acids, this property does not necessarily relate to R- and S-configurations around the central α-carbon. 
Also, this property only applies to 19 of the 20 common amino acids found in proteins, because glycine is 
achiral. Since LAAs are so abundant in animal proteins, it was long assumed that DAAs do not naturally 
occur in animal proteins. DAAs have been known to occur in prokaryotic peptides, such as gramicidin,1 
but these DAAs are incorporated through a non-ribosomal multi-enzyme complex. 
It was not until the discovery of dermorphin as a bioactive DAA-containing peptide (DAACP) 
that this notion was modified. A D-Ala was discovered in the second position from the N-terminus of 
dermorphin.2 Dermorphin was of interest because it was a skin peptide of the frog Phyllomedusa sauvagei 
that had 30 times the analgesic properties of morphine.2,3 However, while the endogenous peptide was 
well-characterized, a synthetic peptide containing only LAA was not found to be bioactive. The peptide 
was found to contain a D-Ala once the peptide was broken down into its component amino acids and the 
activity of a D-amino acid oxidase upon these amino acids was measured. The synthetic DAACP then 
matched the activity of the endogenous peptide, revealing a new idea: that DAAs could occur naturally in 
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animal peptides and that this could carry biological significance for the peptide’s function. 
Modifying an already synthesized peptide containing only LAAs could serve to increase the 
amount of peptide products from a single protein. However, though only subtly different, DAACPs also 
have differing properties from their sequence-matched peptides containing only LAAs. The structure of 
the backbone is altered by the shift from an LAA to a DAA, and this is responsible for a change in the 
overall shape of the peptide by introducing new possibilities for secondary and tertiary interactions. This 
change in both the backbone and overall shape is subsequently responsible for two important ways in 
which DAACPs and their all-LAA-containing peptide counterparts (all-LAACPC) differ: resistance to 
degradation and protein interactions/bioactivity. (Fig. 2.3 as an example of bioactivity changes) For the 
former, DAACPs are more resistant to degradation by some nonspecific peptidases than their all-
LAACPC, especially those that rely on the peptide backbone to break them down.4 For the latter, the 
change in shape of the peptide means differential binding of a DAACP and an all-LAACPC in the binding 
pocket of their cognate receptor. A receptor is one way in which peptides can carry out an effect on a cell, 
and thus this interaction can be quite specific. Lending evidence to this is the fact that in most cases where 
they have been studied, DAACPs are the bioactive form of the peptide or at least carry a similar role in 
bioactivity to their all-LAACPC. 
However, these patterns are difficult to establish because there is one important similarity 
between a DAACP and their all-LAACPC: molecular weight. As mass spectrometry (MS) has been a 
driving force behind non-targeted, high throughput identification of proteins, including the modification 
of peptides,5,6 such experiments would naturally miss a change that carries no difference in its molecular 
weight. This inability of MS to characterize DAACPs has limited the pace of DAACP discovery to slow 
by necessity. DAACP discovery has often required years of study into the bioactivity of a peptide, as was 
the case with dermorphin, or homology to known DAACPs. The reason for this slow discovery could also 
be that DAACPs are merely not widespread, but without the analytical tools to detect them in a rapid 
manner, this hypothesis has not been tested. 
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2.2 DAACPS and their biological significance 
Inquiry into the nature of this phenomenon has yielded evidence that DAACPs are the result of a 
post-translational modification (PTM): peptidyl-aminoacyl-L/D-isomerization, hereafter referred to as 
isomerization. Where gene information has been available, each D-amino acid has been found to have a 
normal codon for the L-amino acid in the same position.7 The enzymes for isomerization have been 
described in frog,8-11 spider,12 and platypus.13 These enzymes catalyze the conversion of L-residues into 
the D-form. The spider enzyme isomerizes amino acids near the C-terminus, while the platypus and frog 
enzymes isomerize amino acids near the N-terminus. The spider enzyme was isolated from the venom of 
Agelenopsis aperta, a funnel web spider. It was active without pyridoxal phosphate, which is used in 
several bacterial amino acid racemases, and it was active in the presence of EDTA, so it is likely metal ion 
independent. Its active site shares some sequence similarity with serine proteases. The frog enzyme, 
studied separately, was seen to have a His but not a Cys in its active site based on its inhibition with 
diethyl pyrocarbonate but not iodoacetamide. Hydroxylamine also has no inhibitory effect, so the frog 
enzyme does not use pyridoxal phosphate. The frog enzyme was not inhibited by 
phenylmethylsulfonylfluoride, unlike the spider enzyme. This enzyme was found to be optimally active at 
pH 6.5. Based on sequence alignment, there was no known mammalian enzyme with a high degree of 
homology to this enzyme, but some characterized proteins were found to be somewhat similar. To study 
the cellular events of peptide isomerization, the isomerization of crustacean hyperglycemic hormone 
(CHH),14-16 a DAACP in crayfish, was studied using ultrastructural immunocytochemistry in CHH-
secreting cells of the crayfish Astacus leptodactylus. This study reported that isomerized CHH was only 
detected in secretory granules,16 demonstrating that isomerization occurs late in peptide synthesis and 
processing, as a PTM. (Fig. 2.2) Peptide isomerization involves the conversion of a residue from the L-
form to the D-form, near the C- or N-terminus of the peptide.7 Unlike many other PTMs, isomerization is 
a zero-Dalton shift in the molecular weight of the peptide, so it is not easily observable by MS or most 
sequencing techniques. 
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Since dermorphin was discovered, over 30 other DAACPs have been described, from the toxins 
of frogs,17-19 spiders,20,21 snails,22-29 and the platypus,30,31 to hormones in arthropods,14,15,32 and 
neuropeptides in mollusks.33-39 (Table 2.1) Thus, these peptides have been identified in mollusks, 
arthropods, and chordates (vertebrates). Eight DAACPs have been identified in mollusks, including the 
cardioactive peptide Asn-D-Trp-Phe (NdWFa),34 first identified in Aplysia kurodai. For the purpose of 
nomenclature, dW in NdWFa is a D-Trp. NdWFa has also been identified in Aplysia californica, where 
GdFFD was also first discovered, discussed in Chapter 4. Achatina fulica has been the source of 
discovery for three molluskan DAACPs, including the neuropeptides Achatin I (Gly-D-Phe-Ala-Asp, 
GdFAD),33 Fulicin (Phe-D-Asn-Glu-Phe-Val-amidated, FdNEFVa),36 and Fulyal (Tyr-D-Ala-Glu-Phe-
Leu-amidated, YdAEFLa).37 Other DAACP neuropeptides include Ocp-1 (GdFGD) and Ocp-4 (GdSWD) 
in Octopus minor40 and Mytilus-FFRFamide (AdLAGDHFFRFa) in Mytilus edulis.41 As can been seen in 
the previous sequences, in the molluskan DAACPs, which are all the known DAAC neuropeptides, 
isomerization occurs at the second residue from the N-terminus.26-31 Two DAACPs have been found in 
arthropods. These two DAACPs function as neurohormones, secreted into the organism’s circulatory 
system. Isomerization occurs at the third position of CHH (a D-Phe)14 and the fourth position in 
vitellogenin inhibitory hormone (a D-Trp).32 Since both of these peptides are synthesized by neurons, the 
possibility exists that there exists neuropeptides whose isomerization does not occur at the second 
position from the N-terminus. 
In terms of their bioactivity, these peptides have been found contain diverse functions. For 
example, in Achatina fulica, GdFAD was found to induce a voltage-dependent inward current in the 
periodically oscillating neuron at mM concentrations.33 On the other hand, YdAEFLa and FdNEFVa were 
found to potentiation tetanic contraction of the penis retractor muscle at nM concentrations.33,35 DAACPs 
can even have diverse functions in molluskan nervous systems, as described in Chapter 4, where GdFFD 
was seen to be bioactive in the Aplysia californica feeding network as well as in locomotion. 
Interestingly, in Octopus minor, only GdFGD had chronotropic and inotropic activity on the octopus heart 
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at µM concentrations, whereas GSWD had similar effects, but GdSWD was not bioactive.40 (Fig. 2.3) 
Thus, no particular function can be ascribed to isomerization, much like other PTMs of neuropeptides, 
and there is no guarantee that a discovered DAACP will be bioactive. As such, bioactivity alone would 
not identify the full host of an organism’s DAA-containing neuropeptidome. 
2.3 Discovery and characterization of D-amino acid-containing 
neuropeptides, driven by bioactivity and non-chiral separations  
Discovery of as subtle a modification as isomerization is rendered non-trivial by the lack of mass 
change associated with the PTM. Moreover, identifying such a peptide in a complex mixture of hundreds 
or even thousands of neuropeptides poses its own challenge. How, then, were any DAACPs discovered in 
molluskan nervous systems? The established methods are discussed below. 
In 1989, achatin-I was the first D-amino acid-containing neuropeptide to be discovered. At the 
time, the only other animal DAACP that was known was dermorphin. This peptide was discovered 
because Kamatini et al were searching for short, neuroactive peptides in Achatina fulica.33 The 
endogenous peptide had activity on the periodically oscillating neuron but a peptide, synthesized only of 
LAA, did not have activity even at the high mM concentrations. When they compared the 
chromatographic behavior using liquid chromatography (LC) and circular dichroism signatures, they have 
they found a peptide synthesized to have only LAAs did not match the endogenous peptide. They 
synthesized peptides with a D-amino acid at each position, and found that GdFAD matched the 
endogenous peptide in every characteristic, which they expected based on the fact that dermorphin is also 
isomerized in the second position from the N-terminus. Following the discovery of achatin-I, fulicin was 
next identified by near-identical methodology, except that the peptides were isolated from a set of 
neuropeptides known to induce contraction of the penis retractor muscle.33 Interestingly, the all-LAA 
synthetic peptide of fulicin (FNEFVa) did, however, match the chromatographic retention time of the 
native fulicin on a C18 column, but not on an anion-exchange column. Finally, fulyal was a peptide 
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predicted from the cloned cDNA of the prohormone of fulicin, so it was suspected to be a DAACP, which 
was confirmed by synthetic standards.35 
NdWFamide from Aplysia kurodai had the same route of discovery as achatin-I.32 Unlike achatin-
I and fulicin, the synthetic all-LAACPC of mytilus-FFRFamide was seen to be bioactive, but its 
chromatographic behavior was dissimilar to an endogenous peptide of mytilus-FFRFamide was seen to be 
bioactive, but its chromatographic behavior was dissimilar to an endogenous peptide.39 In Octopus minor, 
Ocp-1 and Ocp-4 were seen to have different chromatographic behaviors from mass and sequence-
matched peptides that were also present endogenously. In addition, the bioactivity of these endogenous 
peptides was different in terms of their activity on perfused hearts.38 (Fig. 2.3) In Chapter 4, I discuss the 
discovery of GdFFD, a DAACP in the nervous system of A. californica.39 This was targeted for its 
homology to achatin-I. 
The targeting of endogenous D-amino acid-containing neuropeptides for analysis has thus largely 
been driven by several avenues: homology to known DAACPs, bioactivity of synthetic standards, or 
retention times of synthetic standards. These synthetic standards were compared to the endogenous 
peptides by non-chiral high performance liquid chromatography separations, using reversed phase C18 or 
anion exchange chromatography. As these are the techniques used to separate endogenous peptides, it 
follows that chromatographic behavior is a natural way by which to compare endogenous peptides with 
synthetic standards. However, by relying on synthetic standards or homology to just a few known 
sequences, these methods are difficult to apply to all possible neuropeptides. The developing 
methodology for non-targeted analysis of DAACPs is discussed as a review in Chapter 3, and a method I 
have helped to develop in Chapters 4 and 5. 
2.4 Chiral separations 
2.4.1 High performance liquid chromatography 
Non-chiral separations can be limited, although its limitations on a particular diastereomer pair of a 
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DAACP and its LAACPC can be difficult to predict. For example, there is nothing inherent to a sequence 
analysis of fulicin, FdNEFVamide, which could make it readily apparent that it will share a 
chromatographic retention time with FNEFVamide using LC with a C18 column. Chiral separations 
attempt to increase the ability to separate peptides and amino acids through their differential binding 
affinity to either a chiral stationary phase or chiral mobile phase additive. 
Crown ethers (macrocyclic polyethers) are chiral stationary phases in LC but also chiral mobile 
phase additives in capillary electrophoresis (CE). Crown ethers contain cavities that confer their chiral 
selective properties. Many examples exist of studies utilizing functionalized versions of crown ethers that 
have been used to separate diastereomeric sets of peptides. A 20-crown-6 ether was first used as a 
stationary phase to separate 4 different L- and D-Alanine combinations of an Ala-Ala dipeptide, then 8 
different L- and D-Alanine combinations of an Ala-Ala-Ala tripeptide.42 A 20-crown-6-ether was also 
used to separate dipeptides pairs of D/L-Ala-Gly, Gly-D/L-Ala, D/L-norVal-Gly, Gly-D/L-norVal, D/L-
norLeu-Gly, and Gly-D/L-norLeu.43 These crown ethers base their separation through interaction with the 
protonated amine, as is found on the N-terminus of unmodified peptides in acidic conditions. 
Cyclodextrins are cyclic oligosaccharides and have also been frequently used as stationary phases 
and chiral mobile phase additives. As an HPLC chiral stationary phase, β-cyclodextrins (which are 
bonded to 7 glucose units) were used to separate dipeptide diastereomers of linear and cyclic peptides of 
various LAA and DAA compositions.44 When β-cyclodextrins and γ-cyclodextrins (which are bonded to 8 
glucose units) were compared as chiral stationary phases in the separation of diastereomer pairs of 
dipeptides, γ-cyclodextrins were found to be less effective at separating all pairs of peptides. 
Pirkle-type chiral stationary phases have been bonded to columns, some of which are composed of 
short peptides. For example, a D-Phe-Gly Pirkle column was used to separate Gly-L-Trp and Gly-D-Trp.44 
Similarly, a chiral stationary phase of LAAs of Val-Ala-Pro was used to separate dipeptide stereoisomers 
of 10 pairs of peptides.45 Other chiral stationary phases use proteins as the basis for separation. For 
example, by immobilizing α-chymotrypsin, free amino acids and dipeptide stereoisomers of 12 pairs of 
peptides were separated using HPLC.46,47 
 18 
 
Macrocyclic glycopeptide antibiotics have come in several forms for chiral stationary phases. 
These large, complex molecules can undergo a variety of interactions that aid in the separation of 
enantiomers and diastereomers, including multiple hydrogen bonds, stacking, π- π interactions, and more. 
These types of interactions are common with polypeptides and amino acids. Teicoplanin has been used for 
the separation of all 4 combinations of D/L di-Leu dipeptides, as well as 18 other sets of di- and tripeptide 
diastereomers in a separate study.48,49 Ristocetin A, another macrocylic antibiotic, was used as a chiral 
stationary phase to separate various amino acids as well as 26 sets of di- and tripeptide diastereomers.50 
Several other chiral stationary phases have been used for the separation of L/D-amino acid 
diastereomer sets of short peptides, including polysaccharides, molecular imprinted polymers, and ligand-
exchange chiral stationary phases. 
 Chiral Edman degradation has also been used for the detection of DAAs in peptides. Edman 
degradation can sequence a peptide, but the technique by itself does not discriminate DAAs from LAAs. 
The first instance of this carried out Edman degradation cycles in the traditional sense, through the 
sequential incubation of phenyl isothiocyanate.51 This was followed by tagging the amino acids with 1-
fluoro-2,4-dinitrophenyl-5-L-alanine, a reagent quite similar to a commercial reagent, Marfey’s Reagent 
(1-fluoro-2,4-dinitrophenyl-5-L-alanine-amide). These amino acids were then separated using HPLC, and 
most of the common chiral amino acids could be resolved. However, isothiocyanate hydrolysis can itself 
lead to racemization. Thus, later, this technique was adapted by using an optically pure isomer of a 
isothiocyanate derivative, R(-)-4-(3-isothiocyanatopyrrol-idin-1-yl)-7-nitro-2,1,3-benzoxadiazole.52 This 
reagent also formed a chemical tag for the amino acids to allow for separation. The cleaved amino acids 
from enkephalin, a DAACP in frogs, was separated on HPLC and assayed.  
2.4.2 Capillary electrophoresis 
Capillary electrophoresis (CE) has been of interest for separations of DAACP and their LAACPC 
because it is capable of handling smaller samples, such as individual neurons. However, the 
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electrophoretic mobility (drift time) of peptides is not as affected by peptide isomerization as their 
retention time with HPLC. Thus, chiral mobile phase additives have been used toward the purpose of 
separating diastereomer pairs of peptides. Interestingly, there is crossover between the additives and the 
chiral stationary phases used in HPLC, discussed above. 
Crown ethers have been used as chiral mobile phase additives. One such crown ether, 18-crown-6 
tetracarboxylic acid, was used in multiple studies involved in CE separations of various sets of di- and 
tripeptide enantiomers and diastereomers.53-56 
Cyclodextrins, which have also been used as HPLC chiral stationary phases, have been widely used 
for enantiomeric separation of amino acids in CE. Several functionalized forms of cyclodextrins have 
been used as chiral mobile phase additives in CE. Hydroxypropyl-β-cyclodextrin has been used in 
enantiomeric separation of L-Ala-L-Phe(O-methyl) and D-Ala-D-Phe(O-methyl).57 For diastereomeric 
separations, carboxymethyl-β-cyclodextrin was used to separate all 8 L/D and α/β-Asp sets of Gly-Asp-
Phe-amide as well as enantiomeric separation of sets of di- and tripeptides.58 Other β-cyclodextrins have 
been used in diastereomeric and enantiomeric separations of peptides.59-61 As an example of how such 
techniques can apply to neuropeptides assayed directly from neurons, the identification of NdWFa, first 
identified in Aplysia kurodai, in the related organism Aplysia californica was accomplished through CE 
using γ-cyclodextrin as a chiral mobile phase additive.62 (Fig. 2.4) Using fluorescamine as a derivatization 
reagent, laser-induced fluorescence was used as the method of detection for NdWFamide; such a sensitive 
detection method was ideal given the low sample volume and presumed low peptide amounts.  
 Macrocyclic glycopeptide antibiotics, including teicoplanin and vancomycin, have been used as 
chiral mobile phase additives. There are challenges associated with these additives, as they can adsorb to 
the capillary surface and thus retention times may not always be reproducible. This adsorption is 
prevented by adding detergents like sodium dodecyl sulfate (SDS). When vancomycin was used, 14 out of 
sets of 15 di- and tripeptides could be separated, although some sets of isomers could only have 3 out of 4 
isomers could be separated for some dipeptides, with the L-form of peptides eluting earlier.63 Teicoplanin 
at various concentrations could change the elution orders of D- and L-forms of Ala-Gly and Gly-Asp 
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dipeptides.64 
2.4.3 Nuclear Magnetic Resonance  
Nuclear magnetic resonance (NMR) has been used to characterize endogenous DAACPs in 
animals. One study analyzed NMR structures of deltorphin analogs, which are known to interact with 
certain opioid receptors. The critical structural difference for the N-terminal amino acids (sequence: Tyr-
D-Met-Phe-His-Leu-Met-Asp-amide) is that the turn formed by the second position DAA changes the 
confirmation of the peptide such that the R group of Met is between the two aromatic rings in Tyr and 
Phe.65 This structure is similar to that of some non-peptide opioid agonists. The endogenous peptide of 
achatin-I (GdFAD) was also compared to synthetic peptides with D-amino acids in several positions using 
a variety of techniques including 1H NMR, where the endogenous peptide was found to best match the 
NMR signatures of GdFAD.33 Conomarphin, a DAACP in cone snails, was seen to adopt a helix structure 
near the C-terminus which was absent in its synthetic LAACPC using, in part, information from 1H 
NMR.66 (Fig. 2.5) The platypus C-type natriuretic peptide is a known DAACP that was compared to its 
LAACPC using 1H NMR and 2D NMR spectra; these were performed on the endogenous peptides with 
different chromatographic behavior, and follow-up experiments demonstrated that there was in fact a 
DAA in the second position from the N-terminus.67 1H NMR was also used to study the effects of DAA on 
the disturbance of α-helices on a model peptide. It was found that DAAs of Thr, Phe, Val, Ile, Tyr, and Pro 
were strong α-helix disruptors.68 
2.5 Conclusions and future directions 
Animal DAACPs have historically been discovered as potent bioactive peptides in historical 
screenings. Several techniques have been developed for their characterization, including non-chiral liquid 
chromatography, chiral separations, and NMR. These techniques have done an excellent job in 
differentiating DAACPs from their all-L counterparts, even though these differences are quite subtle. 
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However, the pace of DAACP discovery has been limited because bioactivity-based screenings 
require deep knowledge about the biological system that is being tested. Even though isomerization is 
invisible to MS, advanced methods for screening and characterizing DAACPs will rely on MS for its 
sensitive and capable detection of a broad range of analytes in complex chemical mixtures, such as low 
abundance DAACPs. 
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2.6 Figures and tables 
 
Figure 2.1. L-amino acids and D-amino acids are non-superimposable mirror images. In an L-amino acid, the R, COO-, and 
NH2 groups are arranged clockwise around the α-carbon chiral center (black), while in a D-amino acid, the R, COO-, and NH2 
groups are arranged counter clockwise around the α-carbon chiral center. 
L D 
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Figure 2.2. Immunogold staining of cell body and axons of X-sinus gland in crustaceans reveal that the degree of 
isomerization is increased in the axon as compared to the cell body.16 Immunogold staining used antibodies raised against the 
DAACP form of CHH (10 nm particles, smaller) and the all-LAACPC (20 nm particles, larger). Top – low magnification (left) 
and high magnification (right) of the cell body of a neuron expressing the DAACP CHH. Three populations of vesicles exist, 
containing only the L-peptide, only the D-peptide, or a mix of L and D. Bottom left – axon terminal of a neuron expressing the 
DAACP CHH. Two populations of vehicles exist, containing only the L-peptide or only the D-peptide. Bottom right – 
quantification of the amount of D-peptide granules (DGr) and L-peptide granules (LGr) in the cell body (dark bar) versus the 
axon terminal (hatched bars) demonstrates that far more D-peptide granules exist in the axon terminal as compared to the cell 
body. 
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Figure 2.3. DAACPs and their all-LAACPC have different HPLC retention times and bioactivity, as seen with Ocp-1/2 
(GdFGD/GFGD) and Ocp-3/4 (GSWD/GdSWD).40 Top – HPLC traces reveal the different chromatographic retention times of 
the enantiomer pairs, demonstrating separation of these peptides. This split-peak elution of peptides gave reason for further 
investigation of DAAs, as the peptides had the same molecular weight and sequence but different retention times. Below – 
perfused octopus heart with contraction strength (y-axis) versus time (x-axis) was used as a bioassay to determine which 
molecular forms were bioactive. Ocp-1, a DAACP, and Ocp-3, the all-LAA form of Ocp-4, were the only molecular forms to 
produce bioactivity. This assay demonstrates how DAACPs and their all-LAACPC can have differing bioactivities. 
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Figure 2.4. CE-LIF is capable of separating and detecting DAACPs in individual neurons in Aplysia californica, and this 
was used to discover NdWFamide.62 (A) Electropherogram of an individual neuron. (B) Electropherogram of an individual 
neuron spiked with NdWFamide standard, and the presumed N(l/d)WFamide peak grows. (C) Electropherogram of the neuron 
spiked with NWFamide standard gives a second peak. This confirms the native peak to be NdWFamide. 
 
 
 
C 
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Figure 2.5. Comparison of the molecular structures of endogenous conomarphin, a DAACP, (top) and the synthetic all-
LAACPC (bottom) based on NMR data.66 This demonstrates the importance of DAAs in altering the overall shape of a peptide. 
The endogenous peptide adopts a hairpin structure that is distinct from the linear structure adopted by the all-LAACPC. 
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Table 2.1. More than 30 DAACPs have been discovered in the last 45 years.  
 
Source Peptide [Reference] Sequence* Species 
land mollusk 
Achatina 
neuropeptides 
Achatin I 69 GdFAD Achatina fulica 
Fulicin 70 FdNEFVa   Achatina fulica 
Fulyal 71 YdAEFLa Achatina fulica 
Conus toxins 
Contryphan 72  GCOdWEPWCa Conus radiatus 
Des-[Gly 1]contryphan-R 72 COdWEPWCa Conus radiatus 
Contryphan-P 73 GCPdWDPWCa Conus purpurascens 
Contryphan-Sm 73 GCOdWQPWCa Conus stercusmuscarum 
Bromocontryphan-R 74 GCOdWEPW(6-bromo-W)Ca Conus radiatus 
Contryphan-R 73 GCOdWEPWCa(disulfide bond) Conus radiatus 
Leu-Contryphan-P 75 GCVdLLPWC  Conus purpurascens 
Leu-contryphan-Tx 76 CVdLYPWCa Conus textile 
Contryphan-Tx 76 GCOdWQPYCa Conus textile 
R11a (I-superfamily) 77 dF at 44th in 46 a.a. Conus radiatus 
R11b,c 78 dF at 44th in 46 a.a., dL at 42nd in 44 a.a. Conus radiatus 
Conomap-Vt 79 AdFVKGSAQRVAHGY Conus vitulinus 
Conomarphin (M super family) 66 DWEYHAHPKONSdFWT Conus marmoreus 
Conophan 80 AOANSdVWS Conus gladiator 
marine molluskan 
peptides 
NdWFa 81 NdWFa Aplysia kurodai 
Mytilus-FFRFamide 41 AdLAGDHFFRFa    Mytilus edulis 
Ocp-1/4 40 GdFGD/GdSWD  Octopus minor  
 Achatin-like neuropeptides 
39 
(Chapters 4 and 6 of this thesis) 
GdFFD/GdYFD 
dY at 2nd in 20 a.a. 
Aplysia californica 
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Table 2.1. (continued) 
crustacean 
hyperglycemic 
hormone 
CHHA, cHHB 82 pGlu-VdFDQACK Homarus americanus 
Prc CHH-II 15 dF at 3rd in 72 a.a. Procambarus clarkii 
VIH 32 dW at 4th in 77 a.a. Homarus americanus 
spider venom peptide IVB (ω-agatoxin-TK) 83,84 dS at 46th 46 a.a. Agelenopsis aperta 
frog skin peptides 
Dermorphin 2 YdAFGYPSa Phyllomedusa sauvagei 
Deltorphin(met) 85 YdMFHLMDa Phyllomedusa sauvagei 
Deltorphin(leu) 86 YdLFADVASTIGDFFHSIa Phyllomedusa burmeisteri 
Deltorphin A (Dermenkephalin) 87 YdMFHLMDa Phyllomedusa sauvagei 
Deltorphins I (B) II (C) (ala) 88 YdAFD(E)VVGa    Phyllomedusa bicolor 
Bombinin (H3-H5) 89 daIle at 2nd in 21 a.a. Bombina variegata 
Phenylseptin 90 dF at 2nd in 18 a.a. Hypsiboas punctatus 
GH-2 91 dL at 2nd in 20 a.a. Bombina orientalis 
platypus peptides 
Platypus peptide (OvCNPb) 67 LdLHDHPNPRKYKPANKKGLSKGCFGLKLDRIGSTSGLGC 
Ornithorhynchus anatinus  
DLP-2 92 dM at 2nd in 42 a.a. Ornithorhynchus anatinus  
 
* Each amino acid is represented by its one letter abbreviation, the letter following a “d” indicates that amino acid is in D-form, and “a” means amidation of the C-terminal residue. 
Updated from Bai, et al, 2009. From Springer Science+Business Media.93 
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CHAPTER 3  
 
RECENT AND MS-DRIVEN TECHNIQUES FOR THE 
DETECTION OF D-AMINO ACIDS IN PEPTIDES 
3.1 Introduction 
L-amino acids (LAAs) form the bulk of protein biological material because they are preferentially 
incorporated into proteins by ribosomes. Thus, the detection of their enantiomers, D-amino acids (DAAs) 
has remained a relatively rare phenomenon. However, the presence of D-amino acid-containing peptides 
(DAACPs) in biology has spanned several bacterial and animal systems. Broadly, the animal DAACPs 
can be defined in two categories: endogenous DAACPs and spontaneously formed DAACPs. 
 Endogenous animal DAACPs have been studied since the discovery of dermorphin, a DAACP in 
frogs that was found to be necessary for the bioactivity of the peptide.1 DAACPs result from a post-
translational modification where an enzyme, a peptide isomerase, converts one residue in the polypeptide 
chain from an LAA to a DAA.2-7 In the case of neuropeptide DAACPs, the bioactivity of these peptides 
indicates they have a signaling role in the nervous systems of the animals which they are found.8-14 
Spontaneously formed DAACPs are associated with aging and can lead to pathology. Certain 
amino acids are more prone to spontaneous racemization than others. The amino acid that is most prone to 
spontaneous racemization is the amino acid Asp. Asp spontaneously forms the cyclic structure 
aspartimide, which can randomly convert to either L- or D-Asp.15 (Fig. 3.1) Additionally, specifically in 
the case of Asp, the amino acid may reform with the β-carbon incorporated into the peptide backbone. 
With enough time, these spontaneous racemizations can accumulate within proteins, particularly those 
that are long-lived. In fact, D-Asp accumulation in tooth enamel reached 8% of total Asp content after 60 
years,16 with D-Asp content increasing about 0.15% per year in living organisms.17 There is interest in 
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using D-Asp for forensic age estimation; DAA dating compared favorably to radionuclide dating in some 
cases with fossils that were between 5,000 and 10,000 years old, although older fossils compared less 
favorably.18 D-Asp dating compared favorably to radionuclide dating for some fossils. Sometimes, the 
accumulation of DAAs can cause pathological malformations within proteins. For example, it is possible 
that enough DAAs in lens crystallin can cause these proteins to misfold and aggregate, which would 
explain the inclusions and loss of vision associated with cataracts.19 DAAs have been found in the 
following proteins associated with aging: crystallin in the lens; phosphophoryn in the tooth; osteocalcin 
and type I collagen C-terminal tellopeptide in bone; elastin in aorta and ligaments; myelin, β-amyloid, 
Tau, and Histone H2B in the brain; collagen, elastin, and keratin in the skin; and lysozyme in body fluid.20 
Both spontaneous and endogenous DAACPs represent an analytical challenge because there is no 
mass difference between LAAs and DAAs. As mass spectrometry (MS) remains a sensitive and high 
throughput manner by which peptides are characterized, these peptides would go unnoticed in a typical 
peptidomics experiment because a DAACP and its all-LAA counterpart would be detected as the same 
peptide. A DAACP and its all-LAA counterpart have the possibility of being separated using liquid 
chromatography (LC), which has been used historically to identify DAACPs by comparing the retention 
times of the endogenous peptides with synthetic standards, as covered in Chapter 2. However, using 
reversed phase separations in a non-specific manner, as is common for a peptidomics experiment, likely 
would not yield a considerable set of split-peak elution of a mass and sequence-matched peptide. To 
address this challenge, several adaptations of MS/MS and LC-MS/MS-based techniques have been 
developed for DAACP characterization and discovery. Enzymatic assays, acid hydrolysis, and ion-
mobility spectrometry (IMS) have also been used, but many of these techniques continue to rely on MS-
based technology. 
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3.2 A review of techniques 
3.2.1 Acid hydrolysis followed by detection of LAAs/DAAs 
Acid hydrolysis involves using heat and acid to break a peptide down into its component amino 
acids. This is obviously useful for DAACPs, as these amino acids can then be assayed for their chirality. 
(Fig. 3.2) The options for separation of enantiomer LAAs and DAAs are rather numerous and sensitive.21 
In this section, only those techniques that have related to DAACP discovery and characterization are 
covered, with acid hydrolysis described in more depth in Chapter 5. 
Acid hydrolysis for the discovery of endogenous DAACPs has been used since the discovery of [D-
Leu2]deltorphin as a DAACP in frogs. When it was first analyzed, acid hydrolysis was used to break 
deltorphin down into its component amino acids.22 These amino acids were then tagged with 1-fluoro-
2,4,-dinitro-5-L-alanine and separated using LC, confirming the presence of a D-Leu in the peptide.23 A 
similar procedure was used to determine the presence of D-alloIle in the second position of Bombina H3-
H5 in Bombina variegata, although this study used chiral Edman degradation sequencing for 
confirmation, as well (covered in Chapter 2).24 For a study in using acid hydrolysis for the discovery of 
achatin-like neuropeptides in Aplysia californica, see Chapter 6. 
Spontaneously forming DAACPs were first appreciated in the aging organism using acid 
hydrolysis. Lens proteins were some of the first to be appreciated to have DAAs, associated with 
insoluble proteins plaques in lens cataracts.25 These DAAs were obtained by acid hydrolysis, where it was 
seen that the ratio of D-Asp to L-Asp was up to 0.2 in insoluble lens protein preparations, an estimated 
15%; this ratio increased with the age of the patient from whom the lens was taken. Healthy lens, on other 
hand, had a D-Asp/L-Asp ratio of below 0.1, with one exception. β-amyloid peptides in Alzheimer’s 
patients were first investigated for racemization because a complex mixture of brain proteins was 
previous found to contain more DAAs with age.26 Four elderly patients with Alzheimer’s disease were 
studied, comparing a preparation of amyloid proteins to control tissue (hair, muscle, and tendon) 
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protein.27 These proteins were acid hydrolyzed, labeled with a fluorescent probe, and separated using LC. 
The amyloid protein had a D-Asp content of 4.5% and a D-Ser content of 2.1%, compared to the roughly 
2% D-Asp and undetectable D-Ser in control tissue. Another study associated this isomerization with a 
change in the shape of the peptides, shown in part by shifts in chromatographic retention times.28 Another 
protein that appears to contribute to the pathology of Alzheimer’s is tau protein, a microtubule-associated 
protein. Tau proteins form paired helical filaments within the lesions associated with Alzheimer’s. These 
filaments were isolated and acid hydrolyzed, then the resulting amino acids were derivatized with 
naphthylisocyanate and separated using non-chiral LC.29 Within Alzheimer’s patients, there was about 
6% D-Asp compared to 4% of D-Asp in normal adults. How these DAAs directly relate to the pathology 
of Alzheimer’s remains to be elucidated. 
Acid hydrolysis was thus used historically with LC separations without MS, but this technique 
eventually became less common because acid hydrolysis may spontaneously form DAAs during the 
hydrolysis process. This effect is especially seen with D-Asp, which is why controls in the previous 
experiments still contained DAAs. Acid hydrolysis-induced racemization occurs when the α-carbon loses 
the α-proton and extracts it again from solution, which has an equal chance of reforming an LAA or 
DAA. Obviously, this is an undesirable side effect of analysis which aims to detect low levels of 
DAACPs to begin with. For this reason, more recent techniques have focused on LC-MS/MS instead (see 
next section) to avoid the background of DAAs forming during acid hydrolysis. However, with so many 
options for separation of amino acid enantiomers, acid hydrolysis remains an attractive option for 
DAACP characterization. To overcome detection of acid hydrolysis-induced racemization, 6 M deuterium 
chloride (DCl) in deuterated water (D2O) can be used instead of 6 M hydrochloric acid. Thus, if any acid 
hydrolysis-induced racemization occurs, a deuteron is extracted instead of a proton, and the deuterated 
amino acid now has a +1 Dalton molecular weight from the original amino acids. This is known as 
deuterium-assisted acid hydrolysis. MS instruments that monitor certain molecular weights, like a triple 
quadrupole MS, can thus be used to detect only the original LAAs or DAAs at a specific molecular 
weight, and not the +1 Dalton species. This technique was used for the detection of D-Ala, D-Asp, D-Glu, 
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D-Pro, and D-Ser.30 A two-dimensional LC system was used along with tagging the amino acids with 4-
fluoro-7-nitro-2,1,3-benzoxadiazole (NBD-F) to separate the hydrolyzed AAs, and these AAs was 
detected with a triple quadrupole MS. They then applied this to the detection of DAAs in ovalbumin: 
0.4% D-Ala, 1.2% D-Asp, 1.7% D-Glu, 0.3% D-Pro, and 1.8% D-Ser. These values were less than the 
values indicated by the same experiment except using fluorescence detection. A similar study used 
deuterium –assisted acid hydrolysis for the detection of D-Ser and D-Ala in ovalbumin, confirming D-Ser 
positions that were posited by X-Ray crystallography.31 Deuterium-assisted acid hydrolysis followed by 
detection with a triple quadrupole MS was used for the discovery of endogenous DAACPs in A. 
californica, as covered in Chapter 5 and 6 of this thesis. 
3.2.2 Tandem MS (MS/MS) fragmentation ratios 
While DAACPs and their all-LAACP counterpart have the same mass, they may be distinguished 
using their MS/MS fragmentation. Since the peptides are diastereomers, they may have differing 
preferential fragmentation of certain bonds, which is reflected in different fragment ion ratios between the 
peptides. In the case of peptides, this fragmentation is enhanced through the use certain chiral selectors. 
The ability of the peptide to complex with the selector versus the ability of a reference compound to bind 
to the selector can distinguish peptide diastereomers, a technique known as the kinetic method. The 
reasoning behind how this method works is intuitive: DAACPs and their all-L counterparts have different 
three-dimensional shapes; thus, like with the stationary phase of an LC column, they will have complex 
differences in the forces of interaction with the chiral selector. The weaker the interaction with the chiral 
selector, the lower the observed peak for the resulting selector + peptide fragment. 
CuCl2 was first used to distinguish L- and DAAs.32 Thus, it was then used by Tao and Cooks in 
2001 for peptide purposes. CuCl2 was used as a chiral selector for L/D sets of several dipeptides, 
including Ala-Gly, Gly-Ala, Ala-Ala, Ala-Leu, Leu-Ala, and Ala-Phe.33 Electrospray ionization (ESI) was 
used with collision-induced dissociation (CID) for MS/MS fragmentation. The extent to which the 
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discrimination is achieved between a DAACP and its all-LAA counterpart is expressed as Rchiral, with 
larger numbers (greater than 1) indicated a higher degree of discrimination. These initial studies used 
short peptides with simple, alkyl side chains as a proof of concept. Another set of peptides was studied 
using the kinetic method, L/D stereoisomers of Ser-His-OMe.34 This peptide was chosen not only because 
the His side chain known for metal-chelating properties, but also for the peptide’s ability to cleave DNA. 
This peptide was studied with CuCl2, ESI, and CID, as in the previous study. By establishing a calibration 
curve with different ratios of L/D peptides, they were able to determine the chiral composition of an 
unknown analyte. Interestingly, replacing the copper with calcium yielded no chiral discrimination, 
demonstration the importance of Cu(II) in the formation of complexes leading to differential 
fragmentation. Cu(II) is not the only adduct that has aided in chiral discrimination. To study the steric 
properties of Pro-containing peptides, ESI and CID were used to discriminate Boc-L-Pro-L-Pro-OEt and 
Boc-D-Pro-L-Pro-OEt; the discriminating ions formed complexes with sodium as an adduct.35 Co(II) 
adducts were used in ESI/CID  studies of GLSFA peptide with DAAs substituted at each chiral position, 
leading to chiral discrimination; interestingly, Mn(II) was unable to aid in chiral discrimination in this 
study.36 Also in this study, a tryptic fragment of amyloid β-protein was studied for chiral discrimination 
using Co(II) adducts with our without a D-Asp in seventh position from the N-terminus. Cu(II) and Fe(II) 
complexes were also used to discriminate the stereoisomers YAGFL, YdAGFL, and YdAGFdL also using 
ESI and CID.37 
The technique of using discriminative MS/MS fragmentation for chiral analysis has also used 
electron capture dissociation (ECD) as a fragmentation method. The purpose of using ECD instead of 
CID is that it carries several advantages for some structure elucidation. For example, bonds which also 
participate in neutral hydrogen bonding are less likely to be cleaved and produce fragments, so 
intramolecular bonding can be preserved within the fragment ions.38 Using this analysis, +2 and +3 
charged ions of the Trp-cage peptide were subjected to a chiral analysis, distinguishing the ECD 
fragments of these peptides with a single D-Trp substitution.39 The Trp-cage peptide was chosen because 
it was known to rapidly and spontaneously form a rigid tertiary structure in solution.40 Importantly, no 
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chiral selector was necessary for this study. As a follow up, a similar study used both CID and ECD for 
the chiral discrimination of Trp-cage peptide as well as L/D-Asp isomers of the lactoferrin (406-423) 
peptide and L/D-Ala isomers of dermorphin.41 In these studies, higher temperatures, which tend to lead to 
protein unfolding and loss of tertiary structure, diminished the degree to which isomers could be 
discriminated (evidenced by a lower Rchiral or Rchiral being equal to 1). Interestingly, since ECD and a 
related fragmentation method, electron transfer dissociation (ETD), cleave at different bonds than CID, 
the resulting fragments can be used for isoAsp (also known as β-L/D-Asp) because the position of the 
isoAsp will give characteristic c+58 or z-57 ions.42 This was demonstrated with a synthetic amyloid β 
peptide as well as a synthetic angiotensin II peptide, both synthesized to contain an N-terminal isoAsp.43 
This method was then applied to identifying isoAsp residues identified in longer synthetic peptides like 
Aβ1-42 and other Aβ peptides using ECD.44 
An attractive application of this method is using matrix-assisted laser desorption/ionization 
(MALDI) MS. The fragmentation that has been used with MALDI in this application is called time of 
flight/time of flight (TOF/TOF), which does not actually indicate the fragment mode. The first studies to 
use MALDI-TOF/TOF analyzed several peptides using CID and metastable decomposition.45 They were 
capable of achieving chiral discrimination of all-LAA/DAACP for N-acetyl dermorphin in both 
fragmentation methods, but not dermorphin. When they studied peptides with DAAs in the second 
through fifth position of the N-terminal heptapeptide of vitellogenesis inhibiting hormone (VIH), all but 
the second position DAACP could be chirally discriminated from the all-LAACP. In general, CID gave 
more reproducible data than metastable decomposition. When the N-terminal decapeptide of VIH was 
studied with or without the D-Trp in the fourth position, they found that both peptides could be chirally 
discriminated, with the most discriminative fragments coming from fragments that contained the fourth 
position Trp. This indicates the importance of the isomerized position in the ability to use fragmentation 
as a method for characterizing and discovering DAACPs. MALDI-TOF/TOF was also used to study 
several molluskan neuropeptide DAACPs, including N(l/d)WFa, Y(l/d)AEFLa, G(l/d)FFD, F(l/d)MRFa 
(using a cobalt adduct), and G(l/d)FAD (using a sodium adduct) using standards and neurons from 
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Aplysia californica.46 CID was used for fragmentation of peptides. By constructing a calibration curve, 
neurons from A. californica that express NdWFa could be quantified for NdWFa amount, which was 
found to be 89.5 ± 9.6%, thus indicating that the majority of the peptide in these neurons are in the 
DAACP form. (Fig. 3.3) As a follow up, this technique was applied to A. californica neurons expressing 
the achatin-like prohormone for the discovery of GdFFD.47 More recently, this technique was used for the 
discovery of a new DAACP in the frog Bombina orientalis, GH-2.48 A D-Leu was confirmed in the 
second position of the peptide by comparing the endogenous peptide fragment ions with synthetic 
standards. Quantification of fragment ion intensities was rendered more reproducible through the use of 
deuterated standards. 
LC-MS/MS remains as a preferred tool for non-targeted peptidomics. As such, some methods 
attempt to keep the LC component while taking advantage of differential fragmentation using MS/MS. An 
adaptation of this fragmentation analysis has recently been used, known as radical-directed dissociation 
(RDD) MS.49 RDD uses peptides labeled with photolabile chromophores. In this case, three 
chromophores were used: 4-iodobenzoic acid for labeling of amines, installation of iodine on tyrosine 
residues, and a modified 18-crown-6-ether for amines. These chromophores generate peptide radicals, a 
reaction that is very sensitive to the chirality of the residue undergoing the radical reaction.50 These 
peptides are fragmented using ECD. For the peptides studied, the chiral discrimination (RChiral) was better 
between DAACPs and all-L-peptides using RDD regardless of the position of the residue or the type of 
residue studied. Peptides containing D-Ser, D-Asp, and D-Ala were chosen for their prevalence in 
spontaneously forming DAAs in lens crystalline proteins. This method was then applied in a peptidomics 
experiment of tryptic digests of lens proteins, using the photolabile tag iodoacetamide.51 9 peptides from 
αA crystalline protein, 5 peptides from αB crystalline protein, and 6 peptides from βB3 crystallin protein 
were seen to contain D-Asp or D-Ser residues. 
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3.2.3 Ion mobility spectrometry 
Ion mobility spectrometry (IMS) separates ionized analytes based on their ability to migrate 
through a drift tube filled with a buffer gas. Peptide stereoisomers may migrate differently using this 
technique due to differential interactions with the carrier gas. DAACPs and their all-L-counterparts can 
have different migrations times, demonstrated by comparing the migrations times of YAGFL, YdAGFL, 
and YdAGFdL.52 IMS was also used to characterize phenylseptin by comparing the migration times of the 
DAACP and its all-L-counterpart.53 In addition, IMS can be interfaced with a mass spectrometer such that 
MS/MS fragments will also enter the drift tube, to see if fragments migrate differently.54 In fact, the drift 
times of these fragments can determine the position of the isomerized residue. G(l/d)FAD were analyzed 
with this technique. The dFAD and FAD fragments from these peptides migrated differently while the AD 
fragments of both peptides had the same migration time, indicating that the DAA contributes to the shift 
in migration time, similar to the whole peptides seen in the previous studies. (Fig. 3.4) The same effect 
was demonstrated with Y(l/d)AFDVVGa and YVMGHFR(l/d)WDRFG. This technique was then applied 
to tryptic fragments of crustacean hyperglycemic hormone (CHH), focusing on the N-terminal 
pQV(l/d)FDQACK. The fragments were demonstrated to have different drift times (if they contained the 
D-Phe), and this result could be replicated in endogenous CHH peptides from Homarus americanus. 
3.2.4 Enzymatic assays 
When dermorphin was first discovered, the concept of endogenous DAACPs in animals was not yet 
appreciated. Thus, for higher quality identification of a DAA in a peptide, amino acid analysis needed a 
complimentary technique. Luckily, an enzyme, DAA oxidase, selectively degrades DAAs over LAAs. 
This enzyme was used in the discovery of dermorphin and deltorphins as DAACPs. For the deltorphins, 
using an acid hydrolysis-based assay as described above, the amino acid content of YdAFEVVG and 
YdAFDVVG was probed. The disappearance of a putative D-Ala peak demonstrated that these peptides 
did, in fact, exist as DAACPs in Phyllomedusa. 
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Interestingly, a DAA-specific aminopeptidase was isolated from the bacterium Ochrobactrum 
anthropi that had a high preference for D-Ala residues.55 The peptidase had high activity toward D-Ala-
amide and tripeptide and tetrapeptide repeats of Ala, so long as a D-Ala was in the N-terminus. However, 
when other residues were substituted in the second position from the N-terminus, even with an Ala at the 
N-terminus, the activity dropped significantly. Given that DAACPs have been found with DAAs near the 
N-terminus, it is interesting to speculate that this enzyme could perhaps be selectively evolved to have 
more broad activity toward DAAs in peptides. 
Another enzyme exhibits the opposite activity of the DAA-specific aminopeptidase. This enzyme, 
Aminopeptidase M (APM) has a much higher selectivity of LAAs over DAAs, such that DAACPs with 
DAAs near their N-terminus are degraded much more slowly than peptides composed only of LAAs.56 
This was demonstrated with NdWFa, YdAEFLa, and the all-LAA peptide angiotensin I. (Fig. 3.5) 
Angiotensin I was rapidly degraded within 6 h, YdaEFLa within 24 h, and NdWFa was not degraded at 
all in 24 h. When this enzyme was used in Aplysia californica neuropeptide extracts, observed all-LAA 
peptides were degraded whereas spiked NdWFa remains. Some other peptides were seen to resist 
degradation, but these were noted to contain Pro and N-terminal pyroglutamylation (pGlu). As Pro and 
pGlu cyclize onto the peptide backbone, this is expected to resist APM’s activity as it is presumed the 
enzyme acts on the backbone. For a follow up study using this enzyme, see Chapters 5, 6, and 7 of this 
thesis, which utilizes APM digestions for untargeted analysis of neuropeptides from several rodent 
nervous system and Aplysia nervous system structures. 
 Enzymatic digestions have also been used in a large-scale, non-targeted manner for the detection 
of spontaneously forming DAACPs, focusing on Asp. They rely on a set of endopeptidases: Asp-N which 
degrades Lα-Asp,57 Protein L-isoaspartyl methyltransferase (PIMT) which degrades Lβ-Asp,58 and 
Paenidase which degrades Dα-Asp.59 Dβ-Asp is then presumed to be present in any Asp-containing 
peptide which is not degraded by those three peptidases. (Fig. 3.6) One study used only Asp-N on peptide 
standards and detected isoAsp with the ECD/ETD method discussed above. By digesting the Lα-Asp, 
they enriched the peptides that could detect isoAsp through the peptides’ ECD/ETD profile. All three 
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enzymes were applied to tryptic peptides of lens crystallin proteins from elderly donors, which identified 
many sites of Asp isomerization.20 (Fig. 3.6) 
3.3 Conclusions and future directions 
Although MS cannot easily detect DAACPs, many strategies are currently being used and 
developed to detect DAACPs in a complex mixture of peptides, often utilizing MS in some form. By 
targeting the most common isomers of Asp, enzymatic and MS/MS-based techniques have been detecting 
DAAs in aging proteins with unprecedented positional precision. The MS/MS approaches, particularly 
through deuterium-assisted acid hydrolysis and RDD, have been able to target aging proteins containing 
non-Asp DAAs, like D-Ser, D-Ala, D-Glu, and D-Pro. Studying endogenous DAACPs has also taken 
advantage of some of these techniques. To overcome the traditional problems with acid hydrolysis-
induced racemization, MS/MS and IMS-based detection and characterization of endogenous DAACPs has 
been developed and has lead to the discovery of several new DAACPs, including VIH in arthropods and 
GH-2 and phenylseptin in frogs. With the obvious advantages of rapid and sensitive detection, the future 
development of these techniques should focus on non-targeted detection by not requiring a priori 
information that necessitates standards for all peptides studied. 
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3.4 Figures 
 
 
Figure 3.1. Spontaneous racemization of L-Asp in a peptide can form D-Asp or L/D-isoAsp. The spontaneous racemization 
of L-Asp is higher than other naturally occurring amino acids in peptides. This racemization is potentiated by cyclization of L-
Asp into L/D-succinimide. Adapted from Roher et al.28 
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Figure 3.2. Workflow of acid hydrolysis. An intact peptide is broken down into its component amino acids through the  
combination of heat and acidic conditions. These amino acids can then be separated and detected. While peptide sequences may 
come in many forms with many subtly different properties, individual amino acids have 38 common forms of the chiral amino 
acids and Gly. 
Amino Acid Detection 
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Figure 3.3. An example of using MS/MS fragmentation to distinguish DAACPs and their all-LAA counterparts. This 
example studies N(l/d)WFa in Aplysia californica neurons using MALDI-TOF/TOF with CID. In A, this is the fragmentation 
profile of endogenous N(l/d)WFa from two sets of neurons. In B, the above profile is of NdWFa standard compared to the bottom 
profile, NWFa standard. The endogenous peptides’ profiles more closely matches that of NdWFa, especially when looking at the 
ratio of the b3/b2 ions, confirming the endogenous peptide is present in the majority as NdWFa. Adapted from Bai et al.46 
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Figure 3.4. An example of differentiating GdFAD and GFAD using IMS. Peptides are first fragmented using MS/MS, and 
these MS/MS fragments are subject to IMS. dFAD and FAD fragments have different drift times, 4.63 ms and 4.55 ms, 
respectively. AD fragments from both peptides, which contain no DAAs, arrive at the same time, 2.79 ms. In this way, IMS can 
differentiate DAACPs from their all-LAA counterparts, and the position of the DAA can be localized. Adapted from Jia et al.54 
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Figure 3.5. APM is capable of digesting all-LAA peptides more rapidly than DAACPs. Intensities are measured based on a 
MALDI-TOF MS. Angiontensin I, a known all-LAA peptide, is rapidly degraded. YdAEFLa, a known DAACP, is more slowly 
degraded. NdWFa did not degrade at all within 24 h. Adapted from Ewing et al.56 
 
 
 
Figure 3.6. A non-targeted, enzymatic approach to identifying the four Asp isomers found in aging proteins. Any Asp-
containing peptide which is not degraded by the three enzymes is assumed to be a Dβ-Asp. Adapted from Fuji et al.20 
 54 
 
3.5 References 
1. Montecucchi, P. C., Castiglione, R., Piani, S., Gozzini, L., and Espramer, V. (1981) Amino acid 
composition and sequence of dermoprhin, a novel opiate-like peptide from the skin of Phyllomedusa 
sauvagei, International journal of peptide and protein research 17, 275-283. 
2. A. M. Torres, M. T., C. Tsampazi, E. C. Kennett, K. Belov, D. P. Geraghty, P. S. Bansal, P. F. Alewood, P. 
W. Kuchel. (2006) Mammalian L-to-D-amino-acid-residue isomerase from platypus venom, Febs Letters 
580, 1587-1591. 
3. Jilek, A., Mollay, C., Tippelt, C., Grassi, J., Mignogna, G., Müllegger, J., Sander, V., Fehrer, C., Barra, D., 
and Kreil, G. (2005) Biosynthesis of a D-amino acid in peptide linkage by an enzyme from frog skin 
secretions, Proceedings of the National Academy of Sciences of the United States of America 102, 4235-
4239. 
4. S. D. Heck, W. S. F., P. R. Kelbaugh, N. A. Saccomano, P. F. Thadeio, R. A. Volkmann. (1996) 
Posttranslational amino acid epimerization: Enzyme-catalyzed isomerization of amino acid residues in 
peptide chains, PNAS 93, 4036-4039. 
5. A. Jilek, C. M., K. Lohner, G. Kreil. (2011) Substrate specificty of a peptidyl-aminoacyl-L/D-isomerase 
from frog skin, Amino Acids, DOI: 10.1007/s00726-00011-00890-00726. 
6. V. Gehmayr, C. M., L. Reith, N. Muller, A. Jilek. (2011) Tight Binding of Transition-State Analogues to a 
Peptidyl-Aminoacyl-L/D-Isomerase from Frog Skin, ChemBioChem 12, 1996-2000. 
7. Y. Shikata, T. W., T. Teramoto, A. Inoue, Y. Kawakami, Y. Nishizawa, K. Katayama, M. Kuwada. (1995) 
Isolation and Characterization of a Peptide Isomerase from Funnel-Web Spider Venom, Journal of 
Biological Chemistry 270, 16719-16723. 
8. Kamatani, Y., Minakata, H., Kenny, P. T. M., Iwashita, T., Watanabe, K., Funase, K., Sun, X. P., Yongsiri, 
A., Kim, K. H., Novalesli, P., Novales, E. T., Kanapi, C. G., Takeuchi, H., and Nomoto, K. (1989) Achatin-
I, an endogenous neuroexcitatory tetrapeptide from Achatina fulica Férussac containing a D-amino acid 
residue., Biochemical and Biophysical Research Communications 160, 1015-1020. 
9. F. Morishita, Y. N., S. Kaku, Y. Furukawa, S. Ohta, T. Hirata, M. Ohtani, Y. Fujisawa, Y. Muneoka, O. 
Matsushima. (1997) A novel D-amino-acid-containing peptide isolated from Aplysia heart, Biochemical 
and Biophysical Research Communications 240, 354-358. 
10. E. Iwakoshi, M. H., H. Minakata. (2000) Cardioactive peptides isolated from the brain of a Japanese 
octopus, Octopus minor, Peptides 21, 623-630. 
11. N. Ohta, I. K., T. Takao, Y. Shimonishi, Y. Yasudakamatani, H. Minakata, K. Nomoto, Y. Muneoka, M. 
 55 
 
Kobayashi. (1991) Fulicin, a novel neuropeptide containing a D-amino-acid residue isolated from the 
ganglia of Achatina fulica, Biochem Biophys Res Commun 178, 486-493. 
12. Y. Yasuda-Kamatani, M. K., A. Yasuda, T. Fujita, H. Minakata, K. Nomoto, M. Nakamura, F. Sakiyam. 
(1997) A novel D-amino acid-containing peptide, fulyal, coexists with fulicin gene-related peptides in 
Achatina atria, Peptides 18, 347-354. 
13. Y. Fujisawa, T. I., K. Nomoto, Y. Yasuda-Kamatani, H. Minakata, P. T. M. Kenny, I. Kubota, Y. Muneoka. 
(1992) The FMRFamide-related decapeptide of Mytilus contains a D-amino acid residue, Comp. Biochem. 
Physiol. 1, 91-95. 
14. Bai, L., Livnat, I., Romanova, E. V., Alexeeva, V., Yau, P. M., Vilim, F. S., Weiss, K. R., Jing, J., and 
Sweedler, J. V. (2013) Characterization of GdFFD, a d-Amino Acid-containing Neuropeptide That 
Functions as an Extrinsic Modulator of the Aplysia Feeding Circuit, Journal of Biological Chemistry 288, 
32837-32851. 
15. Battersby, A. R., and Robinson, J. (1955) Studies on specific chemical fission of peptide links. Part I. The 
rearrangement of aspartyl and glutamyl peptides, Journal of the Chemical Society (Resumed), 259-269. 
16. Helfman, P. M., and Bada, J. L. (1975) Aspartic acid racemization in tooth enamel from living humans, 
Proceedings of the National Academy of Sciences 72, 2891-2894. 
17. Man, E. H., Sandhouse, M. E., Burg, J., and Fisher, G. H. (1983) Accumulation of D-aspartic acid with age 
in the human brain, Science 220, 1407-1408. 
18. Bada, J. L., and Helfman, P. M. (1975) Amino acid racemization dating of fossil bones, World Archaeology 
7, 160-173. 
19. Fujii, N., Takata, T., Fujii, N., and Aki, K. (2016) Isomerization of aspartyl residues in crystallins and its 
influence upon cataract, Biochimica et Biophysica Acta (BBA) - General Subjects 1860, 183-191. 
20. Fujii, N., Takata, T., and Fujii, N. (2015) Quantitative analysis of isomeric (l-α-, l-β-, d-α-, d-β-) aspartyl 
residues in proteins from elderly donors, Journal of Pharmaceutical and Biomedical Analysis 116, 25-33. 
21. Wan, H., and Blomberg, L. G. (2000) Chiral separation of amino acids and peptides by capillary 
electrophoresis, Journal of Chromatography A 875, 43-88. 
22. Barra, D., Mignogna, G., Simmaco, M., Pucci, P., Severini, C., Falconieri-Erspamer, G., Negri, L., and 
Erspamer, V. (1994) [d-Leu2]Deltorphin, a 17 amino acid opioid peptide from the skin of the Brazilian 
hylid frog, Phyllomedusa burmeisteri, Peptides 15, 199-202. 
23. Scaloni, A., Simmaco, M., and Bossa, F. (1991) Determination of the chirality of amino acid residues in the 
course of subtractive Edman degradation of peptides, Analytical biochemistry 197, 305-310. 
24. Mignogna, G., Simmaco, M., Kreil, G., and Barra, D. (1993) Antibacterial and haemolytic peptides 
 56 
 
containing D-alloisoleucine from the skin of Bombina variegata, The EMBO Journal 12, 4829-4832. 
25. Masters, P. M., Bada, J. L., and Zigler, J. S. (1978) Aspartic acid racemization in heavy molecular weight 
crystallins and water insoluble protein from normal human lenses and cataracts, Proceedings of the 
National Academy of Sciences 75, 1204-1208. 
26. Bada, J. L. (1984) [9] In Vivo racemization in mammalian proteins, In Methods in Enzymology, pp 98-115, 
Academic Press. 
27. Shapira, R., Austin, G. E., and Mirra, S. S. (1988) Neuritic plaque amyloid in Alzheimer's disease is highly 
racemized, Journal of neurochemistry 50, 69-74. 
28. Roher, A., Lowenson, J., Clarke, S., Wolkow, C., Wang, R., Cotter, R., Reardon, I., Zürcher-Neely, H., 
Heinrikson, R., and Ball, M. (1993) Structural alterations in the peptide backbone of beta-amyloid core 
protein may account for its deposition and stability in Alzheimer's disease, Journal of Biological Chemistry 
268, 3072-3083. 
29. Kenessey, A., Yen, S.-H., Liu, W.-K., Yang, X.-R., and Dunlop, D. S. (1995) Detection of D-aspartate in tau 
proteins associated with Alzheimer paired helical filaments, Brain research 675, 183-189. 
30. Ishigo, S., Negishi, E., Miyoshi, Y., Onigahara, H., Mita, M., Miyamoto, T., Masaki, H., Homma, H., Ueda, 
T., and Hamase, K. (2015) Establishment of a Two-Dimensional HPLC-MS/MS Method Combined with 
DCl/D2O Hydrolysis for the Determination of Trace Amounts of D-Amino Acid Residues in Proteins, 
CHROMATOGRAPHY advpub. 
31. Miyamoto, T., Takahashi, N., Sekine, M., Ogawa, T., Hidaka, M., Homma, H., and Masaki, H. (2015) 
Transition of serine residues to the d-form during the conversion of ovalbumin into heat stable S-
ovalbumin, Journal of Pharmaceutical and Biomedical Analysis 116, 145-149. 
32. Tao, W. A., Zhang, D., Wang, F., Thomas, P. D., and Cooks, R. G. (1999) Kinetic Resolution of d,l-Amino 
Acids Based on Gas-Phase Dissociation of Copper(II) Complexes, Analytical Chemistry 71, 4427-4429. 
33. Tao, W. A., and Cooks, R. G. (2001) Parallel Reactions for Enantiomeric Quantification of Peptides by 
Mass Spectrometry, Angewandte Chemie International Edition 40, 757-760. 
34. Chen, J., Zhu, C.-J., Chen, Y., and Zhao, Y.-F. (2002) Enantiomeric quantification of the bioactive peptide 
seryl-histidine methyl ester by electrospray ionization mass spectrometry and the kinetic method, Rapid 
Communications in Mass Spectrometry 16, 1251-1253. 
35. Tsunematsu, H., Ikeda, H., Hanazono, H., Inagaki, M., Isobe, R., Higuchi, R., Goto, Y., and Yamamoto, M. 
(2003) Differentiation of a pair of diastereomeric tertiarybutoxycarbonylprolylproline ethyl esters by 
collision‐induced dissociation of sodium adduct ions in electrospray ionization mass spectrometry and 
evidence for chiral recognition by ab initio molecular orbital calculations, Journal of mass spectrometry 38, 
 57 
 
188-195. 
36. Serafin, S. V., Maranan, R., Zhang, K., and Morton, T. H. (2005) Mass Spectrometric Differentiation of 
Linear Peptides Composed of l-Amino Acids from Isomers Containing One d-Amino Acid Residue, 
Analytical Chemistry 77, 5480-5487. 
37. Lagarrigue, M., Bossée, A., Afonso, C., Fournier, F., Bellier, B., and Tabet, J. C. (2006) Diastereomeric 
differentiation of peptides with CuII and FeII complexation in an ion trap mass spectrometer, Journal of 
mass spectrometry 41, 1073-1085. 
38. Haselmann, K. F., Jørgensen, T. J. D., Budnik, B. A., Jensen, F., and Zubarev, R. A. (2002) Electron capture 
dissociation of weakly bound polypeptide polycationic complexes, Rapid Communications in Mass 
Spectrometry 16, 2260-2265. 
39. Adams, C. M., Kjeldsen, F., Zubarev, R. A., Budnik, B. A., and Haselmann, K. F. (2004) Electron capture 
dissociation distinguishes a single d-amino acid in a protein and probes the tertiary structure, Journal of the 
American Society for Mass Spectrometry 15, 1087-1098. 
40. Neidigh, J. W., Fesinmeyer, R. M., and Andersen, N. H. (2002) Designing a 20-residue protein, Nature 
Structural & Molecular Biology 9, 425-430. 
41. Adams, C. M., and Zubarev, R. A. (2005) Distinguishing and Quantifying Peptides and Proteins Containing 
d-Amino Acids by Tandem Mass Spectrometry, Analytical Chemistry 77, 4571-4580. 
42. Yang, H., Fung, E. Y. M., Zubarev, A. R., and Zubarev, R. A. (2009) Toward Proteome-Scale Identification 
and Quantification of Isoaspartyl Residues in Biological Samples, Journal of Proteome Research 8, 4615-
4621. 
43. Sargaeva, N. P., Lin, C., and O’Connor, P. B. (2011) Differentiating N-Terminal Aspartic and Isoaspartic 
Acid Residues in Peptides, Analytical Chemistry 83, 6675-6682. 
44. Sargaeva, N. P., Lin, C., and O’Connor, P. B. (2009) Identification of Aspartic and Isoaspartic Acid 
Residues in Amyloid β Peptides, Including Aβ1−42, Using Electron−Ion Reactions, Analytical Chemistry 
81, 9778-9786. 
45. Sachon, E., Clodic, G., Galanth, C., Amiche, M., Ollivaux, C., Soyez, D., and Bolbach, G. (2009) d-Amino 
Acid Detection in Peptides by MALDI-TOF-TOF, Analytical Chemistry 81, 4389-4396. 
46. Bai, L., Romanova, E. V., and Sweedler, J. V. (2011) Distinguishing endogenous D-amino acid-containing 
neuropeptides in individual neurons using tandem mass spectrometry, Analytical Chemistry 83, 2794-2800. 
47. Bai, L., Livnat, I., Romanova, E. V., Alexeeva, V., Yau, P. M., Vilim, F. S., Weiss, K. R., Jing, J., and 
Sweedler, J. V. (2013) Characterization of GdFFD, a D-amino acid-containing neuropeptide that functions 
as an extrinsic modulator of the Aplysia feeding circuit, Journal of Biological Chemistry 288, 32837-
 58 
 
32851. 
48. Koehbach, J., Gruber, C. W., Becker, C., Kreil, D. P., and Jilek, A. (2016) MALDI TOF/TOF-Based 
Approach for the Identification of d- Amino Acids in Biologically Active Peptides and Proteins, Journal of 
Proteome Research 15, 1487-1496. 
49. Tao, Y., Quebbemann, N. R., and Julian, R. R. (2012) Discriminating d-Amino Acid-Containing Peptide 
Epimers by Radical-Directed Dissociation Mass Spectrometry, Analytical Chemistry 84, 6814-6820. 
50. Moore, B. N., Blanksby, S. J., and Julian, R. R. (2009) Ion-molecule reactions reveal facile radical 
migration in peptides, Chemical Communications, 5015-5017. 
51. Tao, Y., and Julian, R. R. (2014) Identification of Amino Acid Epimerization and Isomerization in 
Crystallin Proteins by Tandem LC-MS, Analytical Chemistry 86, 9733-9741. 
52. Wu, C., Siems, W. F., Klasmeier, J., and Hill, H. H. (2000) Separation of Isomeric Peptides Using 
Electrospray Ionization/High-Resolution Ion Mobility Spectrometry, Analytical Chemistry 72, 391-395. 
53. de Magalhães, M. T. Q., Barbosa, E. A., Prates, M. V., Verly, R. M., Munhoz, V. H. O., de Araújo, I. E., and 
Bloch, C. (2013) Conformational and Functional Effects Induced by D- and L-Amino Acid Epimerization 
on a Single Gene Encoded Peptide from the Skin Secretion of Hypsiboas punctatus, PLoS ONE 8, e59255. 
54. Jia, C., Lietz, C. B., Yu, Q., and Li, L. (2014) Site-Specific Characterization of d-Amino Acid Containing 
Peptide Epimers by Ion Mobility Spectrometry, Analytical Chemistry 86, 2972-2981. 
55. Asano, Y., Nakazawa, A., Kato, Y., and Kondo, K. (1989) Properties of a novel D-stereospecific 
aminopeptidase from Ochrobactrum anthropi, Journal of Biological Chemistry 264, 14233-14239. 
56. Ewing, M. A., Wang, J., Sheeley, S. A., and Sweedler, J. V. (2008) Detecting D-amino acid-containing 
neuropeptides using selective enzymatic digestion, Analytical Chemistry 80, 2874-2880. 
57. Ingrosso, D., Fowler, A. V., Bleibaum, J., and Clarke, S. (1989) Specificity of endoproteinase Asp-N 
(Pseudomonas fragi): Cleavage at glutamyl residues in two proteins, Biochemical and Biophysical 
Research Communications 162, 1528-1534. 
58. Kim, E., Lowenson, J. D., MacLaren, D. C., Clarke, S., and Young, S. G. (1997) Deficiency of a protein-
repair enzyme results in the accumulation of altered proteins, retardation of growth, and fatal seizures 
in mice, Proceedings of the National Academy of Sciences 94, 6132-6137. 
59. Takahashi, S., Ogasawara, H., Hiwatashi, K., Hori, K., Hata, K., Tachibana, T., Itoh, Y., and Sugiyama, T. 
(2006) Paenidase, a Novel d-Aspartyl Endopeptidase from Paenibacillus sp. B38: Purification and 
Substrate Specificity, Journal of Biochemistry 139, 197-202. 
 59 
 
CHAPTER 4  
 
CHARACTERIZATION OF G(D)FFD, A D-AMINO 
ACID-CONTAINING NEUROPEPTIDE THAT 
FUNCTIONS AS AN EXTRINSIC MODULATOR OF 
THE APLYSIA FEEDING CIRCUIT 
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peptides on the pedal ganglia. The work is represented in the Results section: Effects of GFFD and 
GdFFD in the isolated pedal neurons of Aplysia and Fig. 4.9 and 4.10. 
4.2 Abstract 
During eukaryotic translation, peptides/proteins are created using L-amino acids. However, a D-
amino acid-containing peptide (DAACP) can be produced through post-translational modification (PTM) 
via an isomerase enzyme. General approaches to identify novel DAACPs and investigate their function, 
particularly in specific neural circuits, are lacking. This is primarily due to the difficulty in characterizing 
this modification and because of the limited information on neural circuits in most species. We describe a 
multipronged approach to overcome these limitations using the sea slug Aplysia californica. Based on 
bioinformatics and homology to known DAACPs in the land snail Achatina fulica, we targeted two 
predicted peptides in Aplysia, GFFD, similar to achatin-I (GdFAD vs. GFAD, where dF stands for D-
Phenylalanine), and YAEFLa, identical to fulyal (YdAEFLa vs. YAEFLa), using stereoselective analytical 
methods: MALDI MS fragmentation analysis and LC-MS/MS. Although YAEFLa in Aplysia was 
detected only in an all L-form, we found that both GFFD and GdFFD were present in the Aplysia CNS. In 
situ hybridization and immunolabeling of GFFD/GdFFD-positive neurons and fibers suggested that 
GFFD/GdFFD might act as an extrinsic modulator of the feeding circuit. Consistent with this hypothesis, 
we found that GdFFD induced robust activity in the feeding circuit and elicited egestive motor patterns. 
In contrast, the peptide consisting of all L-amino acids, GFFD, was not bioactive. Our data indicate that 
the modification of an L-amino acid-containing neuropeptide to a DAACP is essential for peptide 
bioactivity in a motor circuit, and thus provides a functional significance to this modification. 
4.3 Introduction 
Many peptides, particularly neuropeptides, undergo post-translational modification (PTM). An 
unusual PTM that is gaining increasing attention is the generation of D-amino acid-containing peptides 
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(DAACPs) in animals1. Since the isolation of the first animal peptide having a D-isomerization of an 
amino acid, the highly analgesic dermorphin from the skin of the South American frog Phyllomedusa,2,3 
more than 30 bioactive DAACPs (including hormones and antimicrobial peptides) have been discovered 
in frogs,2,4-8 mollusks,9-24 crustaceans,25,26 spiders,27,28 and even mammals.29,30  
DAACPs in animals, usually having one residue in the D-amino acid form, appear to be derived 
through a PTM because the D-residue is encoded by a normal codon for the corresponding L-amino acid. 
Importantly, peptide isomerases that convert an L-amino acid to a D-amino acid have been characterized 
in spider, frog, and platypus31-33. DAACPs are particularly interesting because most studies to date have 
shown that they are functionally important; compared to the all L-amino acid epimer, the D-amino acid-
containing epimer confers distinct and, at times, dramatically enhanced receptor binding affinity.2,6 
Despite the progress in DAACP analysis, multiple unresolved issues remain. First, although it is 
hypothesized that more DAACPs might exist in animals, they are rarely investigated, perhaps because of 
a lack of approaches to characterize this PTM in an untargeted, high throughput manner. Moreover, 
methods that are compatible with small quantities of tissue samples are desirable as neuropeptide studies 
oftentimes are sample limited. Second, although DAACPs have been shown to be more bioactive in the 
CNS in several animals,1,34 it is not known how D-amino acid-containing neuropeptides might ultimately 
act on a specific neural circuit to affect network output and behavior. In fact, to the best of our knowledge, 
no studies have examined the effects of DAACPs on a defined neural circuit, likely due to the limited 
information on well-defined neural circuits in most species. Here, we describe approaches to overcome 
these two limitations using a well-known model animal, the sea slug Aplysia californica.35-37 
Like other PTMs, identification of DAACPs requires the use of biochemical and/or analytical 
chemical methods.1 However, this PTM is challenging to detect as it does not change the elemental 
composition, molecular formula, or even the mass of the peptide. Diastereomer separation techniques 
such as chromatography and capillary electrophoresis have been developed using synthetic peptides and 
used reliably to confirm the presence of DAACPs in various samples.1 Recently, we showed that the 
fragmentation pattern generated during MS/MS sequencing can be useful for distinguishing neuropeptide 
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epimers in identified neurons known to express candidate DAACP prohormones.38 Here, we combined 
MS/MS with off-line multidimensional chromatographic separations to create a screening assay for 
potential endogenous DAACPs in small-volume tissue extracts. To identify candidate DAACPs, we 
applied bioinformatics as a data mining technique to identify peptides from Aplysia that are similar to 
known DAACPs; Aplysia is well suited as the model because of the large amount of genomic information 
available for this animal from the RNAseq transcriptome assembly (http://www.aplysiagenetools.org/), 
the Broad Institute Genomic Database (http://www.broadinstitute.org/scientiﬁc-community/data), and 
others.35,39,40 
Based on the results of our data mining, we targeted two putative neuropeptides in Aplysia,35 
GFFD and YAEFLamide (YAEFLa), which are structurally similar to two known DAACPs in the land 
snail Achatina fulica: achatin-I (GdFAD vs. GFAD)9 and fulyal (YdAEFLa vs. YAEFLa), respectively.24 
In fact, achatin-I is the first putative neuropeptide to be identified as a DAACP 9. Here, we demonstrate 
that GFFD in Aplysia has a DAACP epimer, GdFFD, similar to achatin-I in Achatina. In contrast, and to 
our surprise, we found the YAEFLa in the Aplysia CNS exits predominantly in the all L-form 
conformation, as the DAACP epimer was not detected in any ganglion in Aplysia. The lack of YdAEFLa 
and the presence of GdFFD may have implications for the evolution of peptide functions, and 
demonstrates that sequence similarity is not enough to conclude that the PTM present in the peptide from 
one species is also present in another. We then examined the bioactivity of GFFD/GdFFD in the well-
described Aplysia feeding circuit.41-48 We found that only GdFFD is bioactive and moreover, that it 
functions as an extrinsic modulator of the feeding circuit. 
4.4 Methods 
Animals 
Aplysia californica (120–170 g) were purchased from the University of Miami/NIH National 
Resource for Aplysia or Marinus Scientific, and kept in an aquarium containing aerated and filtered 
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artificial seawater (Instant Ocean, Aquarium Systems Inc.) at ~14 °C until used. Prior to dissection, 
animals were anesthetized by injection of isotonic MgCl2 (30 to 50% of body weight) into the body 
cavity. 
Materials 
Chemicals and reagents: Water was purified from a Milli-Q system (Millipore); the antibiotics, 
2,5-dihydroxybenzoic acid (DHB), and acetonitrile (ACN) containing 0.01% TFA, were obtained from 
Sigma-Aldrich. Peptide standards: YAEFLa, GFFD, and the corresponding epimers with D-amino acids in 
the second position were synthesized by the Protein Sciences Facility of the Roy J. Carver Biotechnology 
Center, University of Illinois at Urbana-Champaign. 
In situ Hybridization 
In situ hybridization was performed as described previously.42,49,50 Ganglia were digested with 1% 
protease type IX (Sigma-Aldrich) in 10 ml of artificial sea water (ASW: 460 mM NaCl, 10 mM KCl, 55 
mM MgCl2, 11 mM CaCl2, and 10 mM HEPES, pH 7.6) for 3 h at room temperature (with rocking) to 
facilitate removal of the sheath. After digestion, the ganglia were washed with ASW and fixed overnight 
at 4 °C with 4% paraformaldehyde (Electron Microscopy Sciences) in PBS. The ganglia were then 
washed, desheathed, and dehydrated in an ascending ethanol series, and then rehydrated. Following 
rehydration, the ganglia were prehybridized and then hybridized overnight at 50 °C in hybridization 
buffer  (50% formamide, 5 mM EDTA, 5 × SSC, 1 × Denhardt’s solution, 0.1% Tween 20, and 0.5 mg/ml 
yeast tRNA) containing 2 μg/ml digoxigenin-labeled cRNA probes made from the corresponding cDNA 
templates. Following wash-out of the probes, the ganglia were then incubated overnight at 4 °C with a 
1:200 dilution of alkaline phosphatase-conjugated anti-digoxigenin antibody (Roche Molecular 
Biochemicals) in PBS containing 0.1% tween, 0.2% BSA, and 1% normal goal serum. After washes with 
poly(butylene terephthalate) (PBT) to remove unbound antibody, the ganglia were washed with detection 
buffer (100 mM NaCl, 50 mM MgCl2, 0.1% Tween 20, 1 mM levamisol, and 100 mM Tris-HCl, pH 9.5) 
and developed with 4.5 μl of nitroblue tetrazolium and 3.5 μl of 5-bromo-4-chloro-3-indolyl phosphate 
(Roche Molecular Biochemicals) in 1 ml of detection buffer. The staining reaction was monitored visually 
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and stopped by washing with PBT when the level of staining was adequate. The stained ganglia were 
photographed using a Nikon microscope (Morrell Instruments) with epi-illumination against a white 
background. Photographs were taken with a Nikon CoolPix 990 digital camera, imported into Photoshop 
(Adobe Systems Inc.), and compiled into figures. 
Cell Sampling for MALDI-TOF MS 
In situ images were used as guidance for the isolation of neurons expressing the GFFD 
prohormone. The abdominal ganglia were dissected and incubated in 1% (w/v) protease (Type IX: 
Bacterial; Sigma-Aldrich) in artificial sea water (ASW: 460 mM NaCl, 10 mM KCl, 10 mM CaCl2, 22 
mM MgCl2, 6 mM MgSO4, and 10 mM HEPES, pH 7.8) supplemented with antibiotics (penicillin G, 
gentamycin, and streptomycin) and maintained at 34 °C for 45 min to loosen the connective tissue sheath. 
Following a 1–3 h rinse in ASW with antibiotics to remove the bulk of the protease, the ganglia were 
stretched onto a silicone elastomer (Sylgard, Dow Corning) layer in a Petri dish containing 3–4 ml of the 
ASW-antibiotic medium using 0.15 mm diameter tungsten needles (WPI); the connective tissue was 
surgically removed to expose neurons.  
Clusters of GFFD-expressing neurons were identified according to their relative position to 
prominent morphological landmarks in the ganglion and excised with tungsten needles. The clusters were 
quickly transferred via a plastic micropipette filled with Milli-Q water to remove excess salts and 
deposited onto the MALDI target. Excess liquid was aspirated from the target and spot-to-spot cell 
transfers were performed for sampling of individual neurons as described previously38,51. Matrix (0.3–0.5 
µl DHB, 10 mg/ml in 50% ACN/0.01% TFA) was added to each spot. An equal volume of matrix and 1 
mg/ml of synthetic peptides dissolved in water were mixed and deposited on the target. 
MALDI TOF/TOF MS Analysis of G(l/d)FFD Standards and Individual Aplysia Neurons 
This analysis adopted previously reported protocols 38. Briefly, MS measurements were 
performed using an ultrafleXtreme™ MALDI TOF/TOF mass spectrometer (Bruker Daltonics). MS/MS 
measurements were performed in “LIFT” mode with the collision-induced dissociation (CID) function 
turned on. With 27 keV collisional energy, under a source pressure of 6 × 10-6 mbar, a potential raise in 
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the “LIFT” chamber assists with the pseudo CID process.  
For these measurements, three spectra were generated from each spot on a MALDI plate, with 
each spectrum being an accumulation of at least 5000 laser pulses surveying all around the spot in a 
random pattern. Peak intensity and area were used for analysis. Laser intensity was held constant across 
all synthetic peptide spots (six for each epimer), including between the pair of all L- and D-amino acid-
containing peptides. For cell samples, laser intensity was adjusted to observe peaks with a signal-to-noise 
ratio higher than 100 but not to saturate the detector, and once optimized, this parameter was kept 
consistent for the cell samples. Three individual neurons from two animals were evaluated for GdFFD 
and GFFD content using the MALDI MS/MS method. All samples were intentionally analyzed in a 
random order between the two isomeric forms by MS.  
The observed fragment ion peaks were mass matched to predicted fragment ions using Protein 
Prospector (http://prospector.ucsf.edu/prospector/cgi-bin/msform.cgi?form=msproduct). The MS/MS 
spectra were analyzed using the FlexAnalysis 3.4 and Biotools 3.2 software packages (Bruker Daltonics). 
Seven major fragment peaks with S/N >= 10 were identified from the peak table for further analysis. The  
peak area of each fragment ion was normalized to the sum of all major fragment ions produced from the 
particular sample spot. Mass assignment accuracy was expressed as parts per million (ppm). 
Principal Component Analysis (PCA) of Fragmentation Spectra 
We used the sum of the peak areas of all major product ions from the MALDI MS/MS analysis 
because it includes all of the detected fragment ions instead of only two chirality indicating fragments, 
and may provide a greater discrimination of different fragmentation profiles between peptide epimers. 
JMP Pro 10 software (SAS Institute Inc.) was used for the multivariate analysis. Peak area data from 
synthetic peptides and cells were first extracted from FlexAnalysis 3.4 into an Excel spreadsheet 
(Microsoft Corp.). In order to improve data consistency, all peak area values were pretreated by 
normalizing to the sum of all major product ions (b2, b3, y2, y3, a2, F immonium, and MH+-H2O ions) 
generated from the respective replicate. All normalized peak area values from these product ions were 
used for the analysis. The default estimation method, REML (restricted maximum likelihood), was used. 
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Summary plots including an Eigenvector plot, and an Eigenvalues table, were generated from the JMP 
Pro software. 
Preparation of Neuropeptide Extracts 
Peptide extracts for LC-MS/MS analysis have been prepared from either isolated neurons or from 
a whole ganglion, as specified in the Results section. In the case of isolated neurons, 20 μl of acidified 
acetone (40:6:1 acetone:H2O:HCl, v/v/v) was added to the isolated neurons in a centrifuge tube. After 
brief sonication, the extract was then dried in a vacuum evaporator (SpeedVac™, Savant Instruments) and 
reconstituted in 20 μl of 5% ACN in water (95% H2O/5% CH3CN/0.01% TFA (v/v/v)). The sample was 
stored at 4 oC before analysis. When extracting from the whole cerebral and buccal ganglia, 500 μl of 
acidified acetone was used. The sample was then sonicated, centrifuged (Centrifuge 5804R, Eppendorf), 
and the supernatant collected. The tissue pellet was resuspended in an additional 500 μl of acidified 
acetone, vortexed and stored at 4 oC overnight and centrifuged; the secondary supernatant was collected 
and combined with the primary supernatant. The combined extract was then dried in the SpeedVac and 
reconstituted in 20 μl of 5% ACN in water.  
First-stage Microbore HPLC Fractionation of Peptide Extracts 
Fractionations of abdominal, cerebral, and pedal ganglia extracts were performed with a 
microbore HPLC system (Magic 2002, Michrom Bioresources) with a reversed-phase C18 column (150 × 
1.0 mm inner diameter (ID), 5 μm particle size, 300 Å pores, Dionex) at a flow rate of 20 μl/min prior to 
LC-MS analysis. Fractionation of the buccal ganglia extracts was performed with an analytical HPLC 
system (Breeze™ 2 HPLC, Waters) with a reversed-phase Symmetry C18 column (75 × 4.6 mm ID, 3.5 
μm particle size, 100 Å pores, Waters Corporation). 
A UV/visible detector set at 220 nm was used for detection. A binary solvent system was used 
with solvents A (95% H2O/5% ACN/0.1% formic acid (FA)/0.01% TFA (v/v/v/v)) and B (95% ACN/5% 
H2O/0.1% FA/0.01% TFA (v/v/v/v)). The solvent gradient started by increasing B from 1 to 5% over 5 
min, up to 50% over the next 45 min, and followed by a 20 min gradient from 50% to 80% B. Fractions 
were manually collected using a fraction collector (FC 203B, Gilson). 
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LC-MS Analysis of Synthetic Gd/lFFD and Yd/lAEFLa Peptides and Tissue Extracts 
Synthetic peptide epimers, GFFD and GdFFD, or YAEFLa and YdAEFLa, were prepared in three 
solutions, 1 µg/ml of L-epimer, 1 µg/ml of D-epimer, and a mixture of both. Two instrumental 
combinations of an HPLC system and electrospray ionization (ESI)-ion-trap (IT) mass spectrometer were 
used for the separations, with both validated using appropriate standards. 
For the initial experiments on all samples except the buccal ganglia extracts, the HPLC fraction of 
interest was analyzed using a capillary HPLC (capLC)-ESI-IT MS setup. The capillary HPLC system 
(CapLC, Waters Corporation) was equipped with a Dionex C18 PepMap column (150 × 0.3 mm ID, 3 μm 
particle size, 100 Å pore size) running at a flow rate of 2.5 μl/min. Gradient elution was adopted (A: 
0.05% TFA (v/v); B: 80% ACN, 20% H2O, and 0.04% TFA). The gradient started with 5% B, rising to 
50% B in 20 min, and then to 95% B in another 5 min. The gradient was dropped down from 95% B at 30 
min to 5% at 31 min toward the end of a 50-min run. The eluent was interfaced online with an ESI-IT 
mass spectrometer (HCTultra PTM Discovery System™, Bruker Daltonics). We acquired data in the 
positive-ion mode with detection ranges of m/z 300–1500 and 50–2000 for MS and MS/MS, respectively. 
The two most intense precursor ions (preferred charge of +2) were automatically picked every min for 
CID fragmentation. 
In order to optimize the separation of YAEFLa and YdAEFLa, a hypercarb column (100 × 0.32 
mm ID, 5 μm particle size, Thermo Scientific), using the same gradient and solvent system as described 
above for the capLC on a C18 column, was interfaced to the HCTultra mass spectrometer.  
The later confirmation of the GFFD/GdFFD peptides in the buccal ganglia used a newer 
instrument combination. For buccal ganglia extracts, each analytical HPLC fraction of interest was 
analyzed using the same capillary HPLC system and column as described above, although with some 
modifications. A flow rate of 4.0 μl/min was employed with gradient elution (A: 95% H2O, 5% ACN, 
0.05% FA; B: 80% ACN, 20% H2O, 0.04% FA). The gradient started with 1% B, rising to 20% B in 20 
min, then 45% B in 7 more min, then to 90% B in another 17 min. The gradient was dropped from 90% B 
to 1% B toward the end of the 60-min run. This eluent was interfaced online with a different ESI-IT mass 
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spectrometer (amaZon speed™, Bruker Daltonics). In addition, a viscosity calibration was performed 
prior to this separation; overall, these changes led to a different retention time for the peptides. However, 
to enable a comparison of results between the earlier and later separations, careful identification and 
calibrations using appropriate peptide standards were performed in all cases. 
Antibodies and Immunostaining 
GdFAD was used to generate the antibodies in rats as described previously.42,52 Briefly, the 
antigen was prepared by coupling synthetic peptide (SynPep) to BSA (catalog #A0281; Sigma-Aldrich) 
using 1-ethyl-3-(dimethylaminopropyl)carbodiimide (catalog #E7750; Sigma-Aldrich). The coupled 
antigen was purified and used to inoculate the rats. Immunocytochemistry was performed as described 
previously 42,52. Tissues were fixed in freshly prepared fixative (4% paraformaldehyde, 0.2% picric acid, 
25% sucrose, and 0.1 M NaH2PO4, pH 7.6). Tissue was permeabilized and blocked by overnight 
incubation in blocking buffer (10% normal donkey serum, 2% Triton X-100, 1% BSA, 154 mM NaCl, 50 
mM EDTA, 0.01% thimerosal, and 10 mM Na2HPO4, pH 7.4). The primary antibody was diluted 1:250 in 
the blocking buffer and incubated with the tissue for 4–7 d. The tissue was then washed twice per day for 
2–3 d with washing buffer (2% Triton X-100, 1% BSA, 154 mM NaCl, 50 mM EDTA, 0.01% thimerosal, 
and 10 mM Na2HPO4, pH 7.4). After the washes, the tissue was incubated with a 1:500 dilution of 
secondary antibody (lissamine rhodamine donkey anti-rat; Jackson ImmunoResearch) for 2–3 d. The 
tissue was then washed twice with the washing buffer for 1 d and four times with storage buffer (1% 
BSA, 154 mM NaCl, 50 mM EDTA, 0.01% thimerosal, and 10 mM Na2HPO4, pH 7.4) for 1 d. 
Electrophysiology of the feeding network 
Intracellular and extracellular recordings of the physiological activity from CNS preparations 
(including the cerebral and buccal ganglia) were performed as described previously.53 The ganglia were 
desheathed, transferred to a recording chamber containing ~1.5 ml of ASW, continuously perfused at 0.3 
ml/min, and maintained at 14–17 °C. Peptides were dissolved in ASW immediately before each 
physiological test and the peptide/ASW solution was perfused into the recording chamber. Intracellular 
recordings were obtained using 5–10 MΩ sharp microelectrodes filled with 0.6 M K2SO4 plus 60 mM 
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KCl.  
Electrophysiological recordings were digitized online using Axoscope (Molecular Devices, Inc.) 
and plotted with CorelDraw (Corel Inc.). Bar graphs were plotted using Axum (Adept Scientific). Data 
are expressed as mean ± SEM. Statistical tests (repeated-measures one-way ANOVA) were performed 
using Prism (GraphPad Software). When the data showed significant effects in ANOVA, further 
individual comparisons were performed with Bonferroni’s correction. 
Electrophysiology of locomotor neurons 
After anesthesia, cerebral and pleural-pedal ganglia were dissected out and maintained in ASW 
containing the following (in mM): 460 NaCl, 10 KCl, 55 MgCl2, 11 CaCl2, and 10 HEPES buffer, pH 7.6, 
in a dish lined with Sylgard (Dow Corning). 
Electrophysiological recordings from CNS preparations were performed as described 
previously.53 The ventral surfaces of right pedal ganglion and/or left pedal ganglia were desheathed, 
transferred to a recording chamber containing 1.5 ml of ASW, continuously perfused at 0.3 ml/min, and 
maintained at 14–17°C. Peptides (GdFFD, UIUC Roy J. Carver Biotechnology Center; GFFD, China-
Peptides Inc) were dissolved in ASW immediately before each application, then the ASW with the 
peptide was perfused into the recording chamber. Before the application of next peptide, it was necessary 
to perfuse the chamber with only ASW for at least 15 min. Extracellular recordings were made from 
polyethylene suction electrodes. Extracellular signals were acquired using a differential amplifier Model 
1700 (A-M systems). Bursting spiking activity in parapedal commissural nerve (PPCN, or P10) was 
defined by higher frequency of more than 3 Hz. 
4.5 Results 
Identifying Putative DAACP–encoding Genes in Aplysia californica 
Orthologous genes oftentimes encode neuropeptide prohormones with similar functions in 
different species.54 Commonly, only amino acid sequences and associated PTMs required for function are 
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conserved while the rest of the prohormone differs among the species. For this study, we looked at 
existing research on Achatina fulica because three DAACPs—achatin-I (GdFAD)9, fulicin (FdNEFVa),10 
fulyal (YdAEFLa)24—and their precursors, have been identified in Achatina. Achatin-I belongs to one 
precursor, named achatin-I precursor55, whereas both fulicin and fulyal belong to another precursor, 
named fulcin gene-related peptide precursor (FGRP).56 Because Achatina fulica and Aplysia californica 
are both gastropod mollusks, there is a distinct possibility that DAACPs in Achatina may have homologs 
in Aplysia. 
Indeed, previous large-scale sequencing projects in Aplysia 35 have already identified two 
precursors that are similar to the above two precursors, named Aplysia achatin-like neuropeptide 
precursor (abbreviated as apALNP in this report, accession NP_001191589) and Aplysia fulicin-like 
neuropeptide precursor (abbreviated as apFLNP, NP_001191590) (Fig. 4.1). Despite this information, 
until the present work no prior study predicted possible peptides from these two precursors, let alone 
characterized the actual peptides produced in Aplysia. 
We began our analysis by first comparing apALNP against the achatin-I precursor as well as 
several related, non-redundant protein sequences from GenBank, PDB, SwissProt, PIR, and PRF using 
blastp. We found that apALNP has overall similarity to achatin-I precursor from Achatina fulica (50%), 
neuropeptide GFAD precursor from Helix lucorum (44%), and achatin from Lehmannia valentiana 
(42%). Next we created a library of putative encoded peptides using the bioinformatics tool NeuroPred 
(http://neuroproteomics.scs.illinois.edu/cgi-bin/neuropred.py),57,58 which predicts cleavage sites based on 
models trained on Aplysia prohormone cleavages and the Known Motif model. Sequence alignment 
showed seven repeats of GFAD in achatin-I precursor, and at those loci there were several similar 
sequences to achatin-like neuropeptide, including GYFD (predicted m/z 501.2), GFFD (m/z 485.2, with 
three copies), GDAS (m/z 349.1), SYAD (m/z 455.2), and GFFG (m/z 427.2) (Fig. 4.1A). In addition, 
YYGS was also predicted. Among these predicted peptides from apALNP, GFFD was the most abundant, 
and more importantly, it was most similar to GFAD. Thus, we hypothesized that GFFD in Aplysia might 
have a DAACP epimer, GdFFD, similar to achatin-I (GdFAD) in Achatina. 
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We then performed a similar analysis on apFLNP with FGRP. A sequence alignment using blastp 
indicated that apFLNP has 37% similarity to FGRP. Predicted neuropeptides included 
LSRMLLNGQLAEQYPEFIa (m/z 2121.1), RPYDFLa (m/z 809.4), NPYEFIa (m/z 781.4), NPYEFVa 
(m/z 767.4), QWEFVa (m/z 707.3), FTEFLa (m/z 655.3), SYDFLa (m/z 643.3), YAEFLa (m/z 641.3), 
PYDFVa (m/z 639.3), YDFLa (m/z 556.3, 2 copies), and YDFVa (m/z 542.2, 3 copies) (Fig. 4.1B). In 
addition, there were two other peptides, RPYDFLa and NPYEFVa. Among these predicted peptides from 
apFLNP, FTEFLa is the analog of the all L-form FNEFVa. In our previous MALDI MS peptide mass 
profiling experiments of this prohormone, we have not detected the peptide FTEFLa (data not shown). 
Thus, we decided to focus on YAEFLa, and hypothesized that Aplysia YAEFLa might have a DAACP 
epimer, YdAEFLa, identical to the Achatina fulyal. We tested these two hypotheses concerning DAACPs 
in Aplysia, as described in the following two sections. 
Expression of Putative DAACP-Encoding Prohormones in the Aplysia CNS 
In order to determine whether apALNP (GFFD) and apFLNP (YAEFLa) are expressed in the 
Aplysia CNS, we performed in situ hybridization experiments using the antisense apALNP (n = 3) or 
apFLNP (n = 3) cRNA (generated from the whole sequences shown in Fig. 4.1A,B) made with T7 or SP6 
RNA polymerase. Control experiments included only vectors, and the antisense apALNP or apFLNP 
cRNA sequences were omitted. These controls resulted in no staining (n = 3).  
For apALNP, we found that the most obvious staining of neuronal somata was in the pedal 
ganglion: i.e., a cluster of large neurons in the vicinity of the peripheral pedal nerve 7. These neurons 
were located primarily on the dorsal surface, but were also partially visible on the ventral surface (Fig. 
4.1C,D) (n = 3). No somata were stained in the cerebral and buccal ganglia, which are involved in the 
generation of feeding behavior.   
For apFLNP, we observed somata staining on the ventral surfaces of the cerebral ganglion: i.e., a 
single neuron near the root of the cerebral-buccal connective and a cluster of small neurons between the 
roots of the cerebral-pedal connective and cerebral-pleural connective (Fig. 4.2A) (n = 3). We also 
observed some staining in the abdominal ganglion (not shown), but found no staining of neuronal somata 
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in the buccal or the pleural-pedal ganglia. 
In addition to showing that both apALNP and apFLNP are expressed in the Aplysia CNS, the 
above data also provided us with potential targets for isolating specific neurons for chemical identification 
of putative DAACPs. 
Chemical Characterization of Putative DAACPs (GdFFD and YdAEFLa) 
In this series of experiments, we first sought to characterize GFFD and putative GdFFD from the 
Aplysia CNS using several small-volume neuropeptide characterization approaches involving MS.59,60 
Based on the distribution of apALNP-positive neurons shown by in situ hybridization, we isolated these 
neurons from the pedal ganglion (Fig. 4.1C,D). Using MALDI-TOF MS peptide mass profiling, we 
detected predicted peptides and their truncated forms from apALNP by mass match (Fig. 4.1E), including 
m/z 484.9, matching that of GFFD, as well as YYGS (Fig. 4.1F); GFFD was detected with 206 ppm (parts 
per million) accuracy under conditions optimized for detection of lower molecular weight peptides. Based 
on previous reports identifying the peptide epimerization process as a PTM31-33, GdFFD would be 
generated by isomerization of GFFD after synthesis and cleavage from the prohormone. Therefore, both 
GFFD and GdFFD could be present in the extracts, but only as a single peak in the MALDI-TOF MS 
spectrum. 
We and others have demonstrated previously that fragmentation of D- and L-epimers by CID on a 
MALDI-TOF/TOF instrument results in different ratios of specific fragment ions, referred to as reporters, 
which aid epimer differentiation during MS/MS analysis.38,61,62 Thus, we used this method to screen 
whether GdFFD was possibly present in the samples. To apply this approach for analysis of GFFD 
peptide chirality, we synthesized GFFD and GdFFD, investigated their characteristic fragmentation 
patterns, and found that y2 and b3 fragment ions served as reporters for discriminating between these two 
epimers (n = 6, Fig. 4.3). The ratios of y2/b3 peak intensities, as well as peak areas, were lower for 
GdFFD (Fig. 4.3A). Likewise, the F-immonium (Fi) ion was observed at a higher intensity in the case of 
GdFFD, and the y2/Fi ratio was lower for GdFFD. In addition, MS/MS analysis of isolated neurons (n = 
3) revealed a fragmentation pattern that did not resemble that of the GFFD standard, suggesting that the 
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endogenous peptide could be GdFFD (Fig. 4.3A,B). In order to demonstrate the difference between 
epimers using the entire fragmentation profile, we applied multivariate analysis using all major product 
ions from the fragmentation spectra. PCA revealed a clustering of the spectra from isolated cells to the 
spectra from the GdFFD standard, distinct from the spectra from the GFFD standard, based primarily on 
principal component (PC) 1 (Fig. 4.4A). Seven fragment ions were used in the PCA analysis (Fig. 4.4B), 
including the ions b3, Fi, and y2. Component 1 accounts for over 70% of the variance, and two groups are 
formed by this component. The isolated neurons are grouped more closely with the synthetic GdFFD 
peptide, meaning the fragmentation profile more closely fits GdFFD than GFFD (Fig. 4.4C). The 
Eigenvector plot in Fig. 4.4B shows the ions that contributed to the discrimination. The y2 ion with an 
arrow pointing toward the left indicates the more abundant y2 ion is observed in the synthetic GFFD 
peptide, and this has contributed to the assignment of these samples to the group on the left of the PCA 
plot (Fig. 4.4A). The more abundant Fi, y3, b3, and b2 ions contribute to the assignment of a sample to 
the right hand side of the plot. The largest contrast of fragment ion ratios came from Fi, y3, b3, and b2 
ions to the y2 ion, and this is consistent with our initial choice of y2/b3 and y2/Fi being our chirality 
reporting ratios. PCA revealed a distinct grouping of the GFFD standard from the GdFFD standard and 
isolated neurons, suggesting a resemblance of features in the fragmentation spectra of isolated neurons 
with the GdFFD standard. Given these results, we decided to confirm the presence of GdFFD in these 
neurons. 
Because peptide epimers can be separated on C18 reversed-phase columns without a chiral 
selector,1 we also used a second method, LC-MS/MS, to confirm whether GFFD and GdFFD were both 
present in the samples. We analyzed extracts from whole pedal ganglia, instead of individual neurons, 
using ESI-IT MS preceded by chromatographic separation, to confirm the chirality of GFFD peptide. We 
used two separate instrument/separation conditions (see Experimental section). One LC-MS/MS method 
achieved baseline separation of the synthetic GFFD and GdFFD mixture, with retention times of 21.4 min 
and 24.3 min, respectively (Fig. 4.5D–F), and the other had retention times of 30.3 and 31.4 min, 
respectively. The LC-MS chromatogram in Fig. 4.5A identifies both GFFD and GdFFD in the neurons 
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isolated from the pedal ganglia extracts. The retention times and fragmentation ions obtained from the 
samples match those from synthetic epimers. The mechanisms of molecular dissociation are distinct in 
our two MS systems and so the MS/MS profiles are different (compare the CID and the TOF/TOF 
fragmentation patterns shown in Fig. 4.5 with Fig. 4.3). Regardless, the intensities of the fragment ions 
m/z 282.3 (y2), m/z 307.7 (x2), and m/z 352.2 (b3) show characteristic patterns for each epimer. In 
addition, GdFFD was detected in cerebral ganglia extracts (data not shown) and whole buccal ganglia 
extracts, seen in the LC-MS chromatogram in Fig 4.6A. Overall, the results from two independent 
methods, i.e., MALDI MS fragmentation analysis and LC-MS/MS using three instrumental platforms, 
verify that both GFFD and GdFFD are present in the Aplysia CNS. 
Next, we sought to characterize YAEFLa and putative YdAEFLa from the Aplysia CNS, because 
apFLNP in Aplysia predicts a peptide identical to the Achatina DAACP, fulyal (YdAEFLa), among 
others. The sparse expression pattern of apFLNP in the Aplysia CNS, as shown by in situ hybridization, 
rendered sampling for MALDI difficult. Therefore, we did not perform MALDI MS fragmentation 
analysis. Instead we decided to investigate the presence and chirality of YAEFLa peptide using our LC-
MS based platform without prior MALDI-TOF/TOF MS structure verification. Synthetic YAEFLa and 
YdAEFLa were used to optimize the separation and MS conditions. First we used a Dionex C18 PepMap 
column, but the epimers had a slight difference (0.8 min) in retention times (Fig. 4.7A), and so we tried a 
stationary phase with a different selectivity, a hypercarb column. The difference in retention time 
increased to 3.4 min, which improved our confidence in the chirality assignment via retention time. Two-
stage HPLC separation was performed on the cerebral ganglia extract to identify Y(l/d)AEFLa (Fig. 
4.7B). In order to comprehensively assay the fractions in an efficient manner, 20 fractions from the first 
stage were scrambled and combined for second-stage analysis (e.g., fractions 1, 7, and 13 were combined; 
fractions 2, 8, and 14 were combined). Only one second-stage scrambled fraction contained a mass 
matching that of YAEFLa, based on the retention times of the YAEFLa and YdAEFLa standards. An 
MS/MS fragmentation profile (Fig. 4.7C) that closely resembled the synthetic YAEFLa provided 
additional support for this identification (Fig. 4.7D, E). 
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In addition, two other peptides from the same apFLNP prohormone, PYDFVa and YDFLa, were 
detected and sequenced, further lending support to the correct identification of m/z 641.3 as YAEFLa 
(data not shown). No signal satisfying our criteria for peak selection could be identified as YdAEFLa at 
the corresponding retention time window. Thus, we conclude that the L-form is the predominant isomeric 
form of YAEFLa in the cerebral ganglia of Aplysia. We also scanned HPLC fractions from the pedal and 
abdominal ganglia using the same LC-MS methods for YdAEFLa, but YdAEFLa was not detected. 
To summarize at this point, our data indicate that although YAEFLa is predominantly or 
completely in the all L-form in the Aplysia CNS, both GFFD and GdFFD are present in significant 
amounts, providing a basis for examining the actions of DAACPs in the Aplysia feeding circuit. 
GdFFD: An Extrinsic Neuromodulator of the Feeding Circuit 
In these experiments, we sought to determine whether GFFD, GdFFD, or both, are bioactive in 
the Aplysia feeding circuit. In situ hybridization with apALNP suggested that GFFD/GdFFD-containing 
neurons were primarily distributed in the pedal ganglion (Fig. 4.1C,D). We performed 
immunocytochemistry on the pedal ganglion and the buccal ganglion using an antibody raised against 
GdFAD (Fig. 4.2B,C). Immunostaining of pedal ganglia (Fig. 4.2B) showed that the antibody labeled a 
group of neurons that is similar to the cluster of neurons labeled with in situ hybridization by apALNP 
(Fig. 4.2A), suggesting that the antibody is immunoreactive to peptides from apALNP. The antibody 
provided information about neurons expressing GdFAD, but it may also have labeled cells with GFFD (as 
the chiral selectivity of the antibody was not tested). The labeled cells matched the same cells in the 
apALNP in situ hybridization experiments. Immunostaining of the buccal ganglion (Fig. 4.2C) did not 
label any neuronal somata, consistent with our in situ hybridization experiments that revealed no positive 
staining of somata in the buccal ganglion. However, the immunostaining did show that there were 
immuno-positive fibers and varicosities in the buccal commissure and the neuropile of the buccal 
ganglion in which the central pattern generator for feeding is located. Indeed, we were able to detect the 
presence of GdFFD in peptide extracts from the whole buccal ganglion (Fig. 4.6). These data suggest that 
peptides (including GFFD/GdFFD) that originate from apALNP-positive somata of other ganglia, e.g., 
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the pedal ganglion, innervate the buccal ganglion, and therefore may act as extrinsic modulators of the 
feeding circuit. 
To test this hypothesis, we examined the potential actions of GFFD and GdFFD on activity in the 
feeding network. First, we investigated the possibility that these peptides can directly activate the feeding 
circuit. After a 5–10 min resting period, when there was typically no spontaneous expression of motor 
programs (Fig. 4.8A), we perfused ASW that contained either GFFD or GdFFD to the bath for 8–15 min. 
We found that GFFD did not produce observable effects at 10-5 M. However, GdFFD was bioactive (Fig. 
4.8B). In two experiments in which the rostral surface of the buccal ganglion was desheathed, we found 
inconsistent results with GdFFD application. Therefore, in the remaining preparations (n = 4), we only 
desheathed the caudal surface of the buccal ganglion. 
In these four preparations, 10-6 M and 10-5 M GdFFD caused statistically significant increases in 
the expression of motor programs (Fig. 4.8D, n = 4, F3,9 = 10.17; p <0.01). The feeding circuit generates 
at least two types of motor programs, ingestive and egestive.43,44,63,64 Each cycle of motor programs 
consists of a protraction-retraction sequence. Motor programs were classified based on the activity phase 
of radula closure motor neuron B8 relative to protraction-retraction. Motor programs are considered as 
ingestive when B8 is predominantly active during retraction, and egestive when B8 is predominantly 
active during protraction.63,64 The motor programs evoked by GdFFD were mostly egestive, as B8 was 
predominantly active during protraction (Fig. 4.8B). Upon washout of GdFFD, the buccal ganglia 
gradually returned to an inactive state (Fig. 4.8C).  
In the next series of experiments, we tested the effects of the peptides on motor programs elicited 
by the command-like interneuron CBI-2. CBI-2 can be activated by food stimuli and when active, drives 
feeding in semi-intact preparations or feeding motor programs in the isolated CNS.65 Similar to the above 
experiments, we observed no obvious effect with GFFD, even with a concentration of 10-5 M (Fig. 4.8E). 
In contrast, 10-6 M GdFFD was effective in changing the parametric features of CBI-2-elicited programs. 
We did not test the effects of 10-5 M GdFFD because there was too much activity evoked by GdFFD. Fig. 
4.8F shows a representative example. In control conditions, stimulation of CBI-2 throughout protraction 
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evoked a motor program in which B8 was active predominantly during retraction, thus the program was 
ingestive (Fig. 4.8F1). However, when we perfused 10-6 M GdFFD, the parametric features of the motor 
program changed, e.g., protraction duration was shorter, and B8 was more active during protraction and 
less active during retraction (Fig. 4.8F2). Upon washout of the GdFFD, the motor program elicited by 
CBI-2 was similar to the control (Fig. 4.8F3). Group data (n = 4, Fig. 4.8F, 4 bar graphs) showed that 10-6 
M GdFFD exerted statistically significant effects on protraction duration (Fig. 4.8F4, F2,6 = 41.53; p 
<0.001), retraction duration (Fig. 4.8F5, F2,6 = 11.43; p <0.01), B8 activity during protraction (Fig. 4.8F6, 
F2,6 = 25.32; p <0.01), and B8 activity during retraction (Fig. 4.8F7, F2,6 = 41.77; p <0.001). Essentially, 
these parametric changes indicate that motor programs elicited by CBI-2 became more egestive with 
GdFFD. This is consistent with the observation that motor programs elicited by the perfusion of GdFFD 
are mostly egestive (Fig. 4.8B). 
 Overall, our data indicated that 10-6 M GdFFD was the effective concentration at which GdFFD 
acted to induce egestive programs in quiescent preparations and to modify parametric features of CBI-2-
elicited programs. In contrast, GFFD was without any observable effects in the Aplysia feeding circuit. 
Effects of GFFD and GdFFD in the isolated pedal neurons of Aplysia 
Although previous work in Aplysia feeding network indicated that only GdFFD was bioactive, a 
priori we did not know if the same holds true in the locomotor network. Thus, one major goal of the 
present work was to examine potential bioactivity of both GFFD and GdFFD on the locomotor network. 
To achieve this, we isolated the cerebral and pleural-pedal ganglia and sought to examine how GFFD and 
GdFFD may impact activity of the locomotor network in these ganglia. Locomotor behavior is mediated 
by a series of rhythmic contractions of foot and body muscles moving from the anterior part of the body 
to the posterior part, called pedal waves.66 Previous work has shown that pedal ganglia contain the central 
pattern generator for locomotion,67-69 and the cerebral ganglion contains command-like and modulatory 
neurons that can influence the expression of locomotor activity.70,71 The locomotor activity was monitored 
by parapedal commissural nerve (PPCN or P10) that innervates the posterior part of the foot, and was 
shown previously to exhibit bursting activity in phase with locomotion, and apparently represents 
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motoneuronal activity (Fig. 4.9A, ,4.10A).67-70,72,73 
In each experiment, we recorded baseline activity of the cerebral and pleural-pedal ganglia for 
more than 15 min, then we perfused 10−6 M peptide for more than 15 min, and followed this by 10−5 M 
peptide perfusion for more than 15 min. Then peptide was washed out with ASW for 20 min or until the 
effect disappeared, whichever was longer. We found that perfusion of GFFD at 10−6 M or 10−5 M did not 
change the activity in PPCN (Fig. 4.9A). Group data showed that there was no significant change in 
PPCN activity with perfusion of GFFD (Fig. 4.9B PPCN average frequency over 10 min, Control: 0.34 ± 
0.25 Hz; 10−6 M: 0.24 ± 0.14 Hz; 10−5 M: 0.24 ± 0.15 Hz; Wash: 0.24 ± 0.17 Hz; F3,9 = 0.8498; p > 0.05; 
n = 4). 
In contrast, perfusion of GdFFD at 10−6 M, and more pronouncedly at 10−5 M, increased activity 
in PPCN (Fig. 4.10A). In particular, during perfusion of 10−5 M GdFFD, the PPCN showed persistent 
bursting activity resembling locomotor activity that lasted for as long as the peptide was present. 
Surprisingly, we also observed apparent increase in PPCN activity between bursts, although at lower 
frequency. Group data showed that GdFFD perfusion significantly increased PPCN activity that was 
reflected in the average frequency (Fig. 4.10B1, Control: 0.29 ± 0.2 Hz; 10−6 M: 1.41 ± 0.81 Hz; 10−5 M: 
5.36 ± 0.68 Hz; Wash: 0.86 ± 0.35 Hz; F3,12 = 26.33; p < 0.001; n = 5), frequency within bursts (Fig. 
4.10B2, Control: 0.99 ± 0.26 Hz; 10−6 M: 2.58 ± 0.7 Hz; 10−5 M: 6.63 ± 1.37 Hz; Wash: 3.28 ± 0.72 Hz; 
F3,12 = 14.77; p < 0.001; n = 5), and frequency between bursts (Fig. 5B3, Control: 0.12 ± 0.07 Hz; 10−6 M: 
0.64 ± 0.26 Hz; 10−5 M: 1.59 ± 0.38 Hz; Wash: 0.25 ± 0.08 Hz; F3,12 = 10.16; p < 0.01; n = 5). 
Thus, the above data indicate that, similar to their effects on the feeding network, GdFFD, but not 
GFFD, is bioactive in the locomotor network. 
4.6 Discussion 
Approaches for Identifying DAACPs in Biological Tissue Samples 
The overall goals of this study were to develop a multidisciplinary approach using bioinformatics, 
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biochemistry, analytical chemistry, and electrophysiological tools to identify the presence of a D-amino 
acid in predicted DAACPs, and to examine their potential physiological actions in neural circuits that 
control behaviors. DAACPs in animals are derived through an isomerase-mediated PTM by converting an 
L-amino acid to a D-amino acid. Similar to PTMs such as amidation, this PTM may serve a variety of 
functions in animals: first, this modification allows the generation of a larger number of products from a 
single gene; second, a variety of physiological functions can be achieved through differential binding to 
the peptide’s cognate receptor; and third, the altered structure can result in a distinct (usually greater) 
resistance to protease degradation and clearance, thus conferring a different effective time frame after 
release. 
However, in contrast to peptides with chemical PTMs, relatively few peptides are currently 
known to undergo endogenous isomerization. As a case in point, in one of the most studied invertebrate 
model systems, the mollusk Aplysia, several hundreds of neuropeptides, many with chemical PTMs, have 
been characterized to date.35,41,42,48-50,52,74-78 Despite this, prior to this study, the cardioexcitatory 
neuropeptide NdWFa was the only known DAACP.11 The lack of a systematic approach for identifying 
putative DAACPs slows the exploration of their complements and roles in signaling in the animal 
kingdom. 
Our initial goal, therefore, was to adopt an MS-based chemical identification technique for 
DAACP discovery. Previously we reported a non-targeted screening approach using aminopeptidase to 
screen for potential DAACPs based on their resistance to proteolytic degradation in crude cell lysates 79. 
D-amino acids, especially those in the second position from the N-terminus, and unusual N-terminal 
PTMs such as polyglutamylation, cause peptides to be particularly resistant to degradation by this 
enzyme. This method, however, works best when combined with additional techniques for peptide 
structural characterization. Gas phase basicities of the diastereomers can be differentiated when they 
break apart into fragments in an MS/MS experiment, and this difference can be manifested as different 
branching ratios among product ions. It has been shown that several different MS techniques can be used 
to probe this thermochemical difference between diastereomers.34,61,62,80-82 We have also shown that 
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simultaneous identification and characterization of potential DAACPs by MALDI-TOF/TOF MS can be 
applied to distinguish D-isomer peptides in biological samples as small as individual neurons38. In this 
context, it is notable that historically, achatin-I was isolated from 30,000 snails using structural 
characterization via NMR.9 By comparison, our MS-based approach allowed low mass/small volume 
sampling and structural analysis of GdFFD. 
A second goal was to empower MS-based proteomics techniques for the characterization of 
putative DAACPs from complex tissue extracts. Proteomics relies on LC-MS/MS techniques, but benefits 
greatly from bioinformatics, i.e., the availability of genome, transcriptome, and proteome information for 
a growing number of species that allows in silico discovery of new signaling peptides. Homology 
searches that exploited structural and functional similarities between prohormone sequences in other 
species83 allowed us to generate a hypothesis for the existence of two Aplysia putative DAACPs encoding 
the prohormones GdFFD and YdAEFLa. Prior to MS characterization, we confirmed the expression and 
distribution of these prohormones in the CNS by molecular techniques and investigated their final gene 
products in isolated neurons using proven MALDI-TOF/TOF MS. We took advantage of the distinct 
fragmentation patterns that can arise between peptide epimers using both MALDI MS/MS- and LC-ESI 
MS/MS-based approaches34,38,61,81,82 to distinguish DAACPs and their all L-peptide counterparts. Our 
identification of GdFFD in Aplysia, similar to achatin-I (GdFAD) in Achatina, validates our homology-
based MS approach as being effective for identifying novel DAACPs in related animals. As more genetic 
information in different animals becomes available, we expect that the utility of this systematic approach 
will increase. Similar to bioactive achatin-I, GdFFD contains a D-Phenyl residue at the 2nd position, 
indicating that this PTM is conserved; such conserved structures suggest a functional context, such as 
receptor binding. For example, the DAACP Ocp-1, an ortholog of achatin-I, is an excitatory peptide in the 
octopus cardiovascular system that acts as a neuropeptide and/or neurohormone.22 
In contrast, despite an identical sequence to fulyal (YdAEFLa) in Achatina, YAEFLa in Aplysia 
was only observed in the L-form, suggesting that homology is not enough to assign a peptide as a 
DAACP. At present, we cannot exclude the possibility that YdAEFLa in Aplysia may exist in small 
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quantities, but given the signal-to-noise ratio of YAEFLa and assuming both epimers have similar limit of 
detection, YAEFLa is clearly the predominant form in Aplysia. We also have not detected the predicted 
homolog of Achatina fulicin (FdNEFVa), FTEFLa, in Aplysia. Regardless, one implication of this result is 
that it is essential to perform chemical identification experiments for the suspected DAACPs, even for the 
peptides that are identical in structure in related animals. Although the mechanisms are presently 
unknown, we speculate that the absence of YdAEFLa in Aplysia may be due to the absence of an 
isomerase or the specificity of the isomerase in the neurons that contain apFLNP (including YAEFLa). 
Future identification of the isomerase in Aplysia and its distribution in the CNS may provide an answer to 
this question. In addition, the apparent different processing of YAEFLa between Aplysia and Achatina 
raises both functional and evolutionary questions. What is the functional significance of this difference? Is 
there an evolutionary reason(s) for the different processing of the similar peptide in different, but related, 
animals? Perhaps future discovery of FGRP orthologs and putative DAACPs in other species will help 
resolve these issues. 
Functional Significance of DAACPs in the Aplysia Feeding Circuit 
Previous work has shown that most currently known DAACPs have potent bioactivity in various 
pathways, including in the peripheral and the central nervous systems, with L-form peptides exhibiting 
less or no bioactivity.1 However, until the present work, it was not known whether (or how) DAACPs can 
modify the activity of a defined neural circuit. Here, by taking advantage of the well-studied Aplysia 
feeding circuit, we describe one of first studies to provide evidence that a DAACP, i.e., GdFFD, but not 
GFFD, is bioactive in the feeding circuit. This finding is therefore consistent with the previous work 
demonstrating that an isomerization can change the bioactivity of a peptide and demonstrates the 
importance of isomerization on circuit function. Notably, the only other DAACP uncovered in Aplysia, 
NdWFa, which contains amidation of the C-terminus in addition to a D-amino acid residue, was shown to 
be much more effective in inducing heart beat in Aplysia than the amidated L-epimer NWFa.11 
We would like to emphasize that the choice of the feeding circuit for the study of circuit function 
of DAACPs is not random, because the expression of specific feeding behavior, which is a motivated 
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behavior, is modulated by many intrinsic and extrinsic factors36,84  that are often mediated by actions of 
neuromodulators.36,85-87 Consistent with this complexity, previous work has shown that the feeding circuit 
is extensively modulated by neuromodulators, including neuropeptides that have been discovered in 
Aplysia.41,42,48,49,74,75,77 The present study constitutes the first example of a DAACP acting as a 
neuromodulator in the Aplysia feeding circuit. Notably, many of the peptides identified before, e.g., 
apNPY,88 SCP,89 FRFamide/FMRFamide,90 and apUII,48 are intrinsic modulators because they are 
localized in either sensory/motor neurons or higher-order interneurons of the feeding circuit, which 
involves the cerebral and buccal ganglia. In contrast, GFFD/GdFFD-positive neurons are localized in the 
pedal ganglion, which is not directly involved in feeding. Thus, the actions of GdFFD on the feeding 
circuit classify it as an extrinsic modulator of the feeding circuit. Along this line, GdFFD is similar to 
myomodulin gene 2-derived peptides (MMG2-DPs),74 which are also located in the pedal ganglion and 
are extrinsic modulators of the feeding circuit. However, GdFFD appeared to exert more robust actions in 
the feeding circuit, as it was capable of evoking network activity in quiescent preparations, while MMG2-
DPs were not. Indeed, although it may not be surprising that intrinsic modulators of the feeding circuit, 
e.g., FCAP77 and SCP89, can directly evoke network activity, GdFFD appears to be the first known 
extrinsic peptide neuromodulator capable of such an action in Aplysia. 
The Aplysia feeding network is multifunctional in that it can generate at least two types of feeding 
motor programs: i.e., ingestive and egestive. From this perspective, GdFFD also differs from MMG2-DPs 
in that GdFFD promotes egestive programs, while MMG2-DPs make the programs less egestive. Thus, 
GdFFD is similar to several intrinsic neuromodulators, e.g., apNPY, SCP, and FRFamide/FMRFamide, 
that promote egestive programs and may serve to interrupt ingestion of food when animals become 
satiated. Although we do not yet know under what circumstances GdFFD-positive neurons would be 
activated, it is attractive to speculate that GdFFD may function to interrupt ingestion when locomotion is 
active because the pedal ganglion is involved in the control of locomotion.70 In this sense, in contrast to 
the actions of intrinsic modulators apNPY and SCP, the extrinsic modulator GdFFD might provide a new 
context in which a modulator may bias the feeding programs toward egestion in the Aplysia feeding 
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system.41,47 To the best of our knowledge, GdFFD represents the first example of a DAACP acting on a 
defined neural circuit that ultimately influences behavior. 
In summary, we describe a multidisciplinary approach that allowed us to identify a novel 
DAACP, GdFFD, in a well-known model system, providing important evidence that post-translational 
conversion of the Phe residue to D-Phe in this peptide is required for circuit actions. We expect that our 
multifaceted technique can be applied to other organisms, including vertebrates, and should accelerate 
studies of PTMs, which are critical for the expression of functional peptides in animals. Indeed, our study 
indicates that it may be fruitful in the future to examine other peptides found within neural networks to 
determine if peptides with no known bioactivity when testing with synthetic all-L form peptides may in 
fact have a D-amino acid that is required for their activity. 
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4.7 Figures 
 
Figure 4.1. Sequence and localization of expression of apALNP and apFLNP, and peptide profiles from apALNP-positive 
cells. (A, B) The precursor protein sequences of apALNP and apFLNP 35.  Predicted peptides are underlined, while peptides that 
have been verified chemically in this report are shown in bold. (A) apALNP includes the predicted peptide GFFD; (B) apFLNP 
includes the predicted peptide YAEFLa. All peptides from apFLNP are amidated. (C, D) In situ hybridization showed that 
apALNP (GFFD) mRNA was expressed in a cluster of neurons near the root of pedal nerve 7 (P7) and pedal nerve 9 (P9) on the 
dorsal surface of the pedal ganglion. (C) Left pleural-pedal ganglia; (D) right pleural-pedal ganglia. In both panels, the pedal 
commissure (PC) is facing upward and the pleural ganglion (Pleural g.) is facing to either the left or right. Calibration: 200 µm. 
(E, F) Peptide profile detected by MALDI-TOF MS from the cells stained positive for cDNA corresponding to apALNP  
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Figure 4.1 (continued)                                                                                                                                          a 
(GFFD/GdFFD) in in situ hybridization. (E) Several of the larger molecular weight peptide products from apALNP are detected 
from these cells by accurate mass match. Achatin-like [86-106] and achatin-like [24-51]-NH2 were detected at 44 ppm and 12 
ppm, respectively. (F) Detection of peptide products from apALNP using MALDI-TOF MS settings optimized for detection of 
smaller molecular weight species. Several products, including GFFD/GdFFD and YYGS, are detected from the cells by accurate 
mass matching. GFFD/GdFFD and YYGS were detected at 206 ppm and 818 ppm, respectively. 
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Figure 4.2. Localization of expression of apALNP and apFLNP. (A) In situ hybridization shows that apFLNP (YAEFLa) 
mRNA is expressed on the ventral surfaces of the cerebral ganglion. A single neuron is located in the E cluster near the root of the 
cerebral-buccal connective (CBC and white arrow, only present at the right. Left CBC was accidently cut), and a cluster of small 
neurons is located between the roots of the cerebral-pedal connective (CPe) and cerebral-pleural connective (CPl). White arrows 
point to the labeled cells at the left side. AT, anterior tentacular nerve; UL, upper labial nerve. Calibration: 500 μm. (B, C) 
Immunocytochemistry with GdFAD antibody. (B) The dorsal surface of the pedal ganglion. The cluster of positive neurons 
matched in situ hybridization with apALNP, suggesting that GdFAD antibody can label apALNP-positive neurons. (C) The 
buccal ganglion. Consistent with in situ hybridization, there are no GdFAD-positive somata in the buccal ganglion, but there are 
GdFAD-positive fibers and varicosities, e.g., in the neuropile, commissure (C) and the radula nerve (RN). Presumably, the 
staining suggests that apALNP-positive fibers and varicosities are in the buccal ganglion. Calibration: 500 μm. 
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Figure 4.3. GFFD and GdFFD can be distinguished by their different fragmentation patterns using MALDI-TOF/TOF 
MS. (A) Overlaid representative MS/MS spectra from GFFD standard (black); GdFFD standard (blue); and isolated pedal 
neurons (red), normalized to the y2 ion as % intensity. (B) Each epimer, i.e., GFFD or GdFFD, produces a unique ratio using two 
of the most discriminative fragment ions, y2 and b3.The ratio measured from the isolated neurons appears to be closer to the 
value for GdFFD, suggesting that the neurons contain both GFFD and GdFFD. 
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Figure 4.4. Statistical analysis demonstrates that peptides from isolated neurons are more similar to GdFFD, such that 
GdFFD is likely the major contributor to m/z 484.9 in MALDI-TOF MS. (A) PCA demonstrates the clustering of GdFFD 
standard (inverted triangle), GFFD standard (upright triangle), and biological samples (circles) based substantially on two 
principal components (PCs), with the biological samples clustering more closely with the GdFFD standard based primarily on PC 
1. Each symbol corresponds to the fragmentation profile of one sample. The average peak area from three acquisitions of each 
sample, normalized to the sum of the peak areas of all ions in the respective MS/MS spectrum, is used for PCA analysis. (B) 
Seven fragment ions are the variables used in the PCA analysis. Their impact regarding to the two PCs are shown in the figure. 
There are two distinctive groups regarding PC 1. Fragment ions such as b3 and Fi ion are in one group showing similar impact in 
group forming, and fragment ion y2 is another. The differences in these two groups of variables have contributed to assigning the 
two clusters. (C) The table of Eigen values shows that only PCs 1 and 2 have an Eigen value higher than 1, and these two are the 
components that explain the majority of the variations.  
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Figure 4.5. GFFD and GdFFD are detected from neurons isolated from the pedal ganglia from Aplysia californica using 
LC-MS. (A) LC separation of GFFD and GdFFD. (B) MS/MS fragmentation spectrum of endogenous GFFD (21.4 min). (C) 
MS/MS fragmentation spectrum of endogenous GdFFD (24.3 min). (D) The retention times on the LC and fragmentation patterns 
(E, F) of both peaks match well with those of synthetic peptides, which confirms the identification. (E) MS/MS fragmentation 
spectrum of synthetic GFFD (21.4 min). (F) MS/MS fragmentation spectrum of synthetic GdFFD (24.3 min). 
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Figure 4.6. GdFFD is detected in whole buccal ganglia extracts from Aplysia californica using LC-MS. (A) LC separation of 
buccal ganglia peptides. Arrow points to a peak at the retention time matching that of the GdFFD standard. (B) MS/MS of 
GdFFD (31.4 min). The fragmentation patterns and retention time of GdFFD matches the synthetic peptide in (C), which 
confirms the identification.  
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Figure 4.7. YAEFLa, but not YdAEFLa, is detected using LC-MS to analyze Aplysia californica cerebral ganglia peptide 
extracts. (A) Solid arrow points to the retention time for YAEFLa and dotted arrow points to the retention time for YdAEFLa. 
While the separation in (A) used a C18 column, the retention times were too close for confident assignment, and a hypercarb 
column was used as the stationary phase for the separations in (B), where the solid arrow points to a peak matching the retention 
time of the YAEFLa standard (37.7 min) and the dotted arrow points to a retention time expected for YdAEFLa (41.0 min), 
although no m/z 641.3 is observed at the mass spectrum at this retention time. (C) MS/MS fragmentation spectrum of YAEFLa. 
(D) MS/MS fragmentation spectrum of synthetic YAEFLa (37.7 min). (E) MS/MS fragmentation spectrum of synthetic 
YdAEFLa (41.0 min). The MS/MS fragmentation pattern of the endogenous YAEFLa matches the expected fragmentation 
pattern of Y(l/d)AEFLa at a retention time matching the YAEFLa standard, confirming that this peptide is predominately in the 
all L-form. 
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Figure 4.8. GdFFD induces cyclic activity in the buccal central pattern generator (CPG). Each cycle of programs consists of 
a protraction (open bar, marked by I2 nerve activity) – retraction (closed bar, marked by hyperpolarization of B65 interneuron) 
sequence. (A) Control: at rest, there was little activity in the buccal CPG protraction interneurons B40 and B65, radula closure 
motoneuron B8, or the I2 nerve. (B) During the perfusion of 10-5 M GdFFD, the feeding network became cyclically active. The 
motor programs induced were mostly egestive because B8 activity occurred during the protraction phase (represented by B65 
bursting). Consistently, B40, a neuron important for ingestive programs, was not active, although it received cyclic synaptic 
inputs. (C) After washout of the peptide, the preparation gradually returned to the inactive state, beginning with the trace, 4.2 min 
after the start of the washout. (D) Summary data (n = 4) showing the effects of 10-6 M and 10-5 M GdFFD on the activity of the 
buccal CPG. The frequency of the motor programs is the number of cycles per min measured over a period of 7 min or more in 
each experimental condition. Both 10-6 and 10-5 M GdFFD increased the frequency of spontaneously-occurring motor programs. 
Bonferroni post-hoc test (with selected comparisons between peptide applications vs. the control or the wash): *, p <0.05, **, p 
<0.01. Error bars represent SEM. (E, F) Effects of GFFD and GdFFD on motor programs elicited by the command-like 
interneuron CBI-2. B34 is a buccal protraction interneuron active during protraction (open bar, marked by I2 nerve activity), 
CBI-2 is an interneuron that triggers programs by activating protraction interneurons in the buccal ganglion, which, in turn, 
activate the retraction neurons. In addition, CBI-2 receives inhibitory feedback during retraction 65, and is not or only weakly 
active during retraction. Thus, single cycle motor programs were elicited by stimulation of CBI-2 at 9 Hz throughout the 
protraction phase with inter-trial intervals of 1 min. (E1–3) Representative examples. (E1) Control: CBI-2 stimulation induced an 
ingestive motor program, in which B8 was predominantly active during retraction (filled bar, marked by hyperpolarization of B34 
interneuron). (E2) Perfusion of 10-5 M GFFD had no obvious effect on the CBI-2-elicited program. (E3) Washout of the peptide.  
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Figure 4.8 (continued)                                                                                                                                          a 
(F1–3) Representative examples. (F1, F3) are the same as E1, E3, except with the perfusion of (F2) 10-6 M GdFFD, which 
increased B8 firing during protraction, and reduced B8 firing during retraction. It also decreased the duration of protraction. (F4–
7) Group data (n = 4) showing the effects of GdFFD on (F4) protraction duration, (F5) retraction duration, (F6) B8 activity 
during protraction, and (F7) B8 activity during retraction. Bonferroni post-hoc test: **, p <0.01. ***, p <0.001. 
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Figure 4.9. Absence of effects of GFFD in the isolated cerebral and pleural-pedal ganglia. (A) The electrophysiological 
recordings of PPCN during control, after perfusion with 10−6 M or 10−5 M GFFD, and during wash, each recording lasting ~ 10 
min. (B) Group data of the average PPCN frequency over 10 min under different conditions. GFFD had no significant effects on 
PPCN activity. Error bars indicate SEM. 
 
 
Figure 4.10. GdFFD induces activity in the isolated cerebral and pleural-pedal ganglia. (A) The electrophysiological 
recordings of PPCN during control, after perfusion with 10−6 M or 10−5 M GdFFD, and during wash, each recording lasting ~ 10 
min. (B) Group data. (B1) The average frequency of PPCN over 10 min; (B2) The average of frequency within bursts in PPCN 
over a period of 10 min; (B3) The average of frequency between bursts in PPCN over 10 min. Bonferroni post hoc tests: *p < 
0.05; **p < 0.01; ***p < 0.001. Error bars indicate SEM. 
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CHAPTER 5  
OPTIMIZATION OF THE D-AMINO ACID-
CONTAINING NEUROPEPTIDE DISCOVERY FUNNEL 
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5.2 Abstract 
 In this chapter, the development and capabilities of a method for the non-targeted discovery of D-
amino acid-containing neuropeptides borrowing from several strategies, including an enzymatic screen, 
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acid hydrolysis and amino acid separation for detection of D-amino acids, and using liquid 
chromatography with synthetic standards to confirm the presence of a D-amino acid-containing peptide. 
Improvements discussed in this chapter helped make the discoveries seen in Chapter 6 feasible. 
5.3 Introduction 
D-amino acid-containing peptides (DAACPs) have been found as bioactive peptides in the nervous 
systems of multiple mollusks.1 Characterization of DAACPs and their discovery has been covered in 
previous chapters, but the more recent method developments have rarely targeted neuropeptides, 
specifically. 
Aplysia californica has been a central part of developing the strategies in this chapter. An important 
reason for choosing A. californica for study is that NdWFa and GdFFD (Chaper 4) have been identified in 
this mollusk, so other DAACPs could be present in its nervous system, as well.2,3 An important reason A. 
californica has been the subject of many neuropeptide studies is that it is an excellent physiological model, 
with large, well-characterized neurons wherein specific neurons have been tied to animal behaviors.3-9 
There exist several strategies for the study of DAACPs, which have been covered extensively in 
the previous chapter. What is lacking in all of these strategies is a systematic approach that takes 
advantage of the properties common to the molluskan DAA-containing neuropeptides. One common 
property to all of the known molluskan DAA-containing neuropeptides is that isomerization occurs at the 
second position from the N-terminus.1 Unlike spontaneous racemization, which tends to favor Ser, Ala, 
Pro, Glu, and especially Asp, more than half of the chiral amino acids have been isomerized in 
endogenous DAACPs, with the exceptions of basic amino acids (His, Arg, Lys), acidic amino acids (Asp, 
Glu), Gln, Tyr, Pro, and Cys. There is no reason to believe that Gln and Tyr could not be isomerized, as 
the structurally similar amino acids Asn and Phe have been isomerized. Indeed, a D-Tyr is reported for the 
first time in an endogenous DAACP in Chapter 6. Thus, a strategy for detecting DAA-containing 
neuropeptides should take advantage of the common property of isomerization at the second position 
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from the N-terminus, while still capable of detecting DAAs in any position. Also, because 
neuropeptidomes tend to contain a complex and diverse set of peptides, initial studies should be able to be 
carried out without the use of synthetic standards, which would not be feasible for all possible 
neuropeptides. 
Towards that goal, the DAA-containing neuropeptide discovery funnel is described here in some 
detail. (Fig. 5.1) Briefly, the funnel has three steps. The first step is a screening step, which uses 
aminopeptidase M (APM) as an enzymatic screen. The second step is chiral analysis, which uses heat and 
acid to break peptides down into their component amino acids, followed by labeling of those amino acids, 
ending with separation and detection of the LAAs and DAAs. Finally, the third step, confirmation, is 
where an endogenous DAACP is confirmed with synthetic standards, comparing such properties as 
retention times on liquid chromatography (LC) and bioactivity. These steps were developed with the 
overall output being the discovery of DAACPs but also with several practical considerations. The first 
step, screening, has the goal of selecting peptides for follow up studies; hence false positives are more 
acceptable than negatives as the former will be caught in the subsequent steps of the funnel. Peptides that 
are missed, however, are lost to discovery. Lastly, while several approaches exist to confirm a chiral 
peptide with the aid of a synthetic peptide, potentially thousands of peptides could be screened from a 
complex brain sample which makes the requirement of standards in the first two steps impractical.  With 
these goals in mind, each of the steps in the funnel, their justification, and their improvements over 
initial/published conditions are discussed in more detail below as separate sections—screening, chiral 
analysis and confirmation.   
5.4 Step 1: Screening 
5.4.1 Introduction 
The first step of the DAA-containing neuropeptide discovery funnel, screening, is key. There are 
many forms of screening for DAACPs. The first and most obvious is to use homology to a known 
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DAACP; after all, if the isomerizing enzyme acts upon a particular peptide motif, similar peptides may 
also be isomerized. Homology was the reason to suspect that the achatin-like prohormone would contain 
GdFFD in Aplysia californica Isobaric LC separation of peptides has traditionally been used to 
definitively identify DAACPs, comparing the retention times of standards with the suspected chirality to 
the endogenous peptides.1 Thus, if a peptide, particularly using LC-MS/MS, can be sequenced and 
detected at two distinct retention times, this information lends evidence to the presence of a DAACP. 
Covered extensively in this section is the enzyme APM. APM is an enzyme that has been used previously 
to study DAACPs, specifically in the context of NdWFamide in A. californica.10 APM cleaves one amino 
acid at a time, starting at the N-terminus, and has a much higher affinity for L-amino acids (LAAs) over 
DAAs. Importantly, it is a general peptidase, such that it can degrade peptides of many different 
sequences of LAAs. This is likely due to its mechanism as a general peptidase, taking advantage of the 
peptide’s backbone. Similarly, a DAA’s peptide bond to an LAA would be expected to have a different 
bond angle and functional group positioning than an LAA peptide bonded to another LAA; this explains 
the relative resistance of DAACPs to this peptidase. 
This following results section focuses efforts to make the APM digestion approach more robust 
from prior efforts.  Thus, this description describes protocol enhancements that improve the APM 
digestion approach, enhancing the usefulness of this enzyme for non-targeted screening. As the method 
existed earlier, there was ambiguity of results from digestion kinetics.  For example, a low abundance 
peptide species may appear to degrade slowly because its rate of degradation would be reduced compared 
to a high abundance peptide species. Homology and split-peak elution have been very helpful approaches 
for DAACP discovery, but like any discovery method, they have their limitations, so development of the 
APM-based approach is important for the further discovery of endogenous DAACPs.  
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5.4.2 Methods 
Reactions use the enzyme APM (EC 3.4.11.2, Merck, Darmstadt, Germany). Peptide reaction 
conditions use 25 mM Tris-HCl with 0.5 M NaCl, pH 7.5, with 0.1 µg of each peptide added. These are 
reacted at 37 oC. NdWFamide and YdAEFLamide were synthesized by the Protein Sciences Facility of 
the Roy J. Carver Biotechnology Center, University of Illinois at Urbana-Champaign. Human angiotensin 
I acetate salt hydrate, Tris, HCl, and NaCl was purchased from Sigma-Aldrich (St. Louis, MO). 
Peptide content is compared between 0 h, 5 h, and 24 h of enzyme digestion. 1 µl of peptides are 
spotted on a 384 spot stainless steel target with 1 µl of dihydrobenzoic acid (DHB) (Sigma-Aldrich, St. 
Louis, MO) in 50% acetone. These spots are analyzed using matrix-assisted laser desorption ionization, 
time of flight MS (MALDI-TOF) (ultrafleXtreme, Bruker Daltonics, Billerica, MA). All data analysis is 
performed using fleXanalysis (Bruker Daltonics). 
5.4.3 Results 
In the published work, APM has been shown to rapidly degrade the all-LAA peptide Angiotensin I, 
while degrading the DAACP YdAEFLa more slowly, and the short DAACP NdWFa not at all. YdAEFLa 
was degraded after roughly 24 h, whereas Angiotensin I was degraded after about 7 h (See previous 
chapter, Fig. 3.5).10 This kinetics is problematic in that the log phase of degradation occurs only for higher 
intensity species. Neuropeptides are present at several orders of magnitude different concentrations in a 
given nervous system.11 Thus, the enzyme would be unable to act effectively upon lower intensity species 
compared to higher intensity species, and this could be interpreted as resistance. In addition, different 
sequences at different concentrations would likely have differing degradation kinetics, and it would not be 
immediately appreciated what a slower degradation looks like for a particular peptide without the use of 
many standards. Thus, it would be more desirable if the enzyme could have a better discriminatory ability, 
such that DAACPs are hardly degraded at all but all-LAAs peptides are degraded within a reasonable 
period of time, such as a 24 h experiment. 
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In the published results by Ewing et al, a buffer composed of 35 mM (NH4)2SO4 was used with 10 
mM MgCl2.10 The APM enzyme has been used for digesting short peptides in several other buffer 
solutions. Many of these used a near-neutral Tris buffer, some of them along with a NaCl solution.12-16 
Some of the first papers studying this enzyme noted a pH of maximum activity at 7.5, and this enzyme 
was eluted off of a column with activity at 500 mM NaCl.16 Simply switching to these conditions 
increased the ability of this enzyme to discriminate between DAACPs and all-LAA peptides (Fig. 5.2). In 
these conditions, while the LAA-peptide Angiotensin I is still rapidly degraded within 4 h, the DAACP 
YdAEFLa does not appear to be degraded at 24 h, especially when compared to the negative control 
NdWFa. 
5.5 Step 2: Chiral analysis 
5.5.1 Introduction 
As discussed in Chapter 3, acid hydrolysis has been used in the discovery of several DAACPs, 
including some deltorphins.17 Acid hydrolysis breaks peptides down into their component amino acids. 
This has a distinct advantage for assaying DAACPs. Whereas the properties of peptides can be quite 
complex depending on the amino acid sequence, protein-contributing amino acids come in a finite 
number of forms. 19 out of the 20 most common amino acids are chiral, and there are a number of ways 
to separate these amino acids. 
Vapor phase acid hydrolysis is capable of rapidly breaking down proteins into their component 
amino acids, finishing this process in less than 1 h.18 The rapid nature of this technique prevents the 
degradation and oxidation of amino acids seen in the slower technique liquid phase acid hydrolysis, which 
takes 24 h to degrade proteins. As neuropeptides can be present at low levels, it is advantageous to use a 
technique that minimizes degradation like vapor phase hydrolysis instead of liquid phase hydrolysis. 
Once a peptide is broken down into its component amino acids, the LAAs and DAAs must first be 
separated then detected. There are many options for amino acid separations, but as mentioned previously, 
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endogenous DAACPs appear to have isomerized residues in most classes of amino acids, with the 
exception of the acidic or basic amino acids. Thus, it is important to utilize a separation technique that is 
capable of simultaneous separation of all LAAs and DAAs. While most chemical tags and techniques are 
specific for some sets of amino acids, one chemical tag with this capability is Marfey’s Reagent (1-Fluoro-
2,4-dinitrophenyl-5-L-alanine amide, FDAA).19,20 The L-form was observed to always elute before the D-
form, presumably due to the fixed structure of the tag where the LAA’s side chain will be in a trans 
formation with the –CH3 of L-alanine amide (already on the tag) compared to the plane of the benzene 
ring on the derivatization reagent, whereas the DAA’s side chain will be in cis formation with the –CH3 of 
L-alanine amide compared to the plane of the benzene ring on the derivatization reagent.20,21 However, 
even in this case, certain LAAs will have similar retention times to one another, even as they are 
separated from their DAA enantiomer. This challenge can be overcome with a detection method capable 
of measuring the labeled amino acids in separate chromatograms. Our chosen method is a triple-
quadrupole mass spectrometer (TQ-MS) interfaced with an LC. The TQ-MS contains quadrupoles, two 
pairs of circular rods placed in parallel. The first quadrupole (Q1) acts as a mass filter, selecting the ion of 
a certain mass of interest, known as the “parent ion”. The parent ion, in this case, would be the molecular 
weight of an amino acid with the label. Q2 is a collision cell, which fragments the parent ion using high 
energy and an inert gas. Q3 acts as another mass filter, so that only the fragment ion (also known as a 
transition) of a particular weight reaches the detector. TQ-MS is capable of multiple reaction monitoring 
(MRM), which generates LC-MS/MS chromatograms simultaneously for multiple monitored ions through 
the rapid scan times of a TQ-MS. Each LC-MS/MS chromatogram is known as a channel. In this way, 
another dimension of separation is added to this procedure; rather than monitor all 19 common chiral 
amino acids and glycine, potentially forming 39 peaks in a chromatogram, a channel for each amino acid 
is established. Thus, at most, one expects two peaks in each channel, making data analysis less ambiguous 
and overcoming the problem of two LAAs co-eluting on LC. 
During acid hydrolysis, a low rate of racemization may occur, which leads to the incorrect detection 
of DAAs. As a solution to this problem, the reactions are carried out in 6 M DCl in D2O.22,23 
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Racemization will extract a deuteron from the solution, causing a shift in mass of 1 Dalton. Since MRM 
monitors parent ions based on their molecular weight, a shift of +1 will cause a racemized amino acid to 
be undetected in the same channel as the amino acids which are not racemized. 
In any detection technique, one wishes to maximize detection of the chosen species and reduce 
the background of undesirable contaminants. Toward that end, improvements upon initial and published 
conditions are discussed below. 
5.5.2 Methods 
Acid hydrolysis 
First, peptides and standards are dried into vapor phase reactional vials (CEM, Mathews, NC). 
Acid hydrolysis is performed in the vapor phase in 6N DCl in D2O (Sigma-Aldrich, St. Louis, MO) at 150 
oC for 30 min in a CEM Discover Microwave (Mathews, NC).18  
Labeling with Marfey’s Reagent 
Marfey's reagent is from Therom Fisher Scientific (Waltham, MA). For derivatization: the amino 
acids from the acid hydrosylates are dried and reconstituted in 25 µl of 0.5 M NaHCO3. (Thermo Fisher 
Scientific, Waltham, MA). 20 µM of an L-Ser was used in this case. (Sigma-Aldrich, St. Louis, MO) 20 
µl of 1 mg/ml and 10 mg/ml FDAA dissolved in acetonitrile are added to these amino acids. Labeling 
conditions were tested at 40 oC, 60 oC, and 80 oC at 1 h. Once 60 oC was determined to be the best 
labeling temperature, labeling occurred at 1, 2, and 3 h at 60 oC. The LC-MS/MS-MRM system uses the 
Advance ultra-high performance LC (UPLC) and Bruker EvoQ triple quadruople-MS (both from Bruker, 
Billerica, MA). The column is a Kinetex 2.6 micron particle Phenyl-Hexyl column, 100 Ǻ pore size, 100 
mm (length) x 2.1 mm (diameter) (Phenomenex, Torrance, CA). A binary solvent system is used, with 
increases in Buffer B (organic) solvent over the course of a 30 min run. Initial conditions used Buffer A: 
25 mM ammonium formate buffer. Buffer B: acetonitrile. Final conditions used Buffer A: 25 mM 
ammonium formate, Buffer B: methanol. (all from Thermo-Fisher Scientific, Waltham, MA) EvoQ MRM 
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chromatograms are analyzed using Data Review (Bruker, Billerica, MA). 
5.5.3 Results 
The chiral analysis component of the discovery funnel utilizes Marfey’s Reagent for separation. All 
of the common chiral amino acids can be separated with this technique, and using MRM allows for 
detection of only two peaks (corresponding to the LAA and DAA) in each LC-MS/MS chromatogram. 
The only exception is L/D-Leu and L/D-Ile, two amino acids that have the same molecular weight but are 
not enantiomers. However, these are separated using LC. (Fig. 5.3) The separation of all the other amino 
acids is covered in Chapter 6. 
A limitation of Marfey’s Reagent is the high degree of background conferred by using a tag that is 
based on L-alanine-amide.19 This tag is often added in excess for labeling amino acids. It appears that in 
the process of producing the tag, impurities in the L-alanine-amide, which mostly includes L-Ala, are also 
labeled. This background signal can sometimes overwhelm the signal from endogenous peptides. As a 
means of reducing this background, the amount of labeling reagent was reduced cut down 10-fold, from 
10 mg/ml to 1 mg/ml (Fig. 5.4). This reduced the background of L-Ala, down nearly 1,000 fold in recent 
experiments compared to previous experiments. 
As neuropeptides can be present at in a nervous system at very low levels, maximizing the 
detection of amino acids by maximizing labeling yield is key. Many studies using Marfey’s Reagent 
incubate the amino acids for 1 h at 40 oC.20,23-26 Considering this may be inadequate for lower levels of 
peptide, several temperatures of reaction were tested, as increased temperatures should yield better 
reaction rates. There was, on average, a 63.6% increase in labeling of L-Ser at 60 oC compared to labeling 
at 40 oC, whereas 80 oC appeared to interfere with labeling. (Fig. 5.5) As 60 oC was considered an 
adequate temperature for labeling, the time of reaction was also tested at 1, 2, and 3 h. There was an 
increase with detected L-Ser with increased labeling time, with a 90.2% increase comparing the 1 and 3 h 
labeling conditions. (Fig. 5.6) 
 112 
 
Aspartic acid is a small, charged amino acid. At the pH and solvent composition compatible with 
our column system, L-Asp carries a negative charge and does not bind to the stationary phase of the 
column as well as the other common chiral amino acids, which can result in poor elution reproducibility 
with undesirable peak shape. (Fig 5.7) Methanol is considered to have a weaker eluting strength when 
combined with water as compared to an acetonitrile and water combination. By changing the eluting 
solvent to methanol instead of acetonitrile, good retention and peak shape was observed. 
5.6 Step 3: Confirmation step 
The final step of the discovery funnel, confirmation, relies on characterizing the endogenous 
neuropeptide with respect to the results obtained from chiral analysis. Synthetic peptides of the 
neuropeptide of interest are synthesized, both in the all-LAA form and the suspected D-form of the 
peptide. One of the most common and traditional ways to confirm the presence of a DAACP is by relying 
on the LC retention, as was done with GdFFD in Chapter 4 and as described in Chapter 2.27-33 Ion 
mobility spectrometry and MS/MS fragment ion intensities are also a good way of confirming the 
presence and position of a DAACP, as outlined in Chapter 3.3,34-39 Finally, once the DAACP form is 
known, its bioactivity can be compared to all-LAA peptide. 
5.7 Discussion 
The DAA-containing neuropeptide discovery funnel is a strategy for the discovery of endogenous 
neuropeptide DAACPs in animals. Its purpose is to focus on techniques applicable to neuropeptides. 
Some of those techniques required optimization to fit the unique needs of neuropeptides, such as using 
APM, the need to separate and detect all 19 common chiral amino acids, and the need for sensitive 
detection of DAAs that may come from low abundance endogenous species. 
The three steps of a funnel work together to produce a discovery pipeline.  The first step involves 
screening for DAACPs, either by homology, split-peak elution, or APM. APM is an excellent tool for the 
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non-targeted discovery of DAA-containing neuropeptides, whose DAAs have been found exclusively at 
the second position from the N-terminus. However, when combined LC-MS/MS, APM could conceivably 
discover DAAs in positions other than the second position from the N-terminus, because automated 
MS/MS software can identify truncated peptides post-APM digestion. APM was seen to have an 
improved digestion profile with alteration of the buffering conditions. (Fig. 5.2) These conditions are 
suitable for the detection of DAACPs in the nervous system of A. californica in Chapter 6. However, 
there are some limitations to the screening step. The list of potential DAACPs that is generated by the 
first step is not exhaustive and may include false positives. There are a number of reasons an isobaric 
peptide might separate on HPLC. For example, different conformations, based on differing secondary and 
tertiary interactions, may lead to two different retention times for a single peptide. Homology to 
previously characterized peptides by no means guarantees that isomerization will be conserved in both 
species, as seen in the case of fulyal (Chapter 4).3 Identifying potential DAACPs by resistance to APM 
digestion is going to inevitably generate a lot of false positives, too, because resistance to APM digestion 
can be mediated by specific residues and PTMs other than isomerization. A notable exception is peptides 
with an L-Pro at their N-termini despite the presence of only LAAs; APM will stop at this residue and will 
not readily degrade a peptide with an L-Pro at the first or second position from the N-terminus of a 
peptide.10 A proline’s R-group cyclizes onto the peptide backbone interrupts access of this enzyme to the 
backbone. In addition, some modifications also render a peptide resistant to digestion by APM, including 
N-terminal acetylation and pyroglutamylation. It could also thus be predicted that a cyclic peptide may 
not be degraded by APM. A consequence of these false positive is that they will be ignored, but a D-Pro 
may still be present in the peptide. Also, an N-terminal acetylation or proglutamylation does not preclude 
the existence of a DAA in a peptide. For example, crustacean hyperglycemic hormone has an N-terminal 
pyroglutamylation and a D-Phe in the third position from the N-terminus. Ultimately, these limitations 
necessitate the second step of the funnel, chiral analysis. 
While the output of the first step is a list of potential DAACPs, the goal of the second step is to 
confirm the peptides from the first step, as well as verify the location of the DAA.  Chiral analysis assays 
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the LAA and DAA content of potential DAACPs. Deuterium-assisted hydrolysis is used with LC-MS/MS 
MRM and a triple quadrupole MS to avoid the detection of acid hydrolysis-induced racemization.22 
Marfey’s Reagent is used as a tag for separating LAA and DAA enantiomers, and it was even capable of 
separating the isomeric L/D-Leu/Ile (Fig. 5.3),19,20 the only set of amino acids that appear in the same 
MRM chromatograms. Increasing the time and temperature of the reactions from 1 h and 40 oC to 3 h and 
60 oC lead to a considerable increase in the labeling efficiency, and thus the technique is more suitable for 
neuropeptides that may be present at much lower levels. (Fig. 5.5 and 5.6) However, 80 oC had a reduced 
labeling efficiency, likely because it was causing evaporation of the organic solvent in the reaction 
(acetonitrile) and thus inhibiting the reaction. By utilizing this method of chiral analysis, the use of 
synthetic standards for all suspected DAACPs is precluded. However, like all the techniques for 
characterizing DAACPs, this method has limitations. Acid hydrolysis can lead to the destruction of 
certain amino acid species, although there are strategies concerning these amino acids.40 Also, this form 
of chiral analysis gives no positional information; if there are multiple alanines in a particular peptide, the 
detection of a D-Ala gives no information about where that D-Ala may be located. This drawback 
necessitates additional confirmation. 
The final step is confirmation of the DAACP by the synthesis of a standard, and then confirmation 
that the endogenous peptide has similar properties based on chiral separation migration time. The 
validated standard also allows follow up bioactivity testing to determine function. The improvements 
outlined in this chapter are summarized in Table 5.1. 
Together, these steps work in concert to eliminate some of the weaknesses of the other steps. Chiral 
analysis and confirmation each eliminate false positives from the previous steps. Likewise, APM 
screenings limit the number of peptides that are targeted for chiral analysis, and chiral analysis limits the 
number of synthetic standards that must be prepared from literally all possible peptides to only those who 
share properties common to other DAACPs. 
The technical limitations of each of the individual steps have been discussed, but there are other 
considerations when deciding to use this approach in regards to neuropeptide samples. While 
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confirmation of a DAACP with standards can be performed even in chemically complex samples, APM 
screenings and chiral analysis require some degree of sample isolation. APM screenings are somewhat 
tolerant to complex samples, but changing the ratio of substrate to enzyme too dramatically can affect 
enzyme kinetics in a way that reduces the reliability of perceiving a resistance to degradation. For this 
reason, initial extracts from a nervous system structure is often fractionated with LC first to reduce 
sample complexity. Deuterium-assisted acid hydrolysis as a method of chiral analysis requires a relatively 
pure sample. When there are hundreds of peptides, up to thousands with peptide truncations and 
nonspecific protein degradation in a given sample,41-44 chemical complexity is problematic. After all, if 
something like a D-Tyr is detected in a chemically complex sample of hundreds of peptides, the source of 
this D-Tyr must be easily identifiable, otherwise there will be no way to understand which peptides should 
be synthesized with a D-Tyr for confirmation. The purity of a peptide fraction is typically achieved by 
more precise sampling techniques, like sampling from fewer cells in A. californica as seen in Chapters 4 
and 6, and/or multiple stages of LC are employed. This presents several challenges in and of itself. 
Peptides in the nervous system can span low pM levels in a brain region to low mM levels in a dense core 
vesicle.45-47 This dynamic range means that a lower intensity peptide may be interesting and important to 
study, but its isolation may prove difficult in the presence of higher intensity, coeluting peptides. Although 
not covered in great detail, this was the case for SdYADSKDEESNAALSDFA, which coeluted with a 
more highly expressed pedal peptide in the pedal ganglia of A. californica. With the additional possibility 
of sample loss occurring over multiple stages of LC, these kinds of challenges should be considered when 
applying chiral analysis to a particular peptide. This can be overcome some of the time, just depending on 
the relationship of the peptide of interest to others that coelute on LC with it. 
Regardless, now that the method for chiral analysis has been improved and made robust, it will be 
validated using the neuropeptides found within the well-characterized A. californica nervous system, used 
to detect new DAACPs in Chapter 6. An advantage of this method is that it can begin probing many 
neuropeptidomes in a non-targeted manner. In this way, the number of species and phyla where 
endogenous DAACPs exist can be expanded.  
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5.8 Figures and tables 
 
Figure 5.1. The DAA-containing neuropeptide discovery funnel is a multi-technique approach for the detection of 
DAACPs. In the first step, screening, potential DAACPs are identified by resisting digestion to APM, sequence homology to 
known DAACPs, or split-peak elution. Once the potential hits from the first step are isolated, the second step, chiral analysis, 
assays the chiral content of a peptide. This begins with acid hydrolysis, which breaks down the peptide into its component amino 
acids. Those L- and DAAs are labeled with Marfey’s Reagent, separated, and assayed using a triple quadrupole MS with MRM. 
The third step, confirmation, confirms the hits from the second step using standards synthesized with the DAA in the suspected 
position, compared to the corresponding peptide composed only of LAAs. These standards are compared to the endogenous 
peptide using its LC retention time or fragmentation patterns. The standards can also be used for bioactivity-based studies. 
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Figure 5.2. Aminopeptidase M (APM) degrades peptides with all-LAAs, but degrades DAACPs more slowly. By changing 
the buffering conditions of the reaction from the published results,10 the discriminative ability of this enzyme is increased. 
Angiotensin I (blue trace), a known all-LAA peptide, is nearly completely degraded after <5 h. In contrast, YdAEFLamide (red 
trace), a DAACP, is not degraded after 24 h as a ratio to the negative control, NdWFamide (black trace). Error bars and points are 
mean ± standard deviation, n = 3 reactions. 
 
 
 
 
 
 
 
 
 
 
 
NdWFa 
YdAEFLa 
Ang 1 
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Figure 5.3. Labeled L/D-Leu and Ile are in the same MRM channel, but are separated via LC. These two amino acids are 
also isomers of one another, but not diastereomers. Because they are isomers, they have the same molecular weight and 
fragmentation, thus they are in the same MRM channel. Labeling with Marfey’s Reagent allows the separation of these amino 
acids, enabling their differentiation. Spiking experiments can thus be used should any peak assignment ambiguity occur. 
 
 
 
 
 
L-Ile 
D-Ile 
D-Leu 
L-Leu 
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Figure 5.4. Reducing the amount of Marfey’s Reagent in reaction solution reduces background detection of L-Ala. 
Marfey’s Reagent is synthesized from L-alanine-amide, and thus contributes to the background detection of L-Ala. Reducing the 
amount of Marfey’s Reagent 10-fold from 10 mg/ml to 1 mg/ml reduces the background detection of L-Ala almost 1000-fold, 
without any recognizable differences in labeling efficiency (data not shown). Bar graphs are mean ± standard deviation, n = 10 
experiments of blank labeling (no amino acids were added to the reaction mixture). 
 
 
 
 
 
Background labeling of L-Ala with 
different levels of Marfey’s Reagent 
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Figure 5.5. Changing the temperature of Marfey’s Reagent labeling changed the labeling efficiency of L-Ser. On the left, 
bar graphs demonstrate that the optimum labeling temperature is 60 oC. At 80 oC, the organic solvent begins to evaporate, 
inhibiting the reaction. Bar graphs are mean ± standard deviation, n = 3 experiments. On the right, representative chromatogram 
of L-Ser. The color of the bar graph temperature corresponds to the color of the chromatogram trace. 
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Figure 5.6. Increased Marfey’s Reagent reaction time increases the labeling efficiency. On the left, there is improvement of 
labeling of L-Ser by increasing the time of reaction. On the right, representative chromatograms of these reactions, with the bar 
graph colors corresponding to the chromatogram traces. 
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Figure 5.7. L/D-Asp experienced enhanced binding and better peak shapes with methanol-based solvents. These traces are 
an MRM channel specific for labeled Asp. Black trace – the organic solvent originally used was acetonitrile, which could lead to 
poor retention of L/D-Asp. This lead to difficulty in assigning peaks and overall poor peak shape. Red trace – when the organic 
solvent is switched to methanol, L/D-Asp can bind to the stationary phase of the LC-column, resulting in better peak shapes and 
separation. 
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Table 5.1. Summary of efforts to optimize various aspects of the screening and chiral analysis steps of the DAA-containing 
neuropeptide discovery funnel. 
Initial conditions Final conditions Improvement 
APM buffer: 35 mM 
(NH4)2SO4 with 10 mM 
MgCl2 
APM buffer: 25 mM Tris-HCl 
with 0.5 M NaCl, pH 7.5 
Negative control YdAEFLa 
not degraded at all within 24 h 
Labeling conditions: 10 mg/ml 
Marfey’s Reagent in reaction 
solution 
Labeling conditions: 1 mg/ml 
Marfey’s Reagent in reaction 
solution 
Reduced background detection 
of L-Ala by 3 orders of 
magnitude 
Labeling conditions: 
40 oC, 1 h 
Labeling conditions: 
60 oC, 3 h 
Avg improve by temp: 63.6% 
Avg improve by time: 90.2% 
Separation conditions: 
ammonium formate + 
acetonitrile 
Separation conditions: 
ammonium formate + 
methanol 
Reliable retention and 
separation of L/D-Asp 
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CHAPTER 6  
A D-AMINO ACID-CONTAINING NEUROPEPTIDE 
DISCOVERY FUNNEL 
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6.2 Abstract 
A receptor binding class of D-amino acid-containing peptides (DAACPs) is formed in animals 
from an enzymatically mediated post-translational modification of ribosomally translated all-L-amino 
acid peptides. Although this modification can be required for biological actions, detecting it is challenging 
because DAACPs have the same mass as their all-L-amino acid counterparts. We developed a suite of 
mass spectrometry (MS) protocols for the nontargeted discovery of DAACPs and validated their 
effectiveness using neurons from Aplysia californica. The approach involves the following three steps, 
with each confirming and refining the hits found in the prior step. The first step is screening for peptides 
resistant to digestion by aminopeptidase M. The second verifies the presence of a chiral amino acid via 
acid hydrolysis in deuterium chloride, labeling with Marfey’s reagent, and liquid chromatography–mass 
spectrometry to determine the chirality of each amino acid. The third involves synthesizing the putative 
DAACPs and comparing them to the endogenous standards. Advantages of the method, the D-amino acid-
containing neuropeptide discovery funnel, are that it is capable of detecting the D-form of any common 
chiral amino acid, and the first two steps do not require peptide standards. Using these protocols, we 
report that two peptides from the Aplysia achatin-like neuropeptide precursor exist as GdYFD and 
SdYADSKDEESNAALSDFA. Interestingly, GdYFD was bioactive in the Aplysia feeding and locomotor 
circuits but SdYADSKDEESNAALSDFA was not. The discovery funnel provides an effective means to 
characterize DAACPs in the nervous systems of animals in a nontargeted manner. 
6.3 Introduction 
Neuropeptides are a class of cell–cell signaling molecules processed from protein prohormones. 
They are produced in the nervous system and exert effects on virtually all organs, being implicated in 
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processes like reproduction,1 food intake,2 and circadian rhythms.3 The proteins used to generate 
neuropeptides are ribosomally translated using only L-amino acids. During this process, they undergo 
enzymatic post-translational modifications (PTMs), which include cleavages by prohormone convertases 
and additional modifications such as amidation.4 These PTMs are required to create the bioactive form of 
the peptide. One understudied PTM of neuropeptides is peptide isomerization, where roughly 40 
DAACPs have been found as toxins, neurohormones, and neuropeptides.5,6 In neuropeptides, this involves 
enzymatic conversion of one residue near the N-terminus from an L-amino acid to a D-amino acid.5,7-13 
However, unlike most other PTMs, isomerization is a zero-Dalton shift in molecular weight and 
so it is not easily detectable by mass spectrometry (MS); several strategies have thus emerged to enable 
isomerization detection.6 One way to overcome this difficulty is via the use of MS/MS-based techniques 
and comparing peptides with only L-amino acids to their DAACP epimers.7,14-18 Recently, MALDI-
TOF/TOF was used for the discovery of D-Leu in the peptide GH-2.19 This study also established a 
stereosensitive fragmentation effect of D-amino acids from various amino acid classes on different 
peptide sequences, which can aid in the discovery of DAACPs through MALDI-TOF/TOF by observing 
the fragmentation ratios of specific peptides. Another way to facilitate the discovery is to use 
bioinformatics to find neuropeptides that are homologous to known DAACPs in related species.7 What is 
needed is a set of measurement techniques capable of identifying DAACPs in a nontargeted manner, 
rather than targeting a suspected DAACP based on homology. 
Other methods, such as those using chemical tags or enzymatic approaches, have been developed 
to detect DAACPs that are formed spontaneously, where racemization of a residue is a pathological or 
aging-related process.18,20-22 Using photolabile tags combined with electron capture dissociation MS, D-
Ala, D-Ser, and D-Asp were identified in peptides of lens proteins.18 Isomers of L-Asp, including D-Asp, 
L-iso-Asp, and D-iso-Asp, were distinguished in lens protein peptides using differential enzyme digestion 
with endoprotease Asp-N, protein-L-isoaspartyl methyltransferase, and paenidase (D-aspartic acid 
endopeptidase).21 Deuterium chloride-assisted acid hydrolysis was also used in conjunction with 4-fluoro-
7-nitro-2,1,3-benzoxadiazole (NBD-F) labeling to identify D-amino acid enantiomers of Ala, Asp, Glu, 
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Pro, and Ser in peptides of ovalbumin.22 
While these methods have increased the rate and sensitivity of identifying spontaneously forming 
DAACPs, the ability to identify endogenous DAACPs in a complex biological system remains elusive. 
Moreover, these approaches have been directed to specific proteins and also have involved the use of 
standards for initial inquiry, an undesirable option if hundreds of peptides are potential DAACPs. If the 
incorrect L-form of the peptide is tested, this potentially creates a gap in peptidomic studies, thereby 
underestimating the number of biologically active peptides in an organism. Since MS has been an 
enabling tool in modern peptidomic studies, there could be DAACPs hiding among the peptides already 
discovered. 
We report a toolset, or discovery funnel, for the nontargeted detection of DAACPs, particularly 
neuropeptides, that takes the following issues into consideration. First, for neuropeptides (unlike 
spontaneously formed DAACPs and some toxins), isomerization occurs at the second position from the 
N-termini, except for the crustacean neurohormones.23,24 Second, the variety of amino acid residues that 
are isomerized may include any of the chiral amino acids. When including toxin peptides, endogenous 
DAACPs have included D-amino acid enantiomers of aromatic amino acids, polar amino acids, and 
aliphatic amino acids.5,6 Thus, a method to uncover DAACPs should take advantage of isomerization near 
the termini and be able to simultaneously assay the enantiomers of the 19 common chiral amino acids. 
Third, there are literally hundreds to thousands of brain peptides in most animal models. Thus, requiring 
peptide standards for the initial screening steps for DAACP discovery appears impractical and 
economically infeasible. 
Specifically, the first stage of discovery takes advantage of the fact that DAACPs are resistant to 
peptidases such as aminopeptidase M (APM) (Fig. 6.1, stage 1).25 Next, candidate DAACPs are isolated 
and subjected to a chiral amino acid analysis, where deuterium chloride-assisted acid hydrolysis and 
labeling with Marfey’s reagent (1-fluoro-2,4-dinitrophenyl-5-L-alanine amide, FDAA) are used to assay 
the chirality of amino acid residues in peptides (Fig. 6.1, stage 2).26,27 On the basis of information from 
the chiral analysis, a short list of candidate peptides is determined. The peptides of interest are 
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synthesized and their retention times compared to the native forms with liquid chromatography (LC) 
coupled to MS (Fig. 6.1, stage 3). Some MS-based approaches for DAACP discovery require a peptide 
standard for initial inquiry or targeting specific sequences, a limitation that is reduced in this method 
through the use of the enzyme APM. Synthetic peptides were also used in the current study for 
characterization of the bioactivity of DAACPs in a system-specific manner. 
We validated the approach using Aplysia californica because two D-amino acid-containing 
neuropeptides have already been identified in its nervous system: NdWFamide (Asn-D-Trp-Phe-NH2) and 
GdFFD (Gly-D-Phe-Phe-Asp-OH).7,28 More importantly, GdFFD originates from the Aplysia achatin-like 
neuropeptide precursor (apALNP), which produces additional peptides.7 However, whether these 
additional neuropeptides are DAACPs has not been explored because of the lack of a systematic method 
for their study. Interestingly, in most known cases, a single neuropeptide precursor appears to contain a 
single DAACP.7,10,13 However, there is at least one example where a single precursor produced two 
DAACPs.11,12 Thus, we both validate our discovery funnel and then use it to determine whether there may 
be additional DAACPs in the Aplysia apALNP precursor. The value of using Aplysia as our model is that 
its neuropeptidome has been the subject of intensive study, and it is an excellent physiological model 
organism.29-35 
The discovery funnel can be readily applied to investigating biological model systems in which 
DAACPs have not been discovered, uncovering potential DAACPs from any precursor with N-terminally 
modified DAACPs. Indeed, this approach has allowed us to identify three DAACPs from a single 
precursor in Aplysia, suggesting that more DAACPs in Aplysia remain to be discovered. 
6.4 Methods 
Animals 
A. californica (120–1200 g) were purchased from Marinus Scientific (Long Beach, CA) and the 
Aplysia Research Facility (Miami, FL). Animals were kept in an aquarium containing aerated and filtered 
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artificial seawater (Instant Ocean, Aquarium Systems Inc., Mentor, OH) at ∼14 °C until used. Prior to 
dissection, animals were anesthetized by injection of isotonic 333 mM MgCl2 (about 50% of body 
weight) into the body cavity. 
Reagents and Peptides 
All reagents were purchased from Sigma-Aldrich (St. Louis, MO) except where otherwise 
indicated. NdWFamide was synthesized by the Protein Sciences Facility of the Roy J. Carver 
Biotechnology Center, University of Illinois at Urbana–Champaign. Other peptides (GFFamide, 
GdFFamide, GYFD, GdYFD, SYADSKDEESNAALSDFA, and SdYADSKDEESNAALSDFA) were 
synthesized by CPC Scientific (Sunnyvale, CA). Human angiotensin I acetate salt hydrate was purchased 
from Sigma-Aldrich. 
Cell Sampling of GdFFD Neurons 
In situ hybridization data were used as guidance for the isolation of neurons expressing the GFFD 
prohormone (apALNP).7 The pedal ganglia were dissected and incubated in 1% (w/v) protease (type IX, 
Bacterial; Sigma P8811) (Sigma-Aldrich, St. Louis, MO, USA) in artificial sea water (ASW: 460 mM 
NaCl, 10 mM KCl, 10 mM CaCl2, 22 mM MgCl2, 26 mM MgSO4, 2.5 mM NaHCO3, and 10 mM 
HEPES, pH 7.7) supplemented with antibiotics (penicillin G, gentamycin, and streptomycin) and 
maintained at 34 oC for 30 min to loosen the connective tissue sheath. Following a 1 h rinse in ASW with 
antibiotics to remove the bulk of the protease, the ganglia were stretched onto a silicone elastomer 
(Sylgard, Dow Corning, Midland, MI, USA) layer in a Petri dish containing 3–4 ml of the 
ASW/antibiotic medium using 0.15 mm diameter tungsten needles (WPI, Sarasota, FL, USA); the 
connective tissue was surgically removed to expose neurons. 
Clusters of GFFD-expressing neurons were identified according to their relative position to 
prominent morphological landmarks in the ganglion and excised with tungsten needles. The clusters were 
quickly transferred via a plastic micropipette filled with Milli-Q water to remove excess salts and 
deposited onto the MALDI target. Excess liquid was aspirated from the target, and spot-to-spot cell 
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transfers were performed for sampling of individual neurons as described previously.15,36 Matrix 
consisting of 0.5 µl of 2,5-dihydroxybenzoic acid (Sigma-Aldrich), 50 mg/ml in 50% acetone (Thermo 
Fisher Scientific, Waltham, MA, USA) was added to each spot. An equal volume of matrix and 1 mg/ml 
synthetic peptides dissolved in water were mixed and deposited on the target. 
Peptide Extraction 
For initial screening of DAACPs, neuropeptide extracts from pedal ganglia were pooled from 24 
euthanized animals (including discovery of GdYFD); follow-up studies for 
SdYADSKDEESNAALSDFAED involved 10 animals. Peptide extraction was performed in acidified 
acetone (40:6:1 acetone: H2O:12 N HCl, v/v/v, acetone and HCl from Thermo Fisher Scientific, Waltham, 
MA), followed by centrifugation at 14 000 rpm, at 4 °C for 20 min (Centrifuge 5804R, Eppendorf, 
Westbury, NY). The supernatant was collected, dried (Savant Instruments, Farmingdale, NY), and 
reconstituted in 5% acetonitrile (ACN) in H2O with formic acid (FA) (95% H2O, 5% CH3CN, 0.1% FA 
v/v/v). 
APM Screening 
Potential DAACPs in A. californica were selected from a complex peptide mixture by their 
resistance to digestion by APM.5,6,25 APM (EC 3.4.11.2, Merck, Darmstadt, Germany) reaction conditions 
were 25 mM Tris-HCl with 0.5 M NaCl, pH 7.5, reacted at 37 °C for 24–48 h, depending on the 
application (48 h ensures a more thorough digestion for peptide isolation). APM (at 60.6 U/ml) was added 
to be 0.6% of the final reaction volume. Included in the digestion experiments were a positive control, 
human angiotensin I, which is digested by APM, and a negative control, NdWFamide, which is not 
digested by APM.25 Peptide content was compared between 0 and 24 h of the enzymatic digestion. 
Matrix-Assisted Laser Desorption/Ionization-Time-of-Flight (MALDI-TOF) and MALDI-TOF/TOF 
Analysis 
For APM screening, MALDI-TOF and MALDI-TOF/TOF analyses were performed using an 
ultrafleXtreme mass spectrometer (Bruker Daltonics, Billerica, MA). Mass spectra were analyzed using 
flexAnalysis 3.4 (Bruker Daltonics). The mass was calibrated using a peptide mixture of bradykinin 1–7 
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(757.4 [M + H]+), angiotensin II (1046.5 [M + H]+), angiotensin I (1296.7 [M + H]+), substance P 
(1347.7 [M + H]+), bombesin (1619.8 [M + H]+), ACTH clip 1–17 (2093.1 [M + H]+), ACTH clip 18–39 
(2465.2 [M + H]+), and somatostatin 28 (3147.5 [M + H]+). MS analysis of each neuron was performed 
in positive-ion reflectron mode. The laser size was set to “ultra”, ∼85 μm. Each MALDI-TOF spectrum 
was summed from 5000 laser shots, 500 Hz. Selected masses matching to apALNP peptides were chosen 
for follow-up MALDI-TOF/TOF analysis via the “LIFT” mode with argon as the collision gas. 
Sequencing of Peptides 
Peptide sequences were confirmed using an LC–MS set up comprised of an UltiMate 3000 RSLC 
system (Thermo Scientific Dionex, Sunnyvale, CA) coupled to an amaZon speed ETD mass spectrometer 
(Bruker Daltonics), by comparing MS/MS fragmentation (CID mode) to predicted fragment ions from 
Protein Prospector (UCSF, http://prospector.ucsf.edu) or fragment ion matching using BioTools 3.2 
(Bruker Daltonics), fragment mass tolerance 0.2 Da, minimal intensity threshold 800. 
LC isolation of potential DAACPs 
Separation methods were optimized based on the characteristics of a particular peptide and its co-
eluents. All LC-grade solvents were purchased from Thermo Fisher Scientific. 
For endogenous GYFD, two stages of analytic scale LC were employed using a Breeze 2 HPLC 
instrument (Waters, Milford, MA, USA). In the first stage, a reversed-phase Waters XSELECT CSH C18 
column (3.5 µm particle size, 4.6 mm inner diameter (ID) × 150 mm) was used with the following: 
Buffer A: H2O, 0.1% formic acid (FA). Buffer B: methanol, 0.1% FA. Flow rate: 500 µl/min. The gradient 
started with 5% B for 3 min, rising to 15% B in 2 min, then 50% B in 50 min, then 80% B in 1 min and 
held for 5 min. The gradient was dropped from 80% B to 5% B at the end of the 60-min run. In the 
second stage, Buffer A: H2O, 0.1% FA. Buffer B: acetonitrile (ACN), 0.1% FA. Flow rate 500 µl/min. The 
gradient started with 5% B for 1 min, rising to 30% B in 5 min, then 50% B in 40 min, then 80% B in 4 
min and held for 2 min. The gradient was dropped from 80% B to 5% B at the end of the 55-min run. 
For endogenous SYADSKDEESNAALSDFA, two stages of analytic scale LC using the Breeze 2 
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were employed. In the first stage, a reversed-phase Waters XSELECT CSH C18 column (3.5 µm particle 
size, 4.6 mm ID × 150 mm) was used with the following: Buffer A: H2O, 0.1% FA. Buffer B: methanol, 
0.1% FA. Flow rate: 500 µl/min. The gradient started with 5% B for 5 min, rising to 10% B in 5 min, then 
70% B in 80 min, then 80% B in 10 min and held for 8 min. The gradient was dropped from 80% B to 5% 
B at the end of the 110-min run. In the second stage, a reversed-phase Waters Atlantis T3 column (5 µm 
particle size, 2.1 mm ID × 150 mm) was used with the following: Buffer A: H2O. Buffer B: ACN. Flow 
rate 400 µl/min. The gradient started with 2% B for 5 min, rising to 5% B in 5 min, then 70% B in 60 
min, then 90% B in 15 min and held for 5 min. The gradient was dropped from 90% B to 2% B at the end 
of the 100-min run. 
LC–Tandem Mass Spectrometry (MS/MS) for Structure Confirmation 
Solvents for LC–MS/MS were purchased from Thermo Fisher Scientific. To confirm that a 
peptide was a DAACP, peptide standards were synthesized and compared to the endogenous peptides. For 
this purpose, a hyphenated LC–MS/MS platform was employed; the LC instrument was an UltiMate 3000 
RSLC (Thermo Scientific Dionex) and the mass spectrometer was an amaZon speed ETD (Bruker 
Daltonics). The column was a reversed-phase Acclaim PepMap100 C18 (3 μm particle size, 100 Å pore 
size, 300 μm internal diameter (ID) × 15 cm (length) Thermo Scientific Dionex) with the following: 
Buffer A: H2O, 0.1% FA. Buffer B: ACN, 0.1% FA. Loading solvent: H2O, 0.1% FA. Flow rate: 4 μl/min. 
For the determination of GdYFD, the gradient started with 4% B for 5 min, rising to 15% B in 3 min, then 
50% B in 35 min, then 90% B in 1 min and held for 4 min. The gradient was dropped from 90% B to 4% 
B and held for 15 min at the end of the 60 min run. For the determination of 
SdYADSKDEESNAALSDFA, the gradient started with 5% B for 5 min, rising to 10% B in 3 min, then 
45% B in 32 min, then 90% B in 1 min and held for 4 min. The gradient was dropped from 90% B to 5% 
B and held for 15 min at the end of the 60 min run. 
MS and MS/MS parameters for LC–tandem mass spectrometry (MS/MS) 
The mass spectrometer used was an amaZon speed ETD (Bruker Daltonics, Billerica, MA). The 
 137 
 
MS data was acquired in positive ion/enhanced resolution mode. The mass range scanned was 300 m/z to 
2800 m/z. The MS/MS data was acquired in a data-dependent manner, where the three most intense 
precursor ions were selected for MS/MS fragmentation followed by their active exclusion from MS/MS 
for 0.50 min after 2 spectra each. 
Chiral Analysis—Acid Hydrolysis and Amino Acid Labeling 
Acid hydrolysis was performed on each semipurified peptide fraction in the vapor phase at 
150 °C for 30 min in a CEM Discover microwave (CEM, Mathews, NC).37 The reactions were carried out 
in 6 M DCl in D2O with 0.1% phenol (added to prevent destruction of tryptophan and other amino 
acids).38,39 Next, to enhance separation, L- and D-amino acids were derivatized with FDAA.26,27 The 
amino acids from the acid hydrolysates were dried and reconstituted in 25 μl of 0.5 M NaHCO3 (Thermo 
Fisher Scientific). For derivatization, 20 μl of 1 mg/ml FDAA dissolved in ACN were added to these 
amino acids and reacted at 60 °C for 3 h. 
LC–MS/MS Multiple Reaction Monitoring (MRM) Conditions for the Detection of Labeled Amino Acids 
Solvents and solutes for chiral analysis were purchased from Thermo Fisher Scientific. The LC–
MS/MS-MRM setup consisted of an EVOQ Elite Triple Quadrupole Mass Spectrometer equipped with 
the Advance UHPLC module (Bruker Daltonics). The column was a Kinetex 2.6 μm particle Phenyl-
Hexyl column, 100 Å pore size, 100 mm (length) × 2.1 mm ID (Phenomenex, Torrance, CA). A binary 
solvent system was used (A, 25 mM ammonium formate; B, methanol; flow rate, 300 μl/min). The 
gradient started with 5% B for 2 min, rising to 15% B in 5 min, then 60% B in 5 min and held for 3 min, 
then 100% B in 3 min and held for 3 min. The gradient was dropped from 100% B to 5% B toward the 
end of the 24 min run. The EVOQ source parameters were as follows: HESI, spray voltage (±) 3500 V; 
cone temperature, 250 °C; cone gas flow, 20; heated probe temperature, 400 °C; probe gas flow, 45; 
nebulizer gas flow, 50; exhaust gas, Off. EVOQ MRM chromatograms were analyzed using Data Review 
8.2 (Bruker Daltonics). A standard mixture of the achiral amino acid glycine and the L- and D-forms of 
the 19 common chiral amino acids was derivatized and used in the MRM to establish a table of retention 
times. 
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Electrophysiology 
Intracellular and extracellular recordings of the physiological activity from Aplysia central 
nervous system preparations (either the cerebral and buccal ganglia, or the cerebral and pedal ganglia) 
were performed as described previously.7,35,40,41 The ganglia were desheathed, transferred to a recording 
chamber containing 1.5 ml of artificial seawater (ASW) (460 mM NaCl, 10 mM KCl, 11 mM CaCl2, 55 
mM MgCl2, and 10 mM HEPES, pH 7.6), continuously perfused at 0.3 ml/min, and maintained at 14–
17 °C. Peptides were dissolved in ASW immediately before each physiological test, and the peptide/ASW 
solution was perfused into the recording chamber. As noted in the Results and Discussion section, some 
experiments were also performed in high divalent (HiDi) saline (368 mM NaCl, 8 mM KCl, 13.8 mM 
CaCl2, 115 mM MgCl2, and 10 mM HEPES, pH 7.6), which increases the spiking threshold of neurons 
and therefore curtails polysynaptic influences. Intracellular recordings were obtained using 5–10 MΩ 
sharp microelectrodes filled with 0.6 M K2SO4 plus 60 mM KCl. 
To test the peptide effects on the feeding circuit, we included cerebral and buccal ganglia. The 
buccal ganglion innervates the feeding organ (radula). Feeding motor programs were monitored by cyclic 
bursts in the I2 nerve of the buccal ganglion.42,43 To test the peptide effects on the locomotor circuit, we 
included cerebral and pedal ganglia. The pedal ganglion innervates the foot. Locomotor programs were 
monitored by cyclic bursts in the parapedal commissural nerve of the pedal ganglion.44-46 
Electrophysiological recordings were digitized on line using AxoScope software (version 9, Molecular 
Devices, LLC, Sunnyvale, CA) and plotted with CorelDRAW (version 11, Corel Corporation, Ottawa, 
ON, Canada). Bar graphs were plotted using SigmaPlot (version 10, Systat, San Jose, CA). Data are 
expressed as mean ± SE. All statistical tests (e.g., repeated measures one-way analysis of variance) were 
performed using Prism (version 5, GraphPad Software, La Jolla, CA). When the data showed significant 
effects in analysis of variance, further individual comparisons were performed with Bonferroni’s 
correction. 
Behavioral Studies 
Peptide effects on locomotor behavior were examined with the method and software described 
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recently.41 Each video recording session used to calculate the locomotor path lasted for 25 min. One 
notable difference with the previous work was that we used a round behavior box (diameter, ∼43 cm and 
height, ∼18 cm) instead of the square behavioral box used previously (see Fig. 6.13A). We have not 
observed obvious differences in locomotor behavior between the two boxes. 
6.5 Results 
Discovery Funnel 
The three stages of the discovery funnel involve screening, chiral analysis, and confirmation (Fig. 
6.1). The goal of the first step is to identify suspected DAACPs for follow-up studies, where it is 
acceptable for the first step to have false positives, but it cannot require peptide standards (as it is not 
practical to create standards for all possible DAACPs). Thus, we used enzymatic screening of peptides 
with APM (Fig. 6.1, stage 1). DAACPs are expected to resist degradation by peptidases, and indeed APM 
has been previously shown to degrade peptides containing only L-amino acids at a higher rate than 
DAACPs.25 We observed a distinct difference in the rates at which the all-L-peptides and their 
corresponding DAACPs were degraded, as demonstrated with GFFD and GdFFD. GFFD was rapidly 
degraded within 5 h, whereas GdFFD was virtually intact after 24 h (Fig. 6.1, stage 1), verifying that 
APM is effective for the screening of potential DAACPs. 
Identifying potential DAACPs by resistance to APM digestion generates false positives because 
in addition to isomerization, specific N-terminal residues and select PTMs increase the resistance to APM 
digestion.25 For example, peptides with proline at the N-terminus can resist APM digestion. In addition, 
although every D-amino acid-containing neuropeptide discovered so far has had isomerization occur at 
the second residue from the N-terminus, this does not preclude the possibility of isomerization occurring 
at a different residue near the N-terminus.5,6 Ultimately, the limitations of the first step make the 
subsequent steps in our method necessary. 
The second step is designed to confirm the presence of D-amino acids in suspected peptides and 
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so reduces the number of false positives. First, acid hydrolysis is performed in the vapor phase, which 
hydrolyzes the peptide into its component amino acids.37 While there are several possible 
chromatographic methods, including chiral LC, we derivatized L- and D-amino acids with Marfey’s 
reagent to ensure good separation of all chiral amino acids in one analysis (Fig. 6.2 and Table 6.1),26,27 
and detected them with a triple quadrupole mass spectrometer. 
Many peptides are present at low levels in biological samples, making MRM useful for detecting 
the peptide’s constituent D-amino acids after acid hydrolysis because of MRM’s excellent signal-to-noise 
ratio. However, during acid hydrolysis a low rate of amino acid racemization occurs. This produces D-
amino acids,47 which may lead to the incorrect conclusion of D-amino acids being present in the original 
sample. As a solution to this problem, the reactions were carried out in 6 M DCl in D2O with 0.1% phenol 
(added to prevent destruction of tryptophan and other amino acids).38,39 Under these conditions, digestion-
induced racemization extracts a deuteron from the solution, causing a shift in mass of 1 Dalton compared 
to an amino acid initially in the D-form. Here, we use MRM to monitor parent ions based on their 
molecular weight within an m/z ± 0.35 window. As a result, a shift of m/z +1 causes acid-hydrolysis-
induced racemization to be undetected in the same channel as the endogenously present D-amino acids. In 
addition, MRM measures the labeled L- and D-amino acid enantiomers in different channels in a single 
analysis step (Figure 1, Stage 2).48-55 
Interestingly, following DCl-based acid hydrolysis and analysis, labeled tyrosine (Tyr) was seen 
to have a different molecular weight than expected: two more Daltons than the label plus Tyr (Fig. 
6.3).38,56  This observation did not affect the retention time of the labeled L- or D-Tyr in the MRM that did 
not undergo hydrolysis (Fig. 6.3). Tyr can be substituted with chloride during acid hydrolysis; rapid vapor 
phase hydrolysis is meant to help prevent this phenomenon. A shift of +1 Dalton may be expected due to 
random racemization during deuterium-assisted acid hydrolysis. However, no racemized residue was 
detected in the +2 Dalton channel, so it is unlikely that the deuteron is on the alpha carbon of the amino 
acid (which would result in racemization). In addition, these amino acids were in solutions that were not 
deuterated following deuterium hydrolysis, so the deuteron is not the result of readily exchangeable 
 141 
 
hydrogens. Rather, the deuteron may result from a substitution reaction in the ortho position on both 
sides, as has been noted with chloride substitutions on Tyr while using acid chlorides. No shift was 
observed in Tyr’s molecular weight following HCl-based hydrolysis (Fig. 6.3). 
For Marfey’s Reagent-based labeling, the L-form was observed to always elute before the D-
form, presumably due to the fixed structure of the tag where the L-amino acid’s side chain will be in a 
trans formation with the –CH3 of L-alanine amide (already on the tag) compared to the plane of the 
benzene ring on the derivatization reagent, whereas the D-amino acid’s side chain will be in a cis 
formation with the –CH3 of L-alanine amide compared to the plane of the benzene ring on the 
derivatization reagent.27,57 
This mass shift raises the possibility of other unknown changes during DCl hydrolysis that can be 
observed with MS, which may account for losses of intensity of certain species. DCl hydrolysis may not 
be able to analyze all sequences, as there are amino acids that are destroyed (or modified) by acid 
hydrolysis.58 Short, high temperature vapor-phase hydrolysis mitigates this, but with low enough levels of 
neuropeptide, this may not always be sufficient. Also, certain sequences do not hydrolyze readily, such as 
chains of some aliphatic amino acids. 
The final step of the discovery funnel validates the DAACP and involves synthesizing the 
putative peptide in both the all L-form and the D-form. One way to verify structure is to compare LC 
retention times between endogenous and synthetic peptides. In combination with high quality MS/MS 
data,15 a matching retention time from the LC separation for the native peptide and a synthetic DAACP is 
sufficient to confirm the identity of a DAACP (Fig. 6.1, stage 3).5,6 
Screening: Peptides from apALNP Resist Digestion to Aminopeptidase M 
apALNP is predicted to produce several peptides and in situ hybridization has indicated that 
apALNP is localized in a cluster of neurons in the pedal ganglia.7 This led us to consider that further 
DAACP discovery could be facilitated by targeting the pedal ganglia, as the isomerizing enzyme is 
inferred to be expressed by some neurons of this ganglia (the enzyme is currently unknown). Extracts 
from pedal ganglia were subjected to 48 h of APM digestion. After digestion, several peptides were seen 
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to resist degradation, including GYFD (Fig. 6.4) and SYADSKDEESNAALSDFA (Fig. 6.5). 
Both of these peptides are derived from apALNP. Considering that GdFFD is also present on this 
prohormone, these were promising hits that demonstrated the potential ability of this approach to discover 
novel DAACPs. GFFD was also detected after APM digestion, but was not explored further as it is a 
previously characterized DAACP (data not shown).7,15 GYFD and GFFD are also homologous and differ 
only in the second residue. The isomerized residues Tyr and phenylalanine (Phe) are both aromatic amino 
acids. Thus, it would not be surprising that GYFD could also exist as GdYFD. Importantly, the peptide 
was not targeted for its homology, but was chosen here for further studies based on APM screening. While 
this peptide was not identified in MALDI-TOF profiling of the neurons expressing apALNP previously,7 
here we detected GYFD using MALDI-TOF/TOF from isolated neurons (Fig. 6.6). 
GFFD and GYFD are similar, but there are several longer peptides in apALNP.7 The other 
observed peptide, SYADSKDEESNAALSDFAED, bears some sequence homology in its N-terminus to 
GYFD. Interestingly, a form of this peptide truncated by two C-terminal amino acids 
(SYADSKDEESNAALSDFA) was also seen to resist digestion by APM after 48 h (Fig. 6.5) and was 
identified in previous work.7 In addition, GFFamide was detected, which has not previously been reported 
as an observed peptide from apALNP. However, this peptide was digested by APM (Fig. 6.7), suggesting 
it is not a DAACP. 
Chiral Analysis: Detection of d-Amino Acids in Peptides Resistant to Digestion 
Endogenous GYFD and SYADSKDEESNAALSDFA were purified to relative homogeneity (Fig. 
6.4 and 6.8), seen to contain a D-Tyr following chiral analysis (Fig. 6.9), and confirmed with synthetic 
GdYFD and SdYADSKDEESNAALSDFA (Fig. 6.4 and 6.10). Thus, we have added two new DAACPs 
to the products from apALNP. In Fig. 6.9, the L-amino acids suggest the presence of additional peptides 
in the fraction containing L-amino acids. These may be low levels of the epimeric peptide, which can be 
somewhat difficult to separate through fraction collection. While the epimeric peptides were not detected 
with LC–MS, the TQ-MS channels are especially sensitive to several amino acids over others, based on 
fragmentation energies (see Fig. 6.2; equimolar D- and L-tyrosine favors detection of L-tyrosine, with 
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sometimes dramatic effects, as seen in detection of L- and D-threonine). 
The discovery of GdYFD and SdYADSKDEESNAALSDFA as DAACPs has several interesting 
implications for DAACP formation. This is the first instance of an endogenous DAACP containing D-Tyr. 
In contrast, the peptide GFFamide is not isomerized; as both GFFamide and GFFD have Phe in the 
second position, and yet GdFFamide has not been detected, perhaps the ability of the enzyme to isomerize 
the peptide involves the flanking sequences, as has been noted in the frog enzyme.59 However, GYFD, 
GFFD, and NWFamide are sequences that are recognized by the isomerase, while GFFamide is not. 
Perhaps GdFFamide does not extract under the protocols used, or perhaps it was simply below the limit of 
detection; therefore, the presence of GdFFamide cannot be precluded. 
Our results are defining the endogenous substrates used by a yet unknown isomerizing enzyme in 
Aplysia. It appears to be flexible in regards to sequence and also length. After all, GdFFD is only 4 amino 
acids versus the 20 amino acids of SdYADSKDEESNAALSDFAED. This is consistent with studies of the 
frog enzyme: substrate specificity studies showed the frog isomerase was able to act upon sequences of 
only the N-terminus of the peptide.59 
GdYFD is Bioactive in the Feeding and Locomotor Circuits of A. californica, whereas 
SdYADSKDEESNAALSDFA is Not 
Previous work has shown that GdFFD is bioactive in both Aplysia feeding7 and locomotor41 
circuits, whereas the all L-amino acid epimer, GFFD is not. We therefore tested whether GdYFD and 
SdYADSKDEESNAALSDFA may also be bioactive in the feeding and locomotor circuits. Only GdYFD 
was found to be bioactive in the feeding (Fig. 6.11) and locomotor networks (Fig. 6.12 and 6.13). 
In the first set of experiments with cerebral and buccal ganglia, we examined if the peptides could 
elicit feeding motor programs. We found that under resting conditions (Fig. 6.11A1), there are few 
spontaneous motor programs (note the absence of bursts in I2). However, upon perfusion of both 10-6 M 
and 10-5 M GdYFD, spontaneous motor programs occurred at an increased rate in a concentration-
dependent manner (Fig. 6.11A2, A4, F3,21 = 32.81, p < 0.0001, n = 8). 
Interestingly, the motor programs are mostly egestive as radula closer B8 fired primarily during 
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protraction (open bar) (Fig. 6.11A2). In contrast, GYFD had no obvious effects (n = 3). In addition, 
neither SdYADSKDEESNAALSDFA (n = 3), nor its all L-amino acid epimer (n = 3), had any observable 
effects on the activity of the cerebral and buccal ganglia. 
Previously, we have shown that GdFFD also promotes egestive programs.7 Consistently, B65, an 
interneuron that promotes the generation of egestive programs,60 was strongly active during the 
spontaneously generated programs in the presence of both GdFFD and GdYFD (Fig. 6.11A2). To 
determine if these two peptides might act directly on B65 to promote the generation of egestive programs, 
we examined if both peptides affected B65 excitability. For this, we applied 3-s current pulses every 30 s 
in B65 in high-divalent saline, which was used to curtail polysynaptic connections. We then perfused 10-6 
M and 10-5 M peptides, and found that both GdFFD (Fig. 6.11B, F3,12 = 21, p < 0.001, n = 5) and GdYFD 
(Fig. 6.11C, F3,9 = 17.63, p < 0.001, n = 4) significantly enhanced B65 excitability in a concentration-
dependent manner. 
Given that GdYFD promoted egestive programs, we tested if GdYFD can also influence motor 
programs evoked by a command-like interneuron, CBI-2. We elicited feeding motor programs by 
stimulating CBI-2 at 8–10 Hz, with interstimulation intervals of 1.5 min. Under control conditions, the 
programs were ingestive, as radula closer B8 fired mostly during retraction (filled bar) rather than during 
protraction (open bar) (Fig. 6.11D1, E1). Perfusion of GYFD at a concentration of up to 10-5 M had no 
obvious effects on the programs (Fig. 6.11D2, n = 4). In contrast, perfusion of 10-6 M GdYFD (Fig. 
611E2) shortened protraction duration (Fig. 6.11E4, F2,6 = 19.94, p < 0.01, n = 4; protraction value at 
100%: 22.34 ± 4.92 s). Perfusion of 10-6 M GdYFD also slightly shortened retraction duration, but the 
effects were not statistically significant (Fig. 6.11E5, F2,6 = 2.35, p > 0.05; retraction value at 100%: 7.38 
± 1.06 s). In addition, the programs appeared to be less ingestive because B8 frequency during 
protraction increased somewhat (although not statistically significant, Fig. 6.11E6, F2,6 = 1.97, p > 0.05; 
protraction frequency value at 100%: 3.88 ± 0.70 Hz), and B8 frequency during retraction decreased 
(Fig. 6.11E7, F2,6 = 7.89, p < 0.05; retraction frequency value at 100%: 10.39 ± 0.51 Hz). 
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We also tested the effects of GdYFD on the locomotor network. First, we examined if the 
peptides could elicit activity in the parapedal commissural nerve (PPCN) of the isolated nervous systems 
of cerebral and pedal ganglia. We found that perfusion of 10-6 M and 10-5 M GYFD did not change PPCN 
activity in the pedal ganglion (Fig. 6.12A, F3,9 = 1.85, p > 0.05, n = 4), whereas perfusion of 10-6 M and 
10-5 M GdYFD (Fig. 6.13B4) significantly increased activity (Fig. 6.12B5, F3,15 = 17.77, p < 0.0001, n = 
6). We also found that perfusion of 10-6 M and 10-5 M GdYFD significantly increased frequency within 
bursts (Fig. 6.12B6, F3,15 = 12.38, p < 0.001, n = 6), and frequency between bursts (Fig. 6.12B7, F3,15 = 
10.1, p < 0.001, n = 6). These effects are similar to the effects of GdFFD described earlier.41 In addition, 
S-6 neither SdYADSKDEESNAALSDFA (n = 3) nor its all L-amino acid epimer (n = 3) had any 
observable effects on the activity of cerebral and pedal ganglia. 
Because we showed that the increase in the frequency between bursts in GdFFD appeared to be 
detrimental to locomotor behavior, which acted to reduce locomotion in intact animals,41 we also tested 
the effects of GdYFD on the locomotor behavior. Initially we used 10-7 M GdYFD and found that it 
reduced locomotor velocity but the effects were not statistically significant. We then increased the 
concentration to 10-6 M GdYFD, and found that it reduced locomotor velocity significantly (Fig. 6.12). 
Using normalized data (natural logarithm of velocity) as described in the previous study,41 we found that 
whereas injection of ASW had no effects on locomotion (natural logarithm of velocity, before: 8.53 ±
0.26; after: 8.28 ±0.47; two tailed t-test, p > 0.05, n = 4), injection of GdYFD significantly reduced 
locomotion (natural logarithm of velocity, before: 8.52 ±0.42; after: 5.95 ±0.21; two tailed t-test, p < 
0.05, n = 4). 
The physiological data showed that of the two new DAACPs identified from apALNP, only 
GdYFD is bioactive, whereas the other is not. In addition, for GdYFD, similar to our previous study with 
GdFFD,7 only the DAACP, that is, GdYFD, is active, whereas GYFD is not. Finally, our data also suggest 
that the overall effects of GdYFD and GdFFD in both the feeding and locomotor circuits are similar, but 
the effects of GdYFD may be weaker than GdFFD, particularly the effects on CBI-2 programs (Fig. 
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6.11F) and on fictive locomotor programs (Fig. 6.12). Given that each apALNP produces three copies of 
GdFFD, whereas it only produces one copy of GdYFD, the main bioactivity of the peptides from 
apALNP likely originates from GdFFD. Nonetheless, our discovery funnel does provide an effective 
means to identify functionally important DAACPs from multiple peptides originating from a single 
precursor. 
6.6 Conclusions and future directions 
We developed and validated a series of protocols we term a DAACP discovery funnel, and used it 
to identify two novel D-amino acid-containing neuropeptides in the nervous system of A. californica: 
GdYFD and SdYADSKDEESNAALSDFA. This method is nontargeted and does not require the use of 
bioactivity to identify novel DAACPs. APM digestion takes advantage of a common property of 
neuropeptide DAACPs: that the modification is found near the N-terminus.25 Although the individual 
methods have been used in various contexts, this is the first time that these methods have been combined 
into a cohesive workflow and optimized for the purpose of endogenous peptide discovery. 
We improved every aspect of these methods, most notably, using triple quadrupole MS for the 
sensitive detection of low levels of D-amino acids, as is necessary for low levels of neuropeptides. 
Because we separate the L- and D-forms into different fractions, the ratio of the L-D forms is less 
important, but the absolute amount of the DAACP must be high enough to characterize with MS. We do 
note a limitation of this approach: it assumes that the modification occurs near the N-terminus; if the 
modification occurs near the C-terminus, our method could miss it. Carboxypeptidases may be studied in 
the future to see if they can achieve the kind of selectivity that is seen with APM. Perhaps APM may yet 
be shown to have the capability to degrade certain DAACP sequences more rapidly than anticipated, 
leading to false negatives. 
Regardless, using this approach, further DAACP discovery efforts are underway in other models, 
including vertebrates. We are actively determining the extent to which post-translational amino acid 
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isomerization is found in the nervous systems of animals. In Aplysia, novel peptide precursors have 
recently been identified.61-64 Our approach can determine if there are multiple DAACPs from a single 
precursor, especially those peptides with little or no bioactivity. In mammals, although most bioactive 
DAACPs are exogenous, several are reported to have effects; for example, dermorphin acts upon opioid 
receptors and has a higher potency than morphine.65,66 Discovery of new DAACPs may provide novel 
biologics for therapeutic use, and should help in the hunt for the enzymes responsible for this 
modification. 
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6.7 Figures and Tables 
 
Figure 6.1. The DAACP discovery funnel is capable of identifying DAACPs in three stages, as illustrated with GdFFD. In 
stage 1, MS-based detection of APM digestion is capable of identifying potential DAACPs in the screening phase of the 
discovery funnel. Here, GFFD, used as an example, is rapidly degraded after 5 h, whereas its DAACP counterpart, GdFFD, is not 
degraded after 24 h. Both are shown as a ratio to NdWFamide, a peptide that is known to resist degradation by APM. In stage 2, 
chiral analysis utilizes the MRM mode of MS to detect L- and D-amino acids in a peptide following acid hydrolysis and labeling. 
First, microwave-assisted vapor phase hydrolysis is carried out in DCl to break down peptides into their component amino acids. 
Importantly, DCl-based acid hydrolysis reduces detection of racemized residues in peptides. The amino acids are then labeled 
with Marfey’s reagent, separated, and detected using a triple quadrupole mass spectrometer. The result of this step is outlined 
using GdFFD, where a D-Phe is detected. In stage 3, confirmation of DAACPs, peptides are synthesized with the suspected 
chirality at each position and then compared to the endogenous peptides. Here, the retention time of the endogenous peptide 
matches that of the GdFFD synthetic standard, confirming its presence as a DAACP. 
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Figure 6.2. Labeled amino acid standard separation using LC-MS with a triple quadrupole MS. Labeling with Marfey’s 
Reagent leads to separation of all the common chiral amino acids.  Their separation allows for identification of D-amino acid 
residues in a peptide either through retention time matching or through spiking. 
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Figure 6.3. Tyrosine (Tyr) had an unexpected molecular weight following DCl-assisted acid hydrolysis. DCl-assisted acid 
hydrolysis Tyr (red trace) versus HCl-assisted hydrolysis (black trace). Tyr reveals that DCl hydrolysis leads to an unracemized 
(but different molecular weight) species. The amino acid used was L-Tyr and the peaks match the retention time of L-Tyr + label 
with no acid hydrolysis (see Fig. 6.2). (A) The expected molecular weight for Tyr + label yields a large peak in HCl-assisted 
hydrolysis, but almost no peak in DCl-assisted hydrolysis. (B) In the channel for Tyr + label + 1 Da, there is still almost no 
molecular species seen in DCl-assisted hydrolysis, even though a single deuteron would lead to Tyr detected in this channel. 
There is still a substantial peak for HCl-assisted hydrolysis Tyr, but this can result from naturally occurring carbon and hydrogen 
isotopes. (C) In the channel for Tyr + label + 2 Da, there is a large peak in the DCl-assisted hydrolysis, which accounts for the 
majority of this species. This is an unracemized (L-Tyr) species. Meanwhile, little (<5% of intensity of original species on the 
left) is detected for Tyr in HCl-assisted hydrolysis. 
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Figure 6.4. LC–MS/MS characterization of GdYFD, which is confirmed by comparing to the retention time of standards. 
(A) Left, LC–MS (base peak chromatogram) trace of endogenous GYFD after 48 h of APM digestion, with a retention time of 
15.9 min. Right, the MS/MS fragmentation with fragment assignments is shown. (B) Left, an LC–MS trace of the all-L-amino 
acid synthetic GYFD, with a retention time of 14.5 min. Right, the MS/MS fragmentation with fragment assignments. (C) Left, 
an LC–MS trace of the synthetic DAACP GdYFD, with a retention time of 15.9 min. Right, MS/MS fragmentation with fragment 
assignments is shown. The matching retention time of the synthetic GdYFD standard with the endogenous GYFD demonstrates 
that the sequence for the endogenous peptide is in fact GdYFD. 
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Figure 6.5. A. californica endogenous peptide digestions lead to the identification of the long SYAD achatin-like peptide as 
a potential DAACP. Top: LC-MS trace of A. californica peptide fraction after 48 h of APM digestion. Black trace – base peak 
chromatogram of peptide fraction. Blue trace – extracted ion chromatogram of m/z 960.4, which with z = +2 matches 
SYADSKDEESNAALSDFA. Bottom: MS/MS spectrum of SYADSKDEESNAALSDFA, with fragment peaks assigned to 
confirm the identity of this peptide. 
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Figure 6.6. Direct cell MALDI-TOF MS/MS of neurons expressing the apALNP prohormone reveals the presence of 
GYFD. (A) apALNP from A. californica, with the sequences of interest in bold for this study, and others in italic. GFFG was 
detected as GFFamide in Fig. 6.7. GDAS has not been detected. GFFD and YYGS have been detected previously.7 (B) MALDI-
MS spectrum of neurons that express apALNP, with some peptides assigned based on mass matching. (C) MALDI-MS/MS 
spectrum of GYFD in neurons that express apALNP. GYFD is assigned based on the fragment spectra. Parent ion 501.2 m/z. (D) 
MALDI-MS/MS spectrum of SYADSKDEESNAALSDFA in neurons that express apALNP. SYADSKDEESNAALSDFA is 
assigned based on the fragment spectra. Parent ion 1919.8 m/z. (E) MALDI-MS/MS spectrum of SYADSKDEESNAALSDFAED 
in neurons that express apALNP. SYADSKDEESNAALSDFAED is assigned based on the fragment spectra. Parent ion 2163.9 
m/z. 
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Figure 6.7. GFFamide, another peptide of the achatin-like prohormone, is not present as a DAACP in the A. californica 
nervous system. (A) The top chromatogram is of an LC-MS (base peak chromatogram) trace of endogenous GFFamide. 
GFFamide was identified in A. californica pedal ganglia peptide extracts, but did not resist digestion by APM (data not shown). It 
had a retention time of 23.6 min. The middle LC-MS trace is of GdFFamide synthetic standard, with a retention time of 25.9 min. 
The bottom LC-MS trace is of GFFamide, with a retention time of 23.6 min. The endogenous peptide matches that of an all-L-
amino acid peptide standard and did not resist digestion by APM, establishing that it is not a DAACP. The MS/MS spectrum 
below is of GFFamide with assigned fragment peaks. (B) The MS/MS spectrum of GFFamide with assigned fragment peaks. 
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Figure 6.8. MALDI-TOF MS spectrum of a peptide fraction collected from multi-stage LC containing endogenous 
SYADSKDEESNAALSDFA. (A) MALDI-TOF spectrum demonstrates relative purity of this fraction. (B) The MALDI-MS/MS 
(LIFT) fragmentation spectrum. 
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Figure 6.9. Chiral analysis and LC–electrospray ionization MRM detection of endogenous A. californica peptide fractions 
containing GYFD and SYADSKDEESNAALSDFA are seen to have a D-Tyr. (A) Retention times of labeled standard amino 
acids. (B) Chiral analysis of YdAEFLamide peptide standard, to demonstrate the retention time of L-Tyr only. (C) An 
endogenous peptide fraction containing GYFD is seen to contain a D-Tyr. This suggests that the endogenous peptide exists as 
GdYFD. (D) An endogenous peptide fraction containing SYADSKDEESNAALSDFA is seen to contain a D-Tyr. This suggests 
that the endogenous peptide exists as SdYADSKDEESNAALSDFA. 
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Figure 6.10. Through spiking of synthetic standards, endogenous SYADSKDEESNAALSDFA is seen to exist as a DAACP, 
SdYADSKDEESNAALSDFA, in the A. californica nervous system. (A) LC–MS (base peak chromatogram) of synthetic 
peptides of SYADSKDEESNAALSDFA (21.6 min, black trace) and SdYADSKDEESNAALSDFA (22.4 min, red trace) 
demonstrates that both peptides separate. (B) LC–MS (base peak chromatogram) of the endogenous SYADSKDEESNAALSDFA 
spiked with either synthetic SYADSKDEESNAALSDFA (black trace) or SdYADSKDEESNAALSDFA (red trace). Black trace: 
Spiking SYADSKDEESNAALSDFA results in two peaks corresponding to 21.6 and 22.4 min; the endogenous peptide, the 
second peak, matches the retention time of the DAACP. This is confirmed in the red trace where spiking 
SdYADSKDEESNAALSDFA results in one larger peak at 22.4 min, the additive intensity of the endogenous peptide and the 
standard. This confirms that the endogenous peptide is in fact SdYADSKDEESNAALSDFA. 
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Figure 6.11. GdYFD was bioactive whereas GYFD was not in the A. californica feeding circuit (with cerebral and buccal 
ganglia). (A) Perfusion of GdYFD increased activity in the cerebral and buccal ganglia (A2) in a concentration-dependent 
manner (A4, group data). Protraction, open bar; retraction, filled bar. Radula closer B8 was mostly active during protraction, so 
the programs were egestive. Note that B65 is strongly active in A2. (B, C) Both GdFFD (B) and GdYFD (C) increased B65 
excitability in a concentration-dependent manner. Bars in B1 and C1 indicate current injections in B65. (B2 and C2) Group data. 
(D) GYFD at 10–5 M had no effects on motor programs elicited by stimulation of CBI-2 (9 Hz) (D2). (E) GdYFD at 10–6 M made 
CBI-2-elicited motor programs less ingestive (E2): that is, it reduced protraction duration (E4) and reduced B8 activity during 
retraction (E7). Experiments were performed in ASW, except B and C, which were performed in HiDi saline. Bonferroni post hoc 
test is as follows: *, p < 0.05; **, p < 0.01; ***, p < 0.001. 
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Figure 6.12. GdYFD was bioactive, whereas GYFD was not, in the A. californica locomotor circuit (with cerebral and pedal 
ganglia). (A) GYFD did not change activity in the PPCN of the pedal ganglion significantly. Motor neuron: a presumed motor 
neuron on the ventral surface of the pedal ganglion. A5: group data. (B) GdYFD increased activity in the PPCN of the pedal 
ganglion, i.e., the average frequency (B5), frequency within bursts (B6), and frequency between bursts (B7). Open bars: Bursting 
activity in PPCN. Bonferroni post hoc test is as follows: *, p < 0.05; **, p < 0.01; ***, p < 0.001. 
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Figure 6.13. GdYFD reduced locomotor activity in intact A. californica animals. (A) Locomotor path within 25 min. Left: 
before injection of GdYFD; right: after injection of GdYFD. (B) Group data. Left two bars: before and after injection of ASW; 
right two bars: before and after injection of GdYFD. 
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Table 6.1 Triple Quadrupole MS Conditions for labeled amino acids. 
 
Amino acid Parent Ion 
Parent 
Resolution 
Collision 
Energy (V) 
Fragment 
Ion 
Fragment 
Resolution 
Time 
(ms) Mode 
Alanine 340.0 Unit (0.7) 14 278.1 Standard (2.0) 50 Negative 
Arginine 426.9 Unit (0.7) 10 70.1 Standard (2.0) 50 Positive 
Asparagine 382.9 Unit (0.7) 33 175.9 Standard (2.0) 50 Negative 
Aspartatic Acid 384.0 Unit (0.7) 24 267.9 Standard (2.0) 50 Negative 
Cysteine 372.1 Unit (0.7) 21 284.9 Standard (2.0) 50 Negative 
Glutamic Acid 398.0 Unit (0.7) 24 201.9 Standard (2.0) 50 Negative 
Glutamine 396.9 Unit (0.7) 20 353.0 Standard (2.0) 50 Negative 
Glycine 326.1 Unit (0.7) 32 162.0 Standard (2.0) 50 Negative 
Histidine 658.2 Unit (0.7) 30 549.1 Standard (2.0) 50 Negative 
Isoleucine/Leucine 382.0 Unit (0.7) 18 319.8 Standard (2.0) 50 Negative 
Lysine 649.1 Unit (0.7) 36 479.1 Standard (2.0) 50 Negative 
Methionine 400.0 Unit (0.7) 17 337.9 Standard (2.0) 50 Negative 
Phenylalanine 416.0 Unit (0.7) 20 337.1 Standard (2.0) 50 Negative 
Proline 365.9 Unit (0.7) 15 321.9 Standard (2.0) 50 Negative 
Serine 355.9 Unit (0.7) 16 263.9 Standard (2.0) 50 Negative 
Threonine 370.0 Unit (0.7) 17 263.9 Standard (2.0) 50 Negative 
Tryptophan 457.1 Unit (0.7) 10 188.0 Standard (2.0) 50 Positive 
Tyrosine 684.1 Unit (0.7) 28 351.9 Standard (2.0) 50 Negative 
Tyrosine(+2) 686.1 Unit (0.7) 27 353.9 Standard (2.0) 50 Negative 
Valine 367.9 Unit (0.7) 15 306.0 Standard (2.0) 50 Negative 
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CHAPTER 7  
THE SEARCH FOR D-AMINO ACID-CONTAINING 
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7.2 Abstract 
There is reason to believe that endogenous D-amino acid-containing peptides may be present in the 
mammalian nervous system, because they have been found in the nervous system of mollusks and as 
toxins in vertebrates like the frog and platypus. The previous chapters have established an approach for 
characterizing and discovering D-amino acid-containing neuropeptides in the mollusk Aplysia californica. 
Here the method is applied to the nervous system of rodents, where no endogenous D-amino acid-
containing neuropeptides are known. The suprachiasmatic nucleus, supraoptic nucleus, and pituitary were 
targeted for analysis. In the pituitary, a low-intensity signal of little SAAS was seen to resist degradation 
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by aminopeptidase M. Similarly, cerebellin peptide was seen to resist degradation by aminopeptidase M 
in the suprachiasmatic nucleus. However, upon further analysis, neither little SAAS nor cerebellin were 
seen to contain a D-amino acid. This unexpected failure of the APM digestion stage of the DAACP 
discovery funnel appears to depend on the specific extraction and other protocols used; these results 
indicate that further protocol optimization are required to detect D-amino acid-containing peptides in the 
rodent nervous system. 
7.3 Introduction 
The possible existence of endogenous D-amino acid-containing peptide (DAACPs) in the nervous 
system of mammals has not been explored, but there is some evidence to suggest they exist. The platypus 
(Ornithorhynchus anatinus) has the only two confirmed mammalian DAACPs: OvCNPb and DLP-2, with 
isomerization occurring at the second residue from the N-terminus.1,2 These DAACPs are toxins. Also, 
mouse heart protein extracts were able to isomerize platypus peptides, synthesized to only have LAA, at 
low levels.3 Interestingly, the frog isomerase gene is homologous to a gene in humans.4 Also, as has been 
covered extensively in this thesis, there are DAA-containing neuropeptides in mollusks, whose 
characteristics could be similar to discovered DAACPs in the nervous system of mammals. 
The tools developed in Chapter 5 and tested in Chapter 6 are capable of detecting DAACPs in the 
nervous system of Aplysia californica. To understand if DAACPs exist in the mammalian nervous system, 
the DAA-containing neuropeptide discovery funnel is applied the nervous systems of rodents in this 
chapter. As rodents serve for models of human health and disease, uncovering endogenous DAACPs in 
rodents could lead to new discoveries of bioactive peptides and their possible involvement in pathology. 
Target structures in this chapter include the suprachiasmatic nucleus (SCN) and pituitary. 
To ensure that the DAACP discovery method was feasible in mammalian peptides, we first used 
the pituitary. The pituitary is a critical endocrine structure containing numerous bioactive peptides.  We 
and others have previously characterized the peptides within the pituitary with a range of mass 
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spectrometry-based approaches.5-8 Using the pituitary for preliminary studies is also advantageous 
because there are peptides whose function is already established and these peptides can be used as 
positive controls during an aminopeptidase M (APM) digestion, since one would not expect a DAA in a 
very thoroughly characterized peptide. There are also peptides transported from the hypothalamus to the 
pituitary, and these could be interesting for DAACP discovery. 
 Why study the SCN? The SCN is a peptidergic nucleus of the hypothalamus with a known 
biological role in regulating circadian rhythms.9 In fact, the complexity of the SCN peptidome is such that 
our group, with the Gillette group, have characterized about 200 peptides from characterized 
prohormones have been identified in the SCN.9-12 Circadian rhythm regulation is complex, with more to 
learn about how the SCN communicates between SCN neurons and to the rest of the brain and body.9 
With such a complex mix of peptides found in the SCN, understanding the role of these neuropeptides can 
be a difficult task. Neuropeptide release changes in a time-of-day-dependent manner, which may be an 
indication that these peptides have a circadian function. In addition, there are electrophysiological tests 
that can help classify a peptide’s function in terms of its ability to cause phase shifting in the SCN. A 
phase shift in the SCN is a delay or advance in peak neuronal activity compared to the expected peak 
activity time. One more advantage of studying the SCN is that circadian rhythms are relatively well-
conserved, with signals that have homologs between evolutionarily distant organisms like rodents and 
fruit flies.13 Therefore, if there was a conserved post-translational modification in the mammalian 
neuropeptidome, it may be expected in the SCN. 
 The DAA-containing neuropeptide discovery funnel is well suited for characterizing the 
DAACPs in these structures. With a complex peptide profile in the SCN, synthesizing about 200 peptide 
standards containing various positional changes in chirality would prove to be challenging and cost 
prohibitive. As such, an approach that does not require the use of standards like the discovery funnel 
offers one of the best solutions to approaching DAACP discovery in the rodent nervous system in a non-
targeted manner. Given that isomerization has been found near the N-terminus in platypus toxin and 
molluskan neuropeptide DAACPs, aminopeptidase M (APM) digestions was chosen as the primary 
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screening method. 
7.4 Methods 
Reagents and peptides 
All reagents were purchased from Thermo Fisher Scientific (Waltham, MA) except where otherwise 
indicated. NdWFamide, little SAAS peptide, and D-Leu2-little SAAS peptide were synthesized by the 
Protein Sciences Facility of the Roy J. Carver Biotechnology Center, University of Illinois at Urbana-
Champaign. Cerebellin peptide was synthesized by Phoenix Pharmaceuticals (Burlingame, CA). Human 
angiotensin 1 acetate salt hydrate was purchased from Sigma-Aldrich (St. Louis, MO). 
Peptide extraction 
For the SCN and supraoptic nucleus (SON), 48 animal subjects, aged 6 to 8 months, were 
decapitated. The brain is immediately removed from the skull, and 500 µm slices are obtained using a 
mechanical tissue chopper. Paired SCNs were “punched” with a sample corer using morphological 
features of the SCN and SON. These SCN and SON were pooled between 8 animals and subjected to 
multistage peptide extraction as has been described.10 First, 300 µl of heated (90 oC) deionized water were 
added for 10 min. These are then centrifuged at 14,000 xg for 10 min at 4 oC. The supernatant was 
reserved, then 300 µl of acidified acetone (40:6:1 acetone:H2O:HCl) was added to the pellet. The pellet 
was homogenized and kept on ice for 1 h. Then, it was centrifuged at 14,000 xg for 10 min at 4 oC. The 
supernatant was reserved, then 300 µl of 0.25% acetic acid was added and kept on ice for 1 h. Extracts 
were passed through a Microcon 10-kDA mass cutoff filter (EMD Millipore, Billerica, MA) in order to 
filter out any undesirable proteins in the extract. All three stages of the extract are combined and dried to 
25 µl total volume, which is combined between 24 animals’ extracts. 
 For the pituitary, 8 animal subjects were decapitated, and brain was immediately removed from 
the skull. Pituitary were dissected and immediately stored on wet ice. To each pituitary, 500 µl acidified 
methanol (90% methanol, 9% acetic acid, 1% H2O) is added. These are then heated to 90 oC for 10 min to 
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inactivate enzymes. The tissue is homogenized and left on ice for 1 h to complete extraction. The tissue is 
the centrifuged at 14,000 xg for 10 min at 4 oC to pellet the connective tissue, and the supernatant is 
removed. This homogenate is brought to a pH of 4 using 1 M NaOH and diluted with water until they are 
only 5% methanol, and separated using solid phase extraction. 
Solid phase extraction 
Peptide extract from the pituitary is loaded onto a solid phase extraction column (Discovery C18 
SPE column bed, 3 mg) on a vacuum manifold. (Sigma-Aldrich, St. Louis, MO) Once loaded, the extract 
is washed three times with 5% methanol to remove salts. Then, the peptides are eluted with 40% 
methanol and 0.1% formic acid to recover relatively hydrophilic peptides and collected. Separately, more 
peptides are eluted with 70% methanol and 0.1% formic acid to recover relatively hydrophobic peptides. 
These peptide extracts are then dried for further analysis. 
Liquid chromatography separations 
 In the first stage, used for all tissue, a reversed-phase Waters XSelect CSH C18 column (3.5 µm 
particle size, 4.6 mm ID x 150 mm) was used. (Waters, Milford, MA) Buffer A: H2O, 0.1% formic acid. 
Buffer B: methanol, 0.1% formic acid. Flow rate 500 µl/min. The gradient started with 5% B for 3 min, 
rising to 15% B in 2 min, then 50% B in 50 min, then 80% B in 1 min and held for 5 min. The gradient 
was dropped from 80% B to 5% B at the end of the 60-min run. In the second stage, used only for 
cerebellin peptide analysis, an Atlantis T3 column (5 µm particle size, 2 mm ID x 150 mm) was used.  
(Waters, Milford, MA) Buffer A: H2O, 0.1% formic acid. Buffer B: acetonitrile, 0.1% formic acid. Flow 
rate 400 µl/min. The gradient started with 2% B for 5 min, rising to 5% B in 5 min, then 75% B in 35 
min, then 90% B in 5 min and held for 5 min. The gradient was dropped from 90% B to 2% B at the end 
of the 70-min run. 
APM Digestions 
 APM (EC 3.4.11.2, Merck, Darmstadt, Germany) reaction conditions used 25 mM Tris-HCl with 
0.5 M NaCl, pH 7.5, reacted at 37 oC for 24 h. APM (at 60.6 U/ml) was added to be 0.6% of final reaction 
volume. (Sigma-Aldrich, St. Louis, MO) Included in the digestion experiments were a positive control, 
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known to be digested by APM, human angiotensin I, and a negative control, NdWFamide, which is not 
digested by APM.14 Peptide content was compared between 0 h and 24 h of enzyme digestion using two 
different platforms. For rapid analysis, we employed matrix-assisted laser desorption ionization, time of 
flight MS (MALDI-TOF) (ultrafleXtreme, Bruker Daltonics, Billerica, MA). This data analysis is 
performed using fleXanalysis (Bruker Daltonics, Billerica, MA). The identity of peptides were confirmed 
using an LC–MS system with an UltiMate 3000 Nano HPLC system (Thermo Scientific Dionex, 
Sunnyvale, CA) coupled to amaZon speed ETD MS (Bruker Daltonics, Billerica, MA), by comparing 
tandem-MS fragments (CID mode) to predicted fragments from Protein Prospector (UCSF) or a non-
targeted database search using PEAKS studio 7.5 (Bioinformatics Solutions Inc, Waterloo, Canada).  
Chiral amino acid analysis 
This was performed for cerebellin peptide. First, acid hydrolysis is performed on the peptide in 
the vapor phase at 150 oC for 30 min in a CEM Discover microwave (CEM, Mathews, NC).15 The 
reactions are carried out in 6 M DCl in D2O (to prevent detection of racemized amino acids) with 0.1% 
phenol (added to prevent destruction of tryptophan and other amino acids).16,17 (Sigma-Aldrich, St. Louis, 
MO) To enhance separation, L- and DAAs were derivatized with Marfey's reagent (1-Fluoro-2,4-
dinitrophenyl-5-L-alanine amide, FDAA).18,19 (Sigma-Aldrich, St. Louis, MO) The amino acids from the 
acid hydrosylates were dried and reconstituted in 25 µl of 0.5 M NaHCO3. For derivatization, 20 µl of 1 
mg/m FDAA dissolved in acetonitrile were added to these amino acids and reacted at 60 oC for 3 h. In 
addition to the products of acid hydrolysis, a standard mixture of the achiral amino acid glycine and the L- 
and D-forms of the 19 common chiral amino acids is derivatized and used to compare retention times. 
The LC-MS/MS-MRM system-setup included the Advance ultra-high performance LC (UPLC) 
and Bruker EvoQ triple quadruople-MS (both from Bruker Daltonics). The column was a Kinetex 2.6 µm 
particle Phenyl-Hexyl column, 100 Ǻ pore size, 100 mm (length) x 2.1 mm (internal diameter) 
(Phenomenex, Torrance, CA). A binary solvent system was used, with increases in Buffer B (organic) 
solvent over the course of a 24-min run. A 300 µl/min flow rate was employed with gradient elution (A: 
25 mM ammonium formate; B: methanol). The gradient started with 5% B for 2 min, rising to 15% B in 5 
 174 
 
min, then 60% B in 5 min and held for 3 min, then 100% B in 3 min and held for 3 min. The gradient was 
dropped from 100% B to 5% B toward the end of the 24-min run. EvoQ source parameters: HESI, Spray 
Voltage (+/-) 3500 V, Cone Temperature 250 oC, Cone Gas Flow 20, Heated Probe Temperature 400 oC, 
Probe Gas Flow 45, Nebulizer Gas Flow 50, Exhaust Gas Off. EvoQ MRM chromatograms were 
analyzed using Data Review (Bruker Daltonics). 
7.5 Results 
APM digestion-resistant peptides in the pituitary and SCN 
As part of peptide extraction and APM protocol method development, the pituitary was tested. 
Upon application of APM, while many peptides were degraded, 4 peptides were seen to resist 
degradation. (Table 7.1) Two of these had N-terminal Pro, and since this amino acid resists degradation by 
APM, were not chosen for further study. The two other peptides were considered interesting and chosen 
for further study. One of these peptides was little SAAS, from the proSAAS prohormone. (Fig. 7.1A) The 
other peptide that resisted degradation was the joining peptide from the proopiomelanocortin (POMC) 
prohormone. (Fig. 7.2A,B) 
Since the little SAAS in the pituitary resisted degradation by APM, it is a potential DAACP. To 
see if there was some other reason for resisting degradation, a little SAAS standard containing only LAAs 
was subjected to APM degradation. (Fig. 7.1B) In contrast to the endogenous little SAAS in the pituitary, 
this synthetic all-LAA peptide of little SAAS was quickly degraded by this enzyme. 
The POMC peptides are some of the most abundant peptides in the pituitary. Joining peptide 
(amino acid sequence: AEEEAVWGDGSPEPSPREamide) occurs as a peptide product in the process of 
forming adrenocorticotropic hormone, and it has no assigned signaling function.8 However, it was noted 
that human joining peptide exists as a dimer, so it is possible that the lack of function is due to the poorly 
understood nature of this peptide.20 It is amidated at its C-terminus, indicating that it is present in late 
secretory granules, where amidation occurs. Upon being subjected to degradation by APM, the joining 
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peptide is degraded by 99.99%. However, upon closer inspection, a second peak appears that resists 
degradation, at a later retention time. In fact, this peak is present at 0 h, but blends into the larger, earlier 
peak. Both of these peaks match amidated joining peptide through MS (their mass) and MS/MS (their 
fragmentation profile). 
In the SCN, many peptides were degraded by APM. Two of the peptides that resisted degradation 
contained either an N-terminal Pro or an N-terminal pyroglutamylation, both of which are expected to 
resist degradation by APM even when a peptide contains only LAAs. (Table 7.1) Thus, they were not 
chosen for further study. Unlike in the pituitary, little SAAS in the SCN was potently degraded by APM. 
(Fig. 7.1B) 
One peptide, detected with and without a C-terminal His truncation, was seen to resist digestion 
by APM. This peptide is the cerebellin peptide, from the cerebellin 1 prohormone.21 (Fig. 7.3A) 
Cerebellin peptide is interesting because there is a glycine at the second residue from the N-terminus; this 
is an achiral amino acid. However, this peptide has been observed missing the N-terminal serine, known 
as [des-Ser1]-cerebellin; given its overall sequence, one might expect a D-Ser near the N-terminus of this 
peptide.21  
No D-Glu was detected in POMC joining peptide 
Given its resistance to digestion by APM, it was expected that a D-Glu could be observed, as 
there are three Glu residues  near the N-terminus of the peptide. In a follow up study, the joining peptide 
of POMC was isolated from pituitary extracts. These extracts were subjected to chiral analysis, where a 
peak corresponding to L-Glu was detected. (Fig. 7.2C) No D-Glu peaks, or any other DAAs, were 
detected in these experiments. 
Little SAAS is not detected as a DAACP in the SON 
 Since little SAAS resisted degradation by APM in the pituitary, but not the SCN, one more 
avenue remained to be explored: examining little SAAS in the SON. The SON contains projections from 
the hypothalamus to the pituitary.22 Little SAAS is synthesized in the SON, so the source of the little 
SAAS in the pituitary may be the SON.23 
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 Fractionated peptide extracts from the SON were examined for the presence of little SAAS. Once 
endogenous little SAAS from the SON was located, this was subjected to APM digestions. (Fig. 7.4A) 
The peptide from the SON was degraded. Spiking with all-LAA little SAAS peptide standard yielded 
only one peak, while spiking with D-Leu-little SAAS standard yielded two separate peaks. (Fig. 7.4B) 
This indicates that the endogenous peptide is the all-LAA little SAAS. 
To ensure that the APM digestions were behaving as intended, control experiments were run with 
and without adding the actual APM enzyme, and with either little SAAS (containing only LAAs) or D-
Leu2-little SAAS peptide standards. With no enzyme, both standards had no degradation occur. (Fig. 
7.4C) With enzyme, only little SAAS was degraded while D-Leu2-little SAAS peptide standard was not. 
(Fig. 7.4D) 
No D-Ser was detected in cerebellin peptide 
 Since cerebellin peptide resisted degradation by APM in the SCN, this was examined further. 
There was reason to believe that this peptide contained a D-Ser near its N-terminus. Short, N-terminal 
synthetic peptides of cerebellin were subjected to APM digestions. (Fig. 7.5) When a D-Ser was at the N-
terminus of the peptide, no digestion occurred. (Fig. 7.5C) When a D-Ser was in the third position, the 
peptide was digested. (Fig. 7.5B) Thus, the resistance to digestion seen in the SCN could be potentially 
explained by a D-Ser at the N-terminus. 
 For this reason, the cerebellin peptide in the SCN was isolated and subjected to chiral analysis. 
However, after this analysis, no D-Ser was detected, indicating that cerebellin was not detected as a 
DAACP in the SCN. (Fig. 7.3B) 
7.6 Discussion 
The discovery of DAACPs in the nervous system of rodents would add a new PTM to the 
mammalian neuropeptide repertoire and perhaps suggest that this PTM played a role in human health. The 
tools for characterizing these peptides have been lacking, but a promising technique was developed in 
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Chapter 5 of this thesis, which was successfully applied to the nervous system of A. californica in Chapter 
6 for the discovery of new DAACPs. Thus, this method, which aimed to analyze DAACPs in nervous 
systems of other animals, was applied to two promising structures in the rodent nervous system: the 
pituitary and SCN. Three promising hits were discovered from APM digestions: Little SAAS and joining 
peptide in the pituitary, and cerebellin in the SCN. None of these three were seen to contain DAAs in the 
follow up studies. 
Little SAAS was seen to resist digestion in the pituitary, but not in the SCN and SON. This peptide 
has already been shown to be bioactive in the SCN.24 However, this did not preclude follow up studies; 
few enough DAACPs have been discovered that it is uncertain that the DAACP species is going to be sole 
bioactive form. In fact, in the case of Ocp-4, its all-LAA counterpart is the bioactive form.25 And in the 
case of crustacean hyperglycemic hormone, both the L-form and D-form share bioactivity, although they 
have differential effects; the L-form activates a stronger and more short-lived hyperglycemic response, 
while the D-form activates a weaker and more long-lived hyperglycemic response.26 This highlights a 
limitation in bioactivity-based discovery of DAACPs, because it presupposes that the bioactivity of the 
neuropeptides are known, and that is not the case. With this in mind, chiral analysis of little SAAS was 
bypassed in favor of using synthetic standards, in part because these standards were already available. 
However, in spite of the relative resistance to digestion of little SAAS in the pituitary, it was not found in 
the D-form in either of two of the structures that expresses the peptide, in the SCN and SON. 
Joining peptide from POMC is known as an intervening prohormone sequence because no activity 
has been established for this peptide.8 Such peptides tend to carry many acidic residues, as joining peptide 
does, and help maintain the charge balance of a vesicle. This was seen as an intriguing prospect as well, 
because the reason joining peptide has no established function could be because the wrong molecular 
form, one synthesized only containing LAAs. Joining peptide was also seen to have a split-peak elution, 
as is often seen with DAACPs and their all-LAA counterparts, and one of the forms resisted digestion by 
APM. At the N-terminus of this peptide are only Ala and Glu. However, when this peptide was 
fractionated and chiral analysis performed, no D-Ala or D-Glu was detected. 
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Cerebellin peptide was the only interesting peptide to resist degradation in the SCN. Previous 
studies demonstrated that this peptide is released in a time-of-day dependent manner.27 Some studies on 
the bioactivity of this peptide have revealed an activity for the peptide containing only LAAs in various 
nervous and endocrine structures.28-30 However, as explained above, this does not preclude the presence of 
a DAACP. Studies on short N-terminal peptides of this peptide revealed that a D-Ser at the first position 
in the N-terminus would resist digestion by APM. However, when this peptide was fractionated and 
subjected to chiral analysis, no D-Ser was detected. 
A recurring theme in this discussion is that in the current form of the DAA-containing neuropeptide 
discovery funnel, even those peptides that resist digestion by APM, does not guarantee the presence of a 
DAA in the peptide. This has been noted with N-terminal Pro and N-terminal pyroglutamylation and 
acetylation.31 However, the three peptides discussed here, little SAAS (N-term: SLS), joining peptide (N-
term: AEE), and cerebellin (N-term: SGS) do not fall within these limitations.  
The important question is why these peptides showed resistance to APM. Clearly, APM’s 
limitations go beyond the inability to digest Pro and pyroglutamylation. APM was effectively used to 
discover DAACPs in A. californica, but failed in the SCN. An important difference between A. 
californica and the SCN is the dynamic range of the analytes, as well as the chemical complexity. In 
Aplysia, the region expressing the achatin-like neuropeptides could be more easily targeted, leading to a 
less complex sample. This leads to a more predictable activity of APM, whereas high abundance peptides 
in the SCN or pituitary could have interfered with the digestion of lower abundance peptides. Another 
clue to a limitation in this technique is in how many fewer peptides were detected in this study compared 
to the published study (peptides from 12 prohormones compared to 27 in the published work). APM 
digestions are carried out in neutral conditions, whereas most peptide extracts and studies rely on acidic 
conditions to keep peptides holding a net charge. The losses could come from precipitation of certain 
peptides in those conditions, or lack of loading onto a column, or remaining on a filter. These neutral 
conditions could even explain the lack of APM digestion of a peptide, where a small amount of the 
peptide precipitates in neutral conditions but is then recovered back in solution when it is acidified prior 
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to analysis, leading to the false impression that the peptide has resisted digestion. 
In other words, detecting DAACPs is difficult, and the DAA-containing neuropeptide discovery 
funnel is not an end point, but rather a strategy that continues to be developed. But importantly, later 
stages of the funnel did serve their purpose of identifying false positives from APM digestions. 
As it stands, the discovery funnel has generated a list of peptides that are unlikely to be DAACPs in 
the rodent nervous system. This remains an important first step in endogenous DAACP discovery, as their 
presence in the nervous systems of non-mollusks has been explored for the first time in this work. 
7.7 Conclusion and future directions 
Three peptides in the rodent nervous system were not digested by APM, but ultimately were not 
seen to be DAACPs. This revealed an unexpected limitation in APM-based screening, in that the neutral 
solvents it is carried out in may be leading to unpredictable peptide recovery, such that many published 
peptides in the SCN were not detected. However, the lack of detection of many peptides in the SCN that 
were previously detected in published studies does not mean they are not interesting for DAACP 
discovery. In fact, they represent the next wave of peptides that need to be studied in the SCN for their 
possible DAA content. Rather, the current tools will continue to be optimized to meet this important and 
interesting challenge. 
Such improvements are numerous, including testing carboxypeptidases in case there are C-
terminally modified DAA-containing neuropeptides, or adding tandem-MS fragmentation as a form of 
chiral analysis for particularly promising peptides from the first step. It is also attractive to consider 
sampling techniques that will reduce chemical complexity and dynamic range of analytes, such as single 
cell analysis, whose techniques have been used and continue to be developed by the Sweedler group and 
others.32-36 However, within the confines of the current discovery funnel, APM could be continually 
optimized to address this challenge. The prospect of using MALDI-TOF instead of LC-MS/MS would 
carry some disadvantages, but the advantage is that no filtration of enzyme or further processing of the 
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peptide mixture is necessary, which may lead to better recovery of certain (but maybe not all) peptides. 
This has been performed in Chapter 5, where digestions occur in a vial but are spotted directly on a 
MALDI plate with a matrix and no further processing. This carries the disadvantage of no high 
throughput identification of peptides and peptide fragments, but especially since a list of known peptides 
has been generated, this could work well for intact peptides. In fact, there are digestions which can be 
performed “on-target”; that is, enzymatic digestions that are carried out on a MALDI plate, further 
limiting the processing steps that may lead to peptide loss.37,38 These digestions could be carried out in a 
heated, humid chamber to achieve the same digestions as vial in a heated bath. Also, while the pH 
maximum activity of APM was noted to be at 7.5, there was activity at a pH of 6, and lower pH was not 
even tested.39 Lower pHs, even a pH of 6, could lead to better recovery of peptides, all of which can first 
be tested with standards and then applied to Aplysia extracts to see the selectivity of the enzyme at these 
pHs in regards to other peptides versus the achatin-like neuropeptides. 
It has been mentioned that dynamic range may contribute to problematic enzyme kinetics, which 
makes lower abundance species appear to resist digestion in complex fractions. This aspect can also be 
tested not only to confirm this idea, but also to establish at what levels dynamic range becomes an issue. 
Likely, the variety of peptide sequences will mean that the dynamic range issue affects some peptides 
more than others, but at least some basic ideas can be established. For example, these studies may find 
dynamic range is an issue when some peptides are present at 100-fold higher concentrations than others 
when there are 30 high abundance peptides present. This will improve our understanding of what sample 
complexity is suitable for APM digestions. 
The discovery of DAACPs in the rodent nervous system could lead a whole host of studies in 
rodent nervous systems and beyond to understand the evolutionary and biological need of this 
modification, the enzymes that carry it out, and the systems where it is expressed. Optimization of these 
techniques will continue to be of interest in the Sweedler group, which will require adaptation of the 
DAA-containing neuropeptide discovery funnel approach to the needs of the systems that are studied.  
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7.8 Figures and tables 
Table 7.1. Tables of resistant and digested neuropeptides from the SCN and pituitary using APM digestions. In the SCN, 
these represent detection of 35 peptides from 12 prohormones. +42.01 = acetylation. -17.03 = pyroglutamylation. 
Resisted 
   Prohormone Peptide Sequence Molecular Weight (Da) Location 
Cerebellin 1 SGSAKVAFSAIRSTN 1494.8 SCN 
Cerebellin 1 SGSAKVAFSAIRSTNH 1631.8 SCN 
Chromogranin A WSRMDQLAKELTAE 1676.8 SCN 
POMC AEEEAVWGDGSPEPSPREa 1939.8 Pituitary 
ProSAAS SLSAASAPLAETSTPLRL* 1784.0 Pituitary 
    Resisted with N-terminal PTM or Pro 
  Prohormone Peptide Sequence Molecular Weight (Da) Location 
CART Q(-17.03)EDAELQPR 1067.5 SCN 
ProSAAS PPENVLGALLRV 1276.8 SCN 
POMC RPVKVYPNVAENE 1228.7 Pituitary 
Secretogranin 3 FPKPEGSQDKSLHN 1582.8 Pituitary 
    Degraded 
   Prohormone Peptide Sequence Molecular Weight (Da) Location 
AcCoA Binding Protein S(+42.01)QADFDKA 922.4 SCN 
CART AQEDAELQPR 1155.6 SCN 
Cerebellin 4  AANSKVAFSAVRSTN 1521.8 SCN 
Cerebellin 4  ANSKVAFSAVRSTN 1450.8 SCN 
Cerebellin 4  SKVAFSAVRSTN 1265.7 SCN 
Galanin LGMPTKE 775.4 SCN 
PACAP AVDDRAPLT 956.5 SCN 
PACAP AAAAVDDRAPLT 1169.6 SCN 
PACAP MTM(+15.99)CSGA 715.2 SCN 
PEBP-1 MNRPSSISW 1076.5 SCN 
POMC AEEETAGGDGRPEPSPREa 1881.9 SCN 
Proenkephalin A YGGFMRGL 899.5 SCN 
ProSAAS LENSSPQAPA 1012.5 SCN 
ProSAAS AVPRGEAAGAVQE 1253.7 SCN 
ProSAAS AVPRGEAAGAVQEL 1366.7 SCN 
ProSAAS AVPRGEAAGAVQELA 1437.8 SCN 
ProSAAS GRILTGSSEPEAAPAPRRL 1977.1 SCN 
ProSAAS ILTGSSEPEAAPAPRRL 1764.0 SCN 
 182 
 
Table 7.1. continued 
 
ProSAAS SLSAASAPLAETSTPL 1514.8 SCN 
ProSAAS LSAASAPLAETSTPL 1427.8 SCN 
ProSAAS LSAASAPLAETSTPLR 1583.9 SCN 
ProSAAS SLSAASAPLAETSTPLRL* 1784.0 SCN 
ProSAAS SAASAPLAETSTPLRL 1583.9 SCN 
ProSAAS ASAPLAETSTPLRL 1425.8 SCN 
ProSAAS SAASAPLAETSTPL 1314.7 SCN 
Secretogranin 2 ASFQRNQL 962.5 SCN 
Secretogranin 2 MYEENSRENPF 1414.6 SCN 
Secretogranin 2 ANQKSPYFPNQY 1455.7 SCN 
Secretogranin 2 TNEIVEEQYTPQSL 1649.8 SCN 
Secretogranin 2 YLNQEQAEQGREHLA 1784.9 SCN 
POMC YVMGHFRWDRFa 1511.7 Pituitary 
POMC S(+42.01)YSMEHFRWGKPVa 1663.8 Pituitary 
POMC DDGPYRVEHFRWSNPPKD 2213.0 Pituitary 
POMC YGGFM 572.2 Pituitary 
Secretogranin 1 LLDEGHDPVHESPVDTA 1829.9 Pituitary 
 
* = Note that little SAAS resists degradation in the pituitary but not in the SCN 
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Figure 7.1. Little SAAS resists digestion in the pituitary, but not in the SCN. (A) Little SAAS during APM digestions of 
pituitary extract. LC-MS chromatograms were not illustrative due to high baseline from a coeluting peak, so MS intensities were 
chosen instead. There was no appreciable drop in intensity of the peptide after 24 h of digestion. Peptide identity established 
through MS/MS fragmentation in a database search. (B) Little SAAS during APM digestions of SCN extract, and standard 
digestions. On the left, 0 and 24 h LC-MS chromatograms of little SAAS peptide are presented. At 0 h (black trace), there is a 
significant amount of peptide which is decreased to the point of no detection at 24 h (red trace). On the right, this was repeated 
with a little SAAS all-LAA peptide standard, with the same results (black trace 0 h, red trace 24 h). 
 
 
 
 
 
 
A 
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Figure 7.2. Analysis of the POMC joining peptide from the pituitary. (A) LC-MS extracted ion chromatogram of mass 
window that includes joining peptide. Joining peptide during APM digestions of pituitary extract, zoomed out. (B) Zoomed in 
version of panel A APM digestions. At 0 h (black trace), there is a significant amount of peptide which is decreased 99% at 24 h 
(red trace). This reveals a split peak elution (two distinct peaks seen in this panel). Both of these peaks have the same molecular 
weight and fragmentation pattern. (C) Chiral analysis of joining peptide. No D-Glu was detected when comparing to labeled 
standards. 
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Figure 7.3. Analysis of cerebellin peptide as a potential DAACP. (A) LC-MS extracted ion chromatogram of mass window 
that includes cerebellin peptide. This chromatogram is of APM digestions of SCN extract, zoomed out. At 0 h (black trace), the 
peptide is detected which is decreased 50% at 24 h (red trace). Interestingly, a split peak elution is seen (two distinct peaks seen 
in this panel). Both of these peaks have the same molecular weight and fragmentation pattern. This may be an inconsequential 
shift, as no spiking experiments were performed. (B) Chiral analysis of cerebellin peptide. No D-Ser was detected when 
comparing to labeled standards. 
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Figure 7.4. Analysis of Little SAAS in the SON. (A) Little SAAS during APM digestions of SON extract. LC-MS 
chromatogram of little SAAS peptide. At 0 h (black trace), there is peptide detected which is decreased to the point of no 
detection at 24 h (red trace). (B) LC-MS chromatogram of little SAAS in SON with spiking of all-LAA little SAAS (black trace) 
and D-Leu2-little SAAS (red trace). A single peak is seen with spiking little SAAS, whereas two distinct peaks are seen with 
spiking D-Leu2-little SAAS. This indicates that the form seen in the SON is the all-LAA form. (C) Control experiment of little 
SAAS peptide to ensure APM digests are working as expected. LC-MS chromatogram of 24 h mock digests with no APM. Little 
SAAS (black trace) and D-Leu2-little SAAS (red trace) standards are still present after 24 h, as expected. (D) Another control 
experiment of little SAAS peptide. LC-MS chromatogram of 24 h digests of standards with APM. Little SAAS (black trace) 
standard is digested while and D-Leu2-little SAAS (red trace) standard is still present after 24 h, as expected. 
 
 
A B 
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Figure 7.5. Digestion of cerebellin N-terminal peptide. Molecular weight of cerebellin N-terminal peptide = m/z 570.3 (sodium 
adduct) (A) SGSAKV is degraded after 24 h. (B) SGdSAKV is degraded after 24 h. (C) dSGSAKV is not degraded after 24 h. 
This indicated that if cerebellin peptide exists as a DAACP, a D-Ser would be expected at the first position of the N-terminus. 
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CHAPTER 8  
CONCLUSIONS AND FUTURE DIRECTIONS 
8.1 Conclusions and Future Directions 
D-amino acid-containing peptides (DAACPs) remain enigmatic contributors to the 
neuropeptidome, hiding true bioactive peptides in a way that is invisible to high throughput peptidomics 
techniques. The goals of this thesis have been stated in Chapters 1, 5, and 7: to develop approaches for the 
discovery of DAACPs, and to test these approaches in the Aplysia californica nervous system and the 
rodent nervous system. 
This work began with A. californica, where NdWFa was already known to exist.1 Established 
techniques were first used to characterize GdFFD in Aplysia through its homology to achatin-I in Chapter 
4. In Chapter 5, a new multiple step approach, the DAA-containing neuropeptide discovery funnel, was 
developed and optimized, adapting and leveraging suitable techniques for the detection of DAAs in 
neuropeptides. This was then applied to discovering and characterizing two promising peptides in the 
achatin-like (apALNP) prohormone, GdYFD and SdYADSKDEESNAALSDFA. GdFFD and GdYFD 
were seen to be bioactive, but SdYADSKDEESNAALSDFA was not. Ultimately, this demonstrated the 
ability of the discovery funnel approach to detect DAACPs, with the intention to apply it to other 
prohormones in Aplysia in the future and in other unrelated organisms. 
The discovery of a DAACP in the rodent nervous system would reveal a previously unrecorded 
PTM of neuropeptides in mammals. This would uncover a whole host of questions to pursue, including 
assistance in “deorphanization” of a G-protein-coupled receptor (GPCR). Even with tremendous efforts, 
many GPCRs still have orphan ligands; it is interesting to speculate that some of these could be 
DAACPs.2 In Chapter 7, the rodent nervous system was probed for DAACPs, work that has been rarely 
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performed because the tools for doing so has been lacking. As the discovery funnel can rely on 
aminopeptidase M (APM)-based digestions for screening, this considerably reduced the extremely 
complex approach of trying to see different positional DAA substitutions in hundreds of neuropeptides. 
Two nervous system structures, the suprachiasmatic nucleus and the pituitary, were chosen that have some 
important advantages for DAACP discovery in the nervous system. Although no DAACPs were 
discovered in this initial effort, it helped to gain a new understand of the approach of the discovery funnel, 
as well as identified many peptides that would not be considered DAACPs in an APM-based screening. 
Many more peptides remain to be analyzed in this effort, which will require some fundamental changes in 
the way APM screening is performed. This will perhaps require the integration of other approaches with 
APM, including sampling approaches. In mammals, where we cannot target a well-defined region of a 
few cells, unlike Aplysia, dynamic range becomes more of an issue. This kind of method optimization 
will continue in all of the methods presented in this work. There is no definitive protocol for the most 
straightforward detection of all kinds of DAACPs, and that will likely continue to be the case. In addition, 
other structures beyond the suprachiasmatic nucleus and pituitary may prove to yield more fruitful results, 
but method optimization will be key to avoiding as many false positives in those structures, too. 
What is next? An approach that was only briefly discussed in Chapter 2 has proven to be effective 
for the discovery of DAACPs: discovery by sequence homology. While this method carries limitations, 
sequence homology has been used to identify GdFFD as an interesting peptide in Chapter 4, and this 
peptide turned out to be a DAACP. More indirectly, the results of APM digestions in A. californica 
yielded several peptides of interest, but the most demonstrative of the usefulness of our method continued 
to be achatin-like neuropeptides with sequence homology to GdFFD, which were discovered to also be 
DAACPs in Chapter 6. Thus, in some form or another, sequence homology is an intelligent way to comb 
through first pass results to decide which hits from screenings may be more promising. Along that same 
vein, such potentially interesting peptides have been identified in mammals by studying the substrate 
specificity of the frog peptide isomerase: lingual antimicrobial peptide, β-defensin 2 and 8 from cattle, the 
human peptide LL-37, insulin B chain, and neuropeptide FF.3-6 
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One of the more interesting of these peptides from a DAA-containing neuropeptide perspective is 
neuropeptide FF, and initiating studies on this peptide will be the last of my work in the Sweedler 
laboratory. Its sequence in rodents is FLFQPQRFamide, and this peptide evolved from the same family of 
peptides of known endogenous DAACPs fulicin and mytilus-FFRFamide.7,8 The frog peptide isomerase 
appears to have a high affinity for the consensus sequences aromatic-Xaa-aromatic (among others), which 
matches will with neuropeptide FF.3 In fact, the frog isomerase was able to convert a synthetic all-LAA 
standard into the D-form. Although the position of the isomerization was never specified, one could 
surmise based on the rest of the work that the D-form of neuropeptide FF is FdLFQPQRFa. There are 
other properties of this peptide that make it interesting for isomerization studies. Neuropeptide FF is 
known to inhibit morphine-induced analgesia, and to understand the influence of the N-terminus on the 
bioactivity of neuropeptide FF, modifications of this peptide were studied in this context. While 
truncating the N-terminus decreased and even abolished the affinity of this peptide, introducing DAAs 
into the N-terminus of the peptide did not change the affinity of this peptide compared to the all-LAA 
peptide.9 Thus, if the DAACP form is discovered endogenously, it is already established that the synthetic 
DAACP standard does have bioactivity in inhibiting morphine-induced analgesia. However, this does not 
limit the scope of neuropeptide FF bioactivity-based studies. The peptide appears to be involved in 
several nervous system pathways, including the hypothalamo-pituitary axis and within the spinal cord.10 
Understanding the role of a DAA in the peptide, as well as how it affects the peptide’s activity within 
these systems, will be a complex and interesting undertaking. Taken together, this evidence suggests that 
neuropeptide FF is a potential DAACP based on homology, but the question remains how to target the 
peptide. 
Neuropeptide FF is found at high fmol to low pmol levels in the spinal cord, supraoptic nucleus, 
and pituitary.11 However, current extraction protocols do not seem to yield neuropeptide FF at detectable 
levels in the studies carried out in Chapter 7. There are several strategies to enrich this peptide in extracts. 
First, only the posterior pituitary, where neuropeptide FF is found, can be dissected separately from the 
anterior and intermediate pituitaries, which contain high levels of other neuropeptides. Second, several 
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extraction methods can be tested, as this peptide appears to prefer hydrophilic-based extractions. Third, 
multiple reaction monitoring (MRM) can be used for sensitive detection of peptides include neuropeptide 
FF. Detection of the peptide is obviously necessary for downstream analysis of the peptide, which can 
include the discovery funnel approach or other strategies. Based on Jilek et al’s work, the DAACP form 
of neuropeptide FF readily separates from its all-LAA form using liquid chromatography, so this may be 
sufficient to identify it as a DAACP.3 If neuropeptide FF is detected using MALDI-TOF, recent work with 
MALDI-TOF/TOF indicates that sequences like neuropeptide FF and its DAACP form may be readily 
distinguished using MS/MS fragment ion intensities.12 If these strategies, which are some of the most 
particularly well-developed in the Sweedler laboratory, fail to provide conclusive evidence, this will 
establish a threshold and alternative techniques can be employed in the future. Given its interesting 
properties, there is good reason to continue to target this peptide for analysis. 
While much of the focus of this work has been on mollusks and rodents, DAACPs have been 
found in three different animal phyla: arthropods, mollusks, and vertebrates.13 Given the evolutionary 
diversity of these phyla, it is difficult to believe that the prevalence of DAACPs is limited to the current 
discoveries, especially since characterizing DAACPs is so difficult. The tools presented here establish an 
approach for DAA-containing neuropeptides that will hopefully yield further insights into the prevalence 
of peptide isomerization in nervous systems. In turn, this will improve our understanding of the necessity 
of incorporating a DAA into a peptide on a cell-to-cell communication level. Moreover, the non-targeted 
nature of APM screenings will help discover newly isomerized sequences that may have not been 
anticipated based on homology, which in turn will lead to further discoveries of similar peptides to these 
new sequences. If more bioactive peptides are discovered in this way, this will help not only towards 
understanding the chemical complexity of neuropeptide communication, but also pathological states 
where these peptides are involved. 
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APPENDIX A 
STRUCTURE, BIOACTIVITY, AND RESISTANCE 
MECHANISM OF STREPTOMONOMICIN, AN 
UNUSUAL LASSO PEPTIDE FROM AN 
UNDERSTUDIED HALOPHILIC ACTINOMYCETE 
A.1  Acknowledgments and notes 
This chapter is adapted from published work.1 Reprinted from Chemistry & Biology, 22(2), 
Metelev, M., Tietz, J. I., Melby, J.O., Blair, P. M., Zhu, L., Livnat, I., Severinov, K., Mitchell, D. A., 
Structure, bioactivity, and resistance mechanism of streptomonomicin, an unusual lasso peptide from an 
understudied halophilic actinomycete, 241-250, Copyright (2015), with permission from Elsevier. 
Presented below is some of the work on streptomonomicin relating to structural characterization, 
not the entire published work, which includes exhaustive work on the bioactivity and the resistance 
mechanism of this bacterial peptide. The abstract, introduction, and relevant methods and results sections 
are taken directly from the published work, with references to experimental details found in the paper’s 
supplement omitted. My contributions are in the chiral analysis section, but other work on structural 
elucidation was included to demonstrate the ultimate results of this effort. The conclusions and future 
directions section and Figure A1 are original work for this chapter to place this work in the larger context 
of this thesis, focusing on the lessons for the discovery funnel. 
A.2  Abstract 
Natural products are the most historically significant source of compounds for drug development. 
However, unacceptably high rates of compound rediscovery associated with large-scale screening of 
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common microbial producers have resulted in the abandonment of many natural product drug discovery 
efforts, despite the increasing prevalence of clinically-problematic antibiotic resistance. Screening of 
underexplored taxa represents one strategy to avoid rediscovery. Herein we report the discovery, 
isolation, and structural elucidation of streptomonomicin (STM), an antibiotic lasso peptide 
from Streptomonospora alba, and report the genome for its producing organism. STM-resistant clones 
of Bacillus anthracis harbor mutations to walR, the gene encoding a response regulator for the only 
known widely-distributed and essential two-component signal transduction system in 
Firmicutes. Streptomonospora had been hitherto biosynthetically and genetically uncharacterized, with 
STM being the first reported compound from the genus. Our results demonstrate that understudied 
microbes remain fruitful reservoirs for the rapid discovery of novel, bioactive natural products. 
A.3  Introduction 
Microbial biosynthesis represents the most important historical source of chemical matter for the 
understanding of biology and the development of medicines.2 However, despite the value of natural 
products as medicinal leads, the frequent rediscovery of known compounds renders traditional screening 
methods (i.e. bioassay-guided isolation) increasingly unappealing and economically disadvantageous.3 In 
response, a number of modern natural product discovery strategies have been developed, including 
genome-guided discovery,4 antibiotic resistance-mediated isolation,5 reactivity-based screening,6 PCR-
based strain prioritization,7 mass spectrometry-based network analysis,8 heterologous expression,9 and 
metagenomics10 with the general aim of reducing the burden of rediscovery and thereby accelerating the 
drug discovery process. 
In widely-studied organisms, it is frequently the case that the abundant natural products are 
already known; undiscovered compounds are often believed to be silent or at least below a detection 
threshold. This can complicate identification, purification, structural elucidation, and mechanism-of-
action determination efforts. Moreover, broad metabolic and bioinformatic analysis shows that natural 
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product biosynthetic capability tends to parallel bacterial speciation;4 hence, rather than to solely 
concentrate on screening many strains of one particular known producing species, it may also be useful to 
seek new species in underexplored taxa. Understudied organisms—those that are lab-cultivable yet 
unsequenced or metabolically uncharacterized—thus present the prospect of discovery of novel, abundant 
bioactive metabolites with lower rates of rediscovery.11 Among these organisms are the 
Streptomonospora, a genus within the family Nocardiopsaceae.12 Members of the genus are slow-
growing halophiles, typically requiring cultivation for a month or more in high-salt media (10–25% w/v 
NaCl). At least nine distinct Streptomonospora species have been reported; however, no corresponding 
genome sequences are available. These characteristics have rendered Streptomonospora sp. markedly 
unattractive both from the standpoint of traditional high-throughput natural product screening campaigns 
and more modern genome-driven discovery efforts. Perhaps for this reason, the biosynthetic capacity of 
the Streptomonospora has gone entirely neglected in the 13 years since their first description. As 
actinomycetes in general have been shown to be unusually talented biosynthetic chemists, we reasoned 
that investigating an understudied, yet tractable, genus would shed light on the natural product repertoire 
of these organisms and guide future genome-mining programs. 
Taking into account the above, we cultured Streptomonospora alba YIM 9000313 and found an 
abundant natural product, streptomonomicin (STM), which was isolated and subjected to structural and 
biological characterization. We also performed whole-genome sequencing of S. alba, revealing STM’s 
biosynthetic origin and shedding light into the biosynthetic capability of the genus. 
A.4  Method 
Chiral amino acid analysis 
Acid hydrolysis was performed in the vapor phase at 150 °C for 30 min in a CEM Discover 
microwave (CEM Corp, Mathews, NC). The reactions were carried out in 6 M deuterium chloride (DCl) 
in D2O (Sigma-Aldrich, St. Louis, MO). To enhance separation, D- and L-amino acids were then 
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derivatized with Marfey's reagent (1-fluoro-2,4-dinitrophenyl-5-L-alanine amide, FDAA) (Thermo-Fisher 
Scientific, Waltham, MA). For derivatization, the amino acids from the acid hydrosylates were dried and 
reconstituted in 25 µl of 0.5 M aq. NaHCO3. (Thermo-Fisher Scientific, Waltham, MA) 20 µl of FDAA in 
MeCN (10 mg/ml) (Thermo-Fisher Scientific, Waltham, MA) were added to these amino acids, and the 
labeling was allowed to proceed for 2 h at 40 °C. A standard mixture of the glycine and the L- and D- 
forms of the 19 common chiral amino acids was derivatized (Sigma-Aldrich, St. Louis, MO) and used to 
compare retention times. The LC-MS/MS-MRM system used an Advance ultra-high performance LC 
(UPLC) module with a Bruker EVOQ triple quadrupole-MS (Bruker Daltonics, Billerica, MA) with a 
Kinetex Phenyl-Hexyl column (100 Å, 100 × 2.1 mm; 2.6 µm particle size) (Phenomenex, Torrance, CA) 
operating at 300 µl/min. A binary solvent system was used, with the following linear gradient: 0 min (5% 
B), 3 min (5% B), 8 min (20% B), 19 min (40% B), 24 min (100% B), 26 min (100% B), 30 min (5% B), 
with mobile phase returning to the initial conditions for equilibration for 2 min. Solvent A: 25 mM aq. 
NH4OAc, pH 7.0. Solvent B: MeCN. (Both from Thermo-Fisher Scientific, Waltham, MA) EVOQ MRM 
chromatograms were analyzed using Data Review (Bruker, Billerica, MA). 
NMR spectroscopy 
Samples were prepared by dissolving ca. 4 mg of STM (HPLC-purified and lyophilized) in 500 μl 
of either methanol-d4 (CD3OD; 99.96 atom % D; Sigma-Aldrich) or methanol-d3 (CD3OH; 99.8 atom % 
D; Sigma-Aldrich). NMR spectra were recorded on an Agilent VNMRS 750 MHz narrow bore magnet 
spectrometer equipped with a 5 mm triple resonance (1H-13C-15N) triaxial gradient probe and pulse-
shaping capabilities. Samples were held at 25 °C during acquisition. Standard Varian pulse sequences 
were used for each of the following experiments: 1H, 1H-1H DQF-COSY, 1H-1H TOCSY (80 ms mixing 
time), 1H-13C HSQCAD, 1H-13C HMBCAD, and 1H-1H NOESY (400 ms mixing time). Solvent 
suppression by presaturation (PRESAT) was employed when CD3OH was used as the solvent. Spectra 
were recorded with VNMRJ 3.2A software and data was processed using MestReNova 8.1.1, nmrPipe,14 
and Sparky (Goddard and Kneller). Resonances were referenced internally to the solvent peak (3.30 ppm, 
methanol). 
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Structure calculations 
STM’s solution structure was calculated by simulated annealing using distance and angle 
restraints within XPLOR-NIH v 2.36. 15,16 Standard XPLOR-NIH potentials for bond angles, improper 
angles, van der Waals, and favored/allowed Ramachandran regions were used. The Ser1-Asp9 isopeptide 
linkage was generated using a manual patch of the “protein-1.0.top” XPLOR-NIH file. Distance restraints 
were derived from peak area integrations in the NOESY data sets, which were binned into specific 
distance categories (2.5, 3.5, 5.0, and 6.0 Å). nmrPipe was used for processing of raw NOESY data and 
conversion from Varian to UCSF format (Sparky), and Sparky was used for peak picking, volume 
integration, and creation of the XPLOR distance restraint table. Peptide backbone dihedral restraints were 
derived from coupling constants determined from DQF-COSY. Three hundred structures were calculated, 
of which the 15 structures of lowest energy were chosen for structural analysis. The quality of the NMR 
structures was evaluated using PROCHECK-NMR.17,18 
A.5  Results 
Chiral analysis 
Chiral amino acid analysis was performed on streptomonomicin due to the possibility that its 
unusual shape could be explained by the presence of a D-amino acid.1 For this purpose, deuterium-
assisted peptide hydrolysis and derivatization with Marfey’s reagent were used, which is described in 
further details in Chapters 3, 5, and 6. Ultimately, all of the detected amino acids in chiral analysis were 
found in the L-amino acid form. (Table A.1 and Fig. A.1) The amino acid Asn was not detected in the 
peptide. 
Structural elucidation 
Two aspects of the NMR data pointed to a highly-ordered three-dimensional structure. First, 
many amide protons in the ring and the N-terminal half of the tail showed resistance to deuterium 
exchange (Fig. A.2C). Second, a large number of long-range NOE correlations were apparent, particularly 
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from the methyl group of Ala15 to a number of the ring residues (e.g. Ser1, Ser5, Tyr7, Asn8, Asp9). 
Additionally, the ring/tail topology is characteristic of lasso peptides, a class of conformationally-
constrained peptidic natural products wherein a 7- to 9-membered N-terminal ring is nearly always 
threaded by a C-terminal tail; this conformational lock protects them to a degree from degradation and has 
resulted in recent interest in these scaffolds.19-21 However, lasso peptide conformation cannot be assumed 
from sequence alone, as one recently-described lasso peptide is reported to be unthreaded.22 As such, we 
sought to determine the three-dimensional solution structure of STM. 
Using NOE distance constraints derived from the NOESY spectra and dihedral angle restraints 
extracted from the DQF-COSY, an ensemble solution structure was calculated using XPLOR-NIH (Fig. 
A3B, A3C) (Protein Data Bank [PDB] code 2MW3). The resulting STM structure contains the 
characteristic right-handed lasso; the ring encircles the tail between residues 14–16 (Figure A3B). The 
constrained ring and loop of STM are well-ordered (0.26 Å rmsd against lowest conformer for the 
backbone for residues 1–17), and occlude solvent from inward-oriented amide protons, rationalizing the 
observed slow deuterium exchange of many residues of the ring and the N-terminal half of the tail 
(Figures A2C and A3C). The C-terminal portion of the tail (residues 18–21) is more disordered, 
consistent with the observed rapid deuterium exchange (Figure A2C). In lasso peptides without disulfide 
bonds, bulky residues on the tail immediately flanking the ring serve as steric locks.23 Inspection of the 
van der Waals surface of the ring (residues 1–9) and the tail residues that thread the ring suggests that 
Leu16 serves as this steric lock, preventing the ring from unthreading (Fig. A3C). Ala15 is in close 
contact with the ring but is unlikely to be bulky enough to prevent unthreading. Pro14 may also play a 
role in biasing the conformation of the tail, although mutational studies would be necessary to confirm 
this. Threaded lasso peptides are typically resistant to carboxypeptidase Y digestion;24,25 in contrast, STM 
is unusually susceptible (vide supra). However, the complete tail digestion expected for unthreaded lasso 
peptides was not observed, and a mixture of partially truncated peptides was instead obtained. We 
hypothesize that the comparatively small steric lock of STM (Leu/Ala) combined with its large, 9-
member macrocycle render it more prone to proteolysis. 
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Unlike other lasso peptides, STM is unusually hydrophobic, consisting of 5% hydrophilic and 
52% hydrophobic residues. Known class II lasso peptides (those without disulfide bonds, like STM) are 
10–43% hydrophilic and almost always contain a charged residue. Interestingly, STM’s amino acid 
composition is closer to that common for class I and III lasso peptides (those conformationally restrained 
by two or one ring-tail disulfide bonds, respectively). RP-71955, the siamycins, and BI-32169, like STM, 
contain 5% hydrophilic and 43–53% hydrophobic residues, being rich in Leu/Ile/Val/Ala. Additionally, 
despite little primary sequence identity, the structure of STM aligns closely (backbone rmsd 1.03 Å for 
residues 1–17 against lowest energy conformer of STM) to the crystal structure of BI-32169 (PDB code 
3NJW), a lasso peptide of streptomycete origin.26,27 
Markedly, although a Ser-Glu isopeptide linkage has been recently reported in the caulonodins, 
no lasso peptide with a Ser-Asp isopeptide linkage was formerly known.28 Before the caulonodins and 
STM, it was thought that the first residue of lasso peptides was invariantly Gly or Cys, as amino acid 
substitutions at this site had not been found in nature; even conservative substitutions at this site were not 
tolerated by the enzymatic machinery for microcin J25, capistruin, or astexin-1, for instance.24,29,30 
A.6  Conclusions and future directions 
Prokaryotic peptides have been known to carry D-amino acids for far longer than animal peptides. 
Gramicidin, for example, is an antibiotic peptide whose D-amino acid is necessary for its activity 
discovered 30 years before spontaneously racemized animal peptides were studied.31 Unlike endogenous 
or spontaneously racemized amino acids, these D-amino acids form from non-ribosomal enzyme 
complexes.32 While these peptides also contain unusual post-translational modifications that are not 
normally found in animal peptides, they nonetheless benefit from similar characterization techniques. 
The cyclic nature of STM makes it difficult to sequence with sequencing enzymes. In addition, 
with the interest of D-amino acids in the peptide, a technique was necessary that could detect a D-amino 
acid in any position, combined with other structural information. The discovery funnel’s chiral analysis, 
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described in Chapters 5 and 6 of this dissertation, served the unique needs of STM because it could detect 
a D-amino acid among many possible residues in the ring. 
The work in this chapter helps to elucidate the structural features of an unusual bacterial peptide. 
The ringed structure (Fig. A3) could form in a number of ways, and D-amino acids have been found in 
cyclic bacterial peptides. The thought is that the D-amino acid is necessary to achieve the bond angles that 
can form a cyclic structure in a small number of residues.33,34 To determine if the ringed structure resulted 
from the presence of a D-amino acid, chiral analysis was performed. Only L-amino acids were detected 
(Table A1 and Fig. A1), indicating that there must have been another structural feature involved in the 
ring. This was discovered to be an isoaspartic linkage, where the R-group of an Asp bonds with a Ser, 
rather than the normal peptide bond. This isoaspartic and isoglutamyl linkages have been seen in other 
bacterial peptides; for example, D-Ala in cell wall peptides.35 The lack of D-amino acids and presence of 
the isoaspartic linkage is confirmed by the NMR data. (Fig. A2) 
Several lessons from this work can aid in optimization of the discovery funnel. Notably, L/D-Asn 
was not detected in acid hydrolysates (data not shown). If a D-Asn existed, the current form of acid 
hydrolysis would pick it up as a D-Asp peak,36 necessitating further characterization. Since peptides like 
STM can benefit from chiral analysis, the question becomes if a D-amino acid residue is present with an 
unusual amino acid found in bacterial peptides, such as threo-β-lanthionines in lantibiotics.37 These are 
thought to undergo stereoinversion from an original L-Thr, and this can be directly with chiral analysis of 
sulfated L/D-Thr. In this way, bacterial D-amino acid-containing peptides can benefit from such analyses. 
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A.7  Figures and tables 
 
Table A1 Quantitative amino acid analysis (n = 3; columns 2-4) was consistent with the 21 amino acids present in STM. Chiral 
amino acid analysis (last column) by microwave-assisted peptide hydrolysis and derivatization with Marfey’s reagent, as 
described in the Supplemental Experimental Procedures, revealed all amino acids to be present exclusively as their natural L 
stereoisomer. 
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Figure A1. Chiral amino acid analysis with multiple reaction monitoring (MRM) chromatograms for labeled amino acids. This 
analysis revealed that only L-amino acids are present in STM. Black trace = chromatograms of labeled L- and D-amino acid 
standards. Red trace = STM peptide hydrolysate. See also Table A1. 
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Figure A2. (A) Integrations of amide protons from 1H NMR spectrum in CD3OH indicate a single NH proton is present for each 
residue. Residue assignments are shown above the spectrum. Peaks (ppm) are shown above residue assignments. Integrations are 
shown below the spectrum. (B) Expansion of 1H-1H NOESY spectrum in CD3OD showing amide/side chain through-space 
correlations. The isopeptide Ser1-Asp9 linkage is indicated by the strong NOE crosspeak between the Ser1 NH and the β protons 
of Asp9, as highlighted in red. (C) Overlaid 1H NMR spectra taken in CD3OD shortly after sample dissolution (black) and 1 d 
later (red). Residue assignments are shown above the spectrum. Significant resistance to deuterium exchange is evident for many 
peaks. 
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Figure A3. (A) Schematic representation of the structure of STM with the isopeptide Ser1-Asp9 linkage indicated. Residues 1–9 
(gray) comprise the ring and residues 10–21 (white) are the tail. (B) Ensemble of the 15 lowest energy conformers of NMR 
solution structure; backbone atoms are depicted. (C) Stereo view of one conformer of STM with side chains shown. Backbone 
atoms are depicted in red for the ring and blue for the tail. Side chains are depicted in orange for residues 14–16, which thread the 
ring. Images in panels B and C were generating using PyMOL.  
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